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Considerable excitement has been generated by the discovery of active compounds from 
marine organisms. These compounds have a remarkable role in cancer treatment, with fewer 
side effects on general health. Sulphated glycosaminoglycan (GAGs) are present in all 
animals, vertebrate and invertebrate. They are of proven economic importance, not only in 
the food industry but also in the pharmaceutical field.  
The present study identifies the key structural differences between the GAGs isolated from 
whelk and mammalian GAG and investigates their biological activity in relation to cancer 
and malaria. Glycans from marine sources are unique in terms of their structure and function. 
They work as an alternative natural source to provide effective treatment for several types of 
cancer, especially triple negative breast cancer (TNBC), which is the most aggressive type of 
cancer with fewer available treatment options. In addition, marine GAGs have a proven 
influence on malaria, although their mechanisms of action are not fully understood.  
Several methods have been employed to achieve the aims of this study. The structure of 
whelk GAG was determined using several analytical techniques such as gel filtration 
chromatography, ion exchange chromatography, mass spectrometry and nuclei magnetic 
resonance spectroscopy. Enzymatic depolymerisation was also used to generate a library of 
fragments; each was then evaluated for its biological activity on cancer growth. Anti-
proliferation activity on several cancer cells, including pulmonary adenocarcinoma A459, the 
MCF-7 ER-positive cell line, overexpression of protein HER2- SKBR3 cell line, the 
hepatoblastoma-derived cell line (Hep G2), chronic myelogenous leukaemia (K562), TNBC 
and mammosphere formation in breast cancer subtypes, and on malaria has been investigated 
in vitro using drug sustainable assays. Focusing on TNBC, the label-free quantitative 
proteomic approach has been used to gain overall insight into the mechanisms of action of 
whelk GAG on two TNBC cell lines: MDA-MB-468 and MDA-MB-231.  
ix 
 
The results from whelk GAG analysis suggest a complex fine structure with a high sulphation 
levels that is clearly distinct from mammalian GAG. Few impurities were detected within the 
whelk GAG structure, which exhibits enzymatic resistance; this generated structurally 
indeterminate fragments. These resistant fragments still have significant biological activity 
against cancer growth. In vitro assays demonstrated significant inhibition activity of whelk 
GAG toward all types of cancer cells, mammosphere formation from breast cancer cells and 
malaria.  
The mechanisms of action by which whelk GAG inhibits the growth of two TNBC cell lines 
appear to involve influencing the cell integrin signalling cascade, extracellular organisation 
pathways including the regulation of fibroblast growth factor FGF signalling and fibroblast 
growth factor receptors FGFR, cell adhesion and reduced glycolysis metabolism. In addition, 
whelk GAG affected the cell mitosis pathways by downregulating DNA replication proteins.  
To our knowledge, this is the first study to identify significant structural differences between 
whelk GAGs and mammalian GAGs, which helps to explain the structural-functional 
relationship of marine glycans in inhibiting cancer cell growth. It also examines the 
biological role of GAGs isolated from whelk as anti-proliferation agents toward a wide 
variety of cancer cell lines and mammosphere formation in breast cancer. Finally, this study 
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1.1    General research background 
 
Marine biology is an exceptionally rich source of many biological compounds and exogenous 
sulphated glycans.  They have important values in the pharmaceutical industry.  Interest has 
significantly increased in this field with many reports of compounds that have divers 
biochemical structure (Liu & Rein, 2010). Compositional diversity is predominant in marine 
organisms, almost each class revealing individually unique available compounds.  
Marine species have been the source of a wide variety of metabolites with interesting 
biological effects, interest has increased significantly in this field which has led to 
considering as one of the natural and alternative sources of compounds with vital biological 
functions worthy of further in depth investigation (Nur Hanim Zainudin, 2014).  
Some marine natural products have derived drugs which are registered and published 
either in the EU or in the US while more are under clinical and pre-clinically investigation. 
Over 14,000 natural compounds have been developed from marine organisms recently and 
hundreds of patents illustrating the activities of marine natural products have been 
submitted, most of their remarkable activity have been on cancer (MarinLit, 2003; Proksch 
et al., 2002).  
Marine-derived bio active molecules include polyunsaturated compounds with sulphated 
glycosaminoglycan as a part of their structure and they have been shown  anticancer, anti-
inflammatory, antioxidant and antimicrobial activities in vitro  (Schmitz, 1994). Sulphated 
glycosaminoglycan is present in all animals, vertebrate and invertebrate (Yamada et al., 
2011). The polymeric form of sugars and amino sugars from marine organisms, known as 
glycosaminoglycans (GAGs), are of proven importance not only in the food industry but also 
in the pharmaceutical field. Interest in GAG has increased in response to their remarkable 
biological activity as co-receptors for a variety of growth factors, cytokines, chemokines, and 
their specific role in some enzyme activities and tuomurigenesis (Rostand & Esko, 1997). 
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Many patent applications disclose GAG isolated from various marine species for 
anticoagulant and antithrombotic activity exclusively, while other patents present antituomur 
activity such as GAG extracted from cartilaginous fish. Anti-inflammatory properties 
reported from GAG isolated from Perna canaliculis due to sulphated hexosamine of GAG 
derived. Heparan sulphate glycosaminoglycans express the highest structural variability of 
their GAGs from other forms of sulphated glycosaminoglycan such as keratan sulphate (KS) 
(Newman et al., 2000). Due to their pharmaceutical properties, various structures of heparan 
sulphate glycosaminoglycan have been extensively studied.   
Cancer is one of the major causes of mortality worldwide; it is defined as abnormal cells 
dividing in an uncontrolled manner, which eventually could spread into other tissues. There 
are many types of cancer, this diversity in cancer types and the fact that they are initiated or 
generated from human body’ own cells make it the most complicated disease to treat. There 
are several treatment options for cancer, mainly involve a combination of three approaches, 
surgery, radiotherapy and chemotherapy. All of these three options have severe side effects 
on the patient, especially chemotherapy. For example, doxorubicin is a useful chemotherapy 
agent, it used to treat several cancer types but after surviving cancer, the patient in serious 
danger of develop life- threatening conditions such as cardiomyopathy, nephropathy or 
congestive heart failure  (Sharkey et al., 2013).  
 
1.2    Glycosaminoglycans GAGs 
 
GAGs are found covalently attached to proteins, giving conjugates known as proteoglycans. 
GAGs are a linear glycan chain composed of a repetitive structure of disaccharide units of 
uronic acid and glucosamine. Initially it thought that GAGs only exist in mammals; however, 
they found in wide variety of organisms such as fish, insects, fungi, yeast, and bacteria. It is a 
particularly rich component in the muscle of shellfish (Robyt, 1998). 
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GAGs found on the cell surface and the extracellular spaces in many tissues, especially 
connective tissues. Such as that found in cartilage and the walls of blood vessel. Connective 
tissues contain large amounts of GAGs, which also contains collagen and elastin fibres 
embedded in a gel-like matrix called the ground substance. There are many types of GAG 
families: hyaluronic acid (HA), chondroitin sulphate (CS), dermatan sulphate (DS), keratan 
sulphate (KS), heparin (Hep), and perhaps the most widely studied is heparan sulphate (HS). 
The main differences between the family members are the position and configuration of their 
glyosidic linkages, amount and location of their sulphate substituents and monosaccharide 
composition. Some of these species have very simple structure, for instance; hyaluronic acid, 
whereas the others such as CS, DS, Hep and HS contain extensive blocks of modified 
disaccharide units, with complex sulphation patterns which appear to be under tight 
biosynthetic control (Mathews, 1974).  
 
1.2.1    GAG biosynthesis Pathway  
 
GAG biosynthesis occurs through three steps; chain initiation, chain polymerization and 
polymer modification. It is generally believed that the polymerization takes place by stepwise 
addition of monosaccharide units to non- reducing polysaccharide chain ends. Those chains 
have various properties, which fixed at the initiation phase of polymerization and tightly 
controlled by glycosyltransferases, sulphotransferases and an epimerase enzyme in the lumen 
of the Golgi apparatus. The expression level of these enzymes during chain initiation is 
responsible for the display of high structural complexity within GAG chain later (Wei et al., 
1993). The position and arrangement of glycosides linkages that join the monomer sugar 
residues and determine, in part, the type of GAG synthesised are specified by the local 
configuration of four groups, sulphate, hydroxyl, carboxyl and acetyl within the 
monosaccharide building blocks (Roden & Schwartz, 1975).  
 5 
 
Before the completion of GAG chain elongation, the polymerization products are extensively 
modified to produce sulphate sequences within the polysaccharide using 3 -phosphoadenyl- 
phosphorsulphate (PAPS) as a sulphate donor. The GAG chain contains uronic acid (either L-
iduronic acid or D- glucouronic acid) and hexosamine (represented in D-glucosamine or D- 
galactosamine) residues respectively. The type of monosaccharide building block, the 
position of the glycosidic linkages and the location of sulphate groups on the monosaccharide 
rings will determine the subspecies of GAG synthesised.  
The GAGs chain initiates with the protein core attached to tetrasaccharide contains GAG (n)–
GlcA–Gal–Gal–Xyl–Ser sequence. The chain initiates by adding an O-serine residue using 
glycosyltransferases  (Kim et al., 2001). Glycosyltransferases such as XylT-1 responsible for 
adding next residue Xyl from UDP-Xyl to the hydroxyl group of the serine core proteins in 
the endoplasmic reticulum. Then two D-galactose monosaccharides are transferred to the Xyl 
residue, this occurs by the activity of two types of galactosyltransferases GalT-I and GalT-II 
(Carey, 1997). The GlcAT-I enzyme completes the biosynthesis of the linkage trisaccharide 
by addition of a D-glucuronic acid residue from the UDP - GlcA transferase I (Pedersen et al., 
2000; Perrimon & Bernfield, 2000; Prydz & Dalen, 2000).  
Two extensive modifications are carrying on GAG chain after it has been synthesised. First, 
phosphorylation of the Xyl residue at position 2, which appears to happen in both CS and HS. 
The second modification takes place on Gal residues by sulfation on either one or both Gal 
residues at the 4 or 6 position. This step is found only in CS and DS, thus this might be 
important for the selective assembly of CS/DS rather than HS/heparin as the last two never 
shows any kind of modification in Gal residues onto the linkage region tetrasaccharide 




                                         Figure 1-1:  The biosynthesis of GAG chain. 
                                               Modified from (Moehler et al., 2013) 
 
                                 
1.2.2    HS and Heparin Chain Polymerization and Modifications 
 
Chain polymerisation continues by adding hexosamine residues to the linkage-region 
tetrasaccharide core. The sugar backbone of HS/Heparin is initiated by adding GlcA and α-
GlcNAc by α-GlcNAc transferase I (GlcNAcT-I) and α-GlcNAc transferase II (GlcNAcT-II) 
enzymes respectively, these enzymes are also known as EXT1 and EXT2. In this step, the 
chain will be classified and growing as HS/Hep chain (Fritz et al., 1994; Kim et al., 2001; 
Sugahara & Kitagawa, 2000).  
The addition of these residues results in the final length of the Hep/HS chain which could be 
typically between 50 and 200 disaccharide units (Duncan et al., 2001; Turnbull et al., 2001). 
The next step is an extensive modification of the chain by enzymes, which yields specific 
sequences of sulphated and unsulphated regions within the Hep/HS chain. Glucosaminyl N-
deacetylase/N-sulfotransferase (NDST) is a golgi enzyme that initiates modification steps by 
first replacing N-acetyl groups with N-sulphates on GlcNAc residues (Kjellen, 2003). 
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Phosphoadenosine 5-phosphosulphate PAPS is considered as the main donor for all sulphate 
groups (Kakuta et al., 1999). 
Recently, it was found that The NDST enzyme is active one both N-deacetyl and N-sulphate 
residues, in vitro studies have characterised four isoforms of NDST enzymes in which each 
enzyme’s isoform carrying the same reaction, with regards to the chemical context. NDST 
isoforms 1 and 2 appear to be remarkably important in HS modification due to overlapping 
issuing of two of these isoforms among others which might be produced by different genes 
(Pikas et al., 2000).  
The next step in chain modification is epimerisation by GlcA C5 epimerase, this enzyme 
selectively epimerise GlcA to IdoA (Pinhal et al., 2001). The reaction was found to be freely 
reversible in a solubilised enzyme system in the presence of 3H2O trihydrate which is 
basically 3 molecules of water, and the O-sulphate group on the C2 position of the IdoUA 
residue which both seem to promote this reaction (Lindahl et al., 1998; Pinhal et al., 2001). 
The action of epimerase is to increase the flexibility of the GAG, thus the IdoUA units are 
considered as highly flexible units across the chain (Salmivirta et al., 1996).   
 HS is further modified in the golgi, heparan sulphate O-sulfotransferases (HS-2/3/6OST) 
selectively add sulphate groups to IdoA or GlcA residues at the 2-O position, and the 3-O or 
6-O positions of GlcNS or GlcNAc (Nakato & Kimata, 2002). Ultimately, the final structure 
of the polysaccharide chain is determined by the action of glucosaminyl N-deacetylase/N-
sulphotransferase (the NDST’s) golgi enzymes (Ringvall et al., 2000).  
In specific cells or tissues, further chain modification occurs by the action of 6-O sulfatases 
(sulfs)  which selectively remove the 6-O sulfation (Ai et al., 2003).  
Despite the complicated modifications among HS chain, on average only 40-50% of HS 
disaccharides are sulphated, this giving HS great structural diversity leading to increase the 
ability to bind a variety of proteins. This converts crucial functional actions in many cellular 
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activities, such as anticoagulation when HS binding to antithrombin protein, also promote 
angiogenesis by HS binding to FGF (Lamanna et al., 2006; Robinson et al., 2006).  
 
 
         Figure 1-2:  Typical HS and Heparin Chain Polymerization and Modifications. 
                                     Modified from (Esko et al., 2009) 
 
 
1.2.3    Heparin and Heparan Sulphate Domains 
 
The structural features between Hep/HS has been identified; the disaccharides units that 
configure the heparin chain are extensively modified unlike HS chain. In the HS biosynthesis 
and modification, selected GlcNAc residues likely undergo the N-deacetylation /N-sulfation 
modification with no further modification. This known as an incomplete biosynthetic 
modification pathway. Thus, HS chain appears as blocks of unmodified sequences (NAc- 
domains), separated by highly modified residues or (S- domains).  
However, in heparin the chain essentially contains S-domain interrupted by NAc domains. 
During the modification reactions, three types of domains are likely to be generated. First, 
unmodified N-acetylated regions (NA domains) with GlcA units, which are present in small 
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amounts in the predominant disaccharide unit in HS. The second type is adjacent N-sulphated 
regions with 2-O- and 6-O-sulphated in both IdoA and GlcA residues in (NS domains). 
Finally alternating regions of N-sulphated and N-acetylated disaccharides domains appear in 
HS chains (Mulloy et al., 2011; Robinson et al., 2006).  
 
                  Figure 1-3:  Typical organisation of heparin vs heparan sulphate domains. 
                                    Modified from (Chavaroche et al., 2013) 
 
 
 1.2.4    Patterns of 2-O- sulphation, 6-O- sulphation and 3-O- sulphation groups in HS   
and Heparin 
 
Once the initiated synthesis and modification pathways in Hep/HS chain biosynthesis is 
completed, further modifications will occur to add additional complexity to its structure and 
function. Three types of HS sulphotransferases are responsible for the modification of 
HS/Hep domains. Heparan sulphate 2-O-Sulphotransferase (HS2ST) is one of these 
evaluative enzymes, and has a key role in forming 2-sulphated L-iduronic acid (IdoUA (2S)), 
which widely exists in HS chains. The mechanism of action is to catalyse the transfer of 
sulphate groups from PAPS to the C2 site on the L-iduronic acid (IdoUA) (Kobayashi et al., 
1997).   
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As this enzyme acts only on IdoUA units, it mainly modifies the S-domain sections of the 
GAG chain. It may also play a critical role in HS degradation especially within IdoUA (2S) – 
GlcNS (6S) domains (Habuchi et al., 2000; Kobayashi et al., 1997).  
The second enzyme is heparan sulphate 6-O-sulphotransferase (HS6ST). This enzyme 
catalyses the process of adding a sulphate group to the C6 position of a glucosamine using 
PAPS as a sulphate donor. There are three isoforms of this enzyme, HS6ST-1, HS6ST-2 and 
HS6ST-3. The first enzyme can transfer sulphate groups to GlcNS sites of IdoUA – GlcNS  
disaccharide units (Sedita et al., 2004). 
The second isoform transfers sulphate groups to a wide variety of substrates. More sulphate 
groups may transfer to GlcUA – GlcNS domain, and less to IdoUA – GlcNS domain. Finally, 
the third isoform HS6ST-3 is thought to act on both domains, IdoUA – GlcNS and GlcUA – 
GlcNS (Habuchi et al., 2000; Sedita et al., 2004). In other words, HS6ST only act or transfer 
O-sulphate to GlcNS.  
During the biosynthesis of the HS chain, the final and important modification occurs on 
carbon C3 of N- sulphated GlcN residues, this is the substrate that 3-O-sulphotransferase 
enzyme (3-OST-1) acts on. This enzyme is considered most important, as it is thought to be 
engaged in creating the antithrombin III (AT III) binding site within HS chains, thus 
converting non-anticoagulant HS into anticoagulant HS as the residue is critical for the 
formation of the antithrombin binding region the 3-O-sulphated GlcNS (3S) units (Liu et al., 
1999).  3-O-sulphation has been shown to be rare among other sulphations of glucosamine 
during the modification process. There are three different isoforms of this enzyme, 3-OST-1, 
3-OST-2, 3-OST-3a and 3-OST-3b. Each of these isoforms is expressed in different tissues. 
3-OST-1 is found in the brain, kidney and the heart, while 3-OST-2 is highly represented in 
brain tissue, the third isoform is found within a wide variety of different tissues (Habuchi et 
al., 2000). The sulphation mechanism of 3-OST-2 is not limited to specific residues, it  
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transfers to the GlcNS residue regardless of the proceeding UA unit hence the domain is 
GlcUA – GlcNS or IdoUA(2S) – GlcNS, whilst the 3-OST-3a and b enzymes act on specific 
sequences limited by IdoUA(2S) – GlcNS domains (Liu et al., 1996).  
 
Figure 1-4: Biosynthesis enzymes and 2-O- sulphation, 6-O- sulphation and 3-O- 
sulphation patterns found in HS/Hep. 
            
1.2.5    CS/DS Chain Polymerisation and Modifications 
 
Biosynthesis of CS/DS seems to be similar to that in HS/Hep chain synthesis. The CS/DS 
biosynthesis enzymes are localised in trans-golgi complex, which is different from golgi 
network part in the lower end of the trans-golgi matrix where HS/hep biosynthesis enzymes 
are confirmed in golgi apparatus (Prydz & Dalen, 2000). 
The diverging step in chain polymerisation begins after the formation of the linker 
tetrasaccharide section completed. The enzyme EXTL2, which also known as GalNAcT1 is 
different from the enzyme that adds Gal to the tetrasaccharide residues in chain initiation, it 
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acts by adding GalNAc to the chain, to produce CS/DS chains. EXTL2 is the enzyme that 
adds GlcNAc residue to HS chains. There are two distinct enzymes for the synthesis of the 
CS/DS backbone known as GlcUA transferase II and GalNAc transferase II, the action of 
these enzymes will lead produce chains with repeating 4- GlcUA β1-3 GalNAc  units 
(Sugahara et al., 2003). 
After the biosynthesis, the DS/CS chain undergoes a significant modification process, 
including the epimerization of GlcUA to IdoUA. The outcome of the C5 epimerase enzyme 
leads to the chain classified as DS. The main differences between CS and DS is that CS only 
has a glucuronic acid unit, while DS has both D-glucuronic acid and L-Iduronic acid units 
(Prydz & Dalen, 2000).  
The final chain modifications are by sulphotransferase enzymes action, the chain eventually 
undergoes 2-O, 6-O-sulphation and 4-O-sulphation. The Chondroitin-6-sulphotransferase is 
known as C6ST, the action of this enzyme produces GlcUA – GalNAc (6S) domains from 
GlcUA – GalNAc by catalysing the conveyance of sulphate groups to the 6-O site of GalNAc. 
Unlike Chondroitin-4-sulphotransferase that shift the sulphate groups to the 4-O site of 
GalNAc residues, thus producing in GlcUA – GalNAc (4S) structure. Uronosyl 2-O- 
sulphotransferase is found to only be active on DS chains via the shifting of a sulphate group 





                  Figure 1-5:  CS/DS Chain Polymerisations and Modifications. 
                                          Modified from (Maeda, 2015) 
 
 
1.3    De - Polymerisations Techniques 
 
There are two known methods for de-polymerisation of GAG chains, each one could be used 
separately or combined and yield different compounds. A method for determining the 
sequence type of GAG at the level of disaccharide provides key information for their 
structure-function relationships. Disaccharide is obtained by depolymerisation of the 
polysaccharide chains via enzymes and/or chemical degradation. 
 
1.3.1    Enzymatic De-Polymerisation of HS/Hep 
 
The enzymes generally used for the enzymatic depolymerisation process have varying 
degrees of specificity for HS/Hep chains and are found in the soil bacterium, Flavobacterium 
heparinum. These enzymes act especially on the structure uronic acid-HexA releasing 
disaccharide or oligosaccharide compounds, with approximate fragment lengths of 10-20 
disaccharides. The predictable structures produced containing a reducing end and α/β 
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unsaturated uronic acid at the non-reducing terminal (Galliher et al., 1981). This will create 
an unsaturated double bond between C4 and C5 on the non-reducing end of the chain, which 
is known as unsaturated uronic acid (ΔUA). This has UV sensitivity, which can detected by 
wave length 232 nm, this allows enzyme digestion process to be detected (Linker, 1979). 
There are three different isoforms of heparanase known as lyases I, II and III, each of these 
lyases has a very high substrate specificity making them useful tools when comparing 
isolated GAGs from different cells or tissue types, also they play an important role in 
producing specific types of oligosaccharide fragments which vary in sulphate pattern, chain 
structure and length. Heparanase I (hep I) typically acts on the sequence IdoUA (2S) - 
GlcNS-(6S), thus it will release disulphate disaccharides and as a result releases the modified 
NS regions. The enzyme also cleaves the antithrombin III binding pentasaccharide domain in 
the heparin molecule. Heparanase II (hep II) acts on the sequences IdoUA-2S GlcNS/NA-
3S/6S and GlcUA -GlcNS/NA-3S/6S. This is why Heparanase II is considered the least 
specific of the heparainase enzymes and able to cleave a wide range of substrates in HS/Hep 
chains. Heparanase III (hep III) acts on the sequence GlcUA –GlcNAc6S (Lindahl et al., 





        Figure 1-6:  Heparinase (I, II, III) lyase action on each fractions substrate.   
                                         http://www.sigmaaldrich.com  
 
 
1.3.2    Chemical De-Polymerisation of HS/Hep 
 
Nitrous acid is involved in the chemical method used for generating disaccharide units from 
polysaccharide chains. Nitrous acid acts very selectively and quantitatively on the GlcNS 
sequence, and is also able to convert GlcNS, GlcNS (6S), GlcNS (3S) and GlcNS (3,6S) units 
into 2, and 5- anhydro D-mannose (Man). A specific range of pH is important to nitrous acid 
substrate cleavage sites, high pH (3-4) or a low pH (1.5) can be used (Rabenstein, 2002). Low 
pH nitrous acid-catalyzed deamination, which cleaves chains at N-sulphated GlcN residues 
while high pH nitrous acid-catalyzed deamination will not act on GluNS domains, instead the 







1.3.3    Enzymatic De-Polymerisation of CS/DS 
 
Chondroitin sulphate ABC lyase is the enzyme used to de-polymerise chondroitin sulphate. It 
is purified first from Proteus Vulgaris with two isoforms, known as an endoeliminase, 
capable of depolymerizing chondroitin sulphate to produce, as products, a mixture of ∆4-
unsaturated tetra- and disaccharides and an exoeliminase acting on chondroitin sulphate tetra- 
and hexasaccharides to yield the respective disaccharides. It acts on β1, 4-galactosaminidic 
bonds between N-acetylgalactosamine and either D-glucuronic acid or L-iduronic acid in CS 
or DS and yield oligosaccharide mixtures of unsaturated tetra- and disaccharides (Yamagata 
et al., 1968). The ABC lyase has  a variety of applications, it has been used in the 
quantification of CS  and DS from a crude mixture (Yamagata et al., 1968), also it has an 
important role in structural analysis of the carbohydrate moiety of proteoglycans studies 
(Sugahara et al., 1992). A complete depolymerisation of CS to unsaturated disaccharides 
yields from the combined activity of “endoeliminase (chondroitin sulphate ABC endolyase)” 
and exoeliminase (chondroitin sulphate ABC exolyase) (Hamai et al., 1997). 
 
                                  
                                  
                                   Figure 1-7:  Chondroitin (ABC) lyase action on GAG.  





1.4    Heparan sulphate/heparin-protein interactions 
 
Consensus sequences exist on the surface of some proteins with positively charged amino 
acids that are able to interact strongly with negative-charged groups on the HS chains. The 
interactions occurs within the binding regions in specific HS binding proteins (Goupille et al., 
1997).  
 The type of interaction is principally an ionic interaction involving negatively charged 
groups in HS chain specifically sulphate and the carboxylates, which exists in all GAG chains. 
So far, hundreds of proteins including in particular antithrombin III and the FGF family have 
been shown to have significant interactions with HS chains. In particular with NS domains, 
these domains provide multiple binding sites for protein ligands (Kreuger et al., 2006).  Their 
affinity for HS oligosaccharides basically correlates with the overall degree of  sulfation 
(Jemth et al., 2002). Heparin oligosaccharides were generally the most efficient complex 
promoters, whereas less sulphated HS species were less efficient (Jastrebova et al., 2006). 
More selective interactions would require either sequences containing rare components or 
precise spacing of two or more sulphated domains N-sulphated/acetylated/sulphated (SAS) 
(Kreuger et al., 2006). 
 
1.4.1    FGF and the FGFR 
 
Fibroblast growth factors are known as signalling molecules, which have a capacity to 
promote angiogenesis by stimulating the proliferation of endothelial cells and can act directly 
on tumour cells by increasing their growth. They are considered as one of the principle 
angiogenic factors. Many members of the FGF family have the ability to bind to HS GAGs 
and to FGFR receptors. These receptors bind to members of the fibroblast growth factor 
family of proteins to form complexes on the cell surface. 
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Such interactions have been shown to be an absolute prerequisite for FGF mediated 
biological activity. There are a great number of fibroblast growth factor family members 
(FGF’s) in humans and mice, all of them are similar in terms of structure, but FGF1 is the 
only one which is able to bind to all FGFR’s (Rieckmann et al., 2008; Wu et al., 2003).  
FGF1 and FGF2 are known as essential angiogenic factors more than vascular endothelial 
growth factor (VEGF) or platelet-derived growth factor (PDGF) (Cao et al., 2003).  
These FGFs bind the HSPGs chain with different affinities. There are two types of FGFR 
receptors on the surface of cells, each binding to FGF within different affinities, the low 
affinity cell surface receptors are known as HSPG’s co-receptors, and the high affinity termed 
as tyrosine kinase receptors (FGFR’s). Five distinct mammalian genes are encoding tyrosine 
kinase receptors. Each of these FGFR is expressed in variety of different tissues, for instance, 
FGFR1 is found mainly in connective tissue, FGFR2 mostly exists in bone, FGFR3 
contributes to the structure of cartilage, and finally FGFR4 identified in muscle. There are 
two types of each aforementioned FGFR, unspliced receptors or binding receptors, which are 
divided into many variants known as A, B, and C. Their function secreted as receptor such as 
FGFR- type A or supply binding ligand requirements for interactions such as FGFR- 3c and 
FGFR -3b types. Some of the FGFRs binding to FGF1 and FGF2 equally such as FGFR- 2c, 
while FGFR-3 binds to FGF1 with approximately 1000 fold higher affinity than FGF2 
(Goodger et al., 2008; Rieckmann et al., 2008).  
 
 1.4.2    The FGF signalling pathways 
 
Signal transduction from FGF requires the interaction between the growth factors and their 
specific FGFR receptors including HSPG as a co-receptor, forming a complex that usually 
exists on most of cell surfaces. The interaction between FGF and HS chains occur with many 
residues but most of these interactions are likely to be inactive complexes. 
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 Many factors can influence HS activation of FGFs including chain length and the presence of 
specific saccharide components, for e.g., HS oligosaccharides fractions of (dp6-dp12) have 
different capability to activate bFGF in a mitogenic assay and this was correlated with their 
length and disaccharide composition (Pye et al., 1998).  
Another factor correlates to the charge distribution, which is mainly depend on sulphated 
patterns. For e.g. the N- and 6-O-sulfation apparently sufficed to satisfy the requirement for 
HS in important VEGF and FGF signalling events (Kreuger et al., 2006).  
HSPGs are considered as co-receptors as they have secondary role in FGFR’s signal 
transduction (Goodger et al., 2008). Cellular response initially starts from cell surfaces where 
a particular type of FGF binding to their cell surface receptors, occurs the strength of the 
signalling from this interaction will mainly depend on the environment of the cell including 
the number of receptors available and the activated period of these receptors. All this will 
lead to receptor dimerization followed by tyrosine auto phosphorylation of the receptor and 
eventually activation of the appropriate signalling cascades (Pye et al., 2000).   
 
1.4.3    HS/FGF/FGFR Complex interactions 
 
Highly sulphated residues or NS domains within HS are important in FGF activation as they 
have the ability to bring together FGFs with their tyrosine kinase receptors, they also increase 
the stability of FGF-FGFRs interaction (Goodger et al., 2008; Kreuger et al., 2006). The 
ternary complex of FGF1: HS: FGFR1 is highly stable and  loses its complex structure only 
when heated to 100 °C, while both of FGF1: HS and HS: FGFR1 binary complexes loss their 
binding structure when heated to 60 °C (Wu et al., 2003).  
The second crucial function of the complex interaction between HSPG and FGF-FGFRs is 
the ability to prevent the proteolysis of FGF proteins (Ornitz, 2000), and to protect both 
FGF1 and FGF2 from thermal denaturation (Zhang et al., 2001). The FGF1: HS: FGFR1 is 
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known to occur in different ratio and ways. The FGF: HS: FGFR interactions happen in three 
modes known as Trans, cis and mix (contains both cis and Trans interactions). Multiple 
models generated from each of these modes  (Wu et al., 2003). In these complexes both 
ligand and receptor might interact with HSPGs, or only the ligand might interact with 
HS/Hep chain (Ornitz, 2000; Pellegrini et al., 2000). For example, in Trans model, the HS 
derived hexasaccharide (dp6) is the smallest sequences that might interact with two FGF1’s 
on each side of the isoform interaction. In the cis oriented model, HSPGs of (dp12) units is 
required and the minimum size required for the mix cis/trans  to form 2:2 FGF1:FGFR2 
complex is  a HSPGs of dp16 (Ornitz, 2000).  
There are two well-known structural models for this complex that have been confirmed by X-
ray crystallography, which are the “symmetrical complex model” and the “asymmetrical 
complex model”. The symmetrical complex is more stable among the other complexes this 
due to extensive protein- protein contact (Goodger et al., 2008). This model involves a 2:2:2 
complex, two HS dp10 chains facilitate the complex and were confirmed by the X-ray crystal 
structure (Schlessinger et al., 2000). The asymmetrical complex contains only a single chain 
of HS and is able to join the FGF and FGFR’s together in a 2:2:1 ratio such as FGFR2 IIIc: 
FGF1: hep decasaccharide seen by Pellegrini et al., (2000). The size of the HS chain and the 





                             Figure 1-8:  HS/FGF/FGFR Complex interactions. 
                                       Modified from (Gallo et al., 2015) 
 
                                
1.7    Marine sulphated glycan 
 
Marine organisms have been shown to be one of the most extensive and diverse sources of 
many bioactive compounds. During the last 50 years, over 14,000 different natural products 
from marine organisms or species have been reported (MarinLit, 2003).  
The first isolation of sulphated glycans from a marine organism was by Killing (1913), as he 
reported a structure of sulphated fucan from marine brown algae (Phaeophyta). Different 
types of sulphated GAGs have been purified from microalgae such as brown, green, and red 
algae, and other invertebrate species such as echinoderms (sea cucumber and sea urchins)  
Sulphated GAGs are found in other living phyla and have been confirmed in many other 
classes of invertebrates such as Porifera, Actinopterygii fish (Zierer & Mourão, 2000),  also 
in commercially relevant species such as sharks, skate, codfish, and salmon. Most of these 
sulphated GAG’s have shown biological activites in different aspects such as anti-pathogenic, 
antituomur and anticoagulant (Silva et al., 2012).  
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 Other species have been found with a rich content of sulphated GAG in their composition, 
such as S. hermanni and S. vastus.  Other species of sea cucumbers  known as ‘GAMAT are 
considered as a source of traditional medicines, due to containing high bioactive substances 
(Hawa et al., 1999).   
 
1.7.1    Structural composition of sulphated polysaccharides (SP) from marine sources 
 
Sulphated polysaccharide is a significant component in marine organisms’ structures that 
have been extensively studied to date.  Two types have been identified so far, sulphated fucan 
and sulphated galactans. Essentially, the first type occurs in two forms, heterogeneous non-
repetitive sulphated fucans from algae and homogeneous, repetitive sulphated fucans of 
echinoderm. While heterogeneous sulphated galactans have been extracted from red algae, 
green algal species, some species of invertebrates and marine angiosperm polysaccharide 
(Pomin & Mourão, 2008). Many factors affect the composition of this polysaccharide; first, 
different species express different structures of sulphated polysaccharides. Second factor is 
the method of extraction  
The third factor is the season or the environment of conditions, such as the crude fucan that is 
extracted monthly from makonbu, Laminaria japonica Areschoug, cultured from April to 
October at a southern site of the Hokkaido bay (Japan). The crude fucan tends to increase 
gradually from April to September, and rise markedly in October (Honya et al., 1999; 




              Figure 1-9: types of sulphated polysaccharide from marine organisms. 
 
 Heterogeneous sulphated fucans are more abundant in marine brown algae (Phaeophyta). 
Early study by Percival & Ross, (1950), reported the structure of these sulphated fucan, 
which mainly contain 1→2 glycosidic linkages and sulfation at the 4-position. Recently, 
another structure has been confirmed for brown algae’s sulphated fucan which contains equal 
amounts of alternating units of 2,3-disulphated, 4-linked and 2-sulphated, 3-linked α-L-
fucopyranosyl units and has been confirmed by NMR analysis. The heterogeneous nature of 
these structures is thought to be a result of occurrence of branches of non-sulphated fucose 
residues. However, a unique structure is reported from other brown algae species with NMR 
studies suggesting the occurrence of O-acetylation in very high amounts (Chevolot et al., 
1999). The structure of a polysaccharide from brown algae is known as the most complex 
marine polysaccharide due to branching chains, diverse glyosidic linkages, acetylation, 

















Homogeneous, repetitive sulphated fucans have been reported in marine invertebrates 
especially in sea urchins and sea cucumbers (Echinodermata, Holothuroidea) with simple 
repetitive structures composed of unbranched chain of α-L-fucose either [α (1→3) or α 
(1→4)] type of glycosidic linkages and 4-O and/or 2-O sulfation positions (Pomin & Mourão, 
2008).  
Heterogeneous sulphated galactans are the other main type of suphated glycan and are found 
principally in marine red algae. The main reason for heterogeneity of the glycans isolated 
from red algae is the sulphate distribution along the chain. There are two types of red algae 
termed as Carrageenans and Agarans both express an homogeneous galactan backbone unlike 
other red algae species (Bixler, 1994; Knutsen et al., 1994; Lahaye, 2001; van de Velde et al., 
2004).  
Both of these red algae have glycans with a non-branched (linear) chain comprised of 
alternating 3-linked β-D-galactopyranose and 4-linked α-D/ α-L-galactopyranose residues. 
They have a variety of industrial applications due to their simple structure, they also have a 
unique ability to create strong aqueous gels. The physicochemical properties of these glycans 
are affected by variation in the backbone structure such as modified α-D-galactopyranoses in 
carrageenans to α-L-galactopyranoses in agaran (Lahaye, 2001). Sulphated galactans are also 
found in green algal species like Codium (Bilan et al., 2007; Farias et al., 2008). The chain 
here is without repetitive units of disaccharide and instead has a complicated sulphated 
pattern in positions 4 and/or 6 –sulfation unlike red algae. Chain complexity is higher in 
green algae than red algae but is considered as simpler structure in comparison to brown 
algae (Pomin, 2009). Sulphated galactans have also been reported in some species of 
invertebrates in ascidians (Urochordata, Ascidiacea), and in two species of sea urchins. The 
structures are typically homogeneous and contain linear chains as the backbone structure. 
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In general, the location of these sulphated glycans, either sulphated fucan or galactan, is 
determined within the body wall or extracellular matrix, this matches the amount of 
glycosaminoglycan found in the extracellular matrix of mammalian connective tissue. Marine 
sulphated fucans and galactans are more sulphated than CS and DS in vertebrate GAGs. 
Marine sulphated glycans are found with extremely high molecular weights that can be  >1 
million Da such as the mass of sulphated fucans that found in sea urchin egg jellies for the 
glycan fraction, as this sulphated glycan has high molecular weight itself without any core 
protein interaction, while the GAG molecular mass in mammals could reach ∼15 and ∼60 
kDa, or approximately >100 kDa in case of covalent attach to core protein  (Pomin & Mourão, 
2008).  
The presence of sulphated GAGs in some invertebrates is now well-documented. Different 
classes of invertebrates have shown that CS/DS, HS-like, and/or heparin-like compounds are 
present in many species (Medeiros et al., 2000). studies have also shown that heparin is 
present in several species of molluscs. A compound from the clam Mercenaria mercenaria 
exhibits several structural similarities to heparin (Jordan & Marcum, 1986). Heparins with 
high anticoagulant activity have been isolated from the molluscs Anomalocardia brasiliana, 
TiVela mactroides (Dietrich et al., 1985; Pejler et al., 1987) and Tapes phylippinarum  
(Cesaretti et al., 2004).  CS, DS, and acharan sulphate have also been isolated and 
characterized from different families of molluscs (Cassaro & Dietrich, 1977; Kim et al., 
1996).  
Whereas HSs and CSs are ubiquitous components of most tissues, heparin has shown a very 
peculiar distribution in mammalian and other vertebrate tissues, as well as invertebrates 
(Medeiros et al., 2000). Furthermore, a large variation of the concentration of heparin among 
species is evident, with the non-mammalian vertebrate tissues showing considerably lower 
amounts. In invertebrates, heparin is found in few molluscs, crustaceans, annelida, 
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echinoderma, and cnidaria, with the anticoagulant activity varying according to the species 
analysed (Nader et al., 2004).  
 
1.7.2    Potential drug development from marine glycan. 
 
Marine sulphated polysaccharides can express their activity on mammal’s biological system 
and provide pharmacological activity with different diseases, such as antithrombotic, anti-
inflammatory, antiangiogenic, and antimetastatic. Sulphated fucan from brown and sulphated 
galactans from red and green algae are well known for their activity as anticoagulants as they 
interact with both antithrombin and heparin cofactor II (Berteau & Mulloy, 2003; Pereira et 
al., 2005). However, the complex, heterogeneous structures of these polysaccharides has 
limited the possibility of identifying specific sequences required for their activity.  Many 
researches, have worked in this field in order to confirm the structure of these 
polysaccharides and the relationships related to their activity. Chemical oversulphation or 
desulphation of the intact chain from these algae has been reported (Haroun-Bouhedja et al., 
2000; Soeda et al., 1993). The results suggest that the activity increases with increasing 
sulphate regions and decreases when the crude or intact pattern of sulphation is reduced. The 
same role is applied to the molecular weight, the activity decreases with smaller molecular 
size of oligosaccharide or polysaccharide (Soeda et al., 1993).  
 In order to identify the structure-function relationships of these polysaccharides, it was 
important to identify clearly oligosaccharides type, glycosidic bonds between the residues, 
and sulphate positions which are required for blood coagulation protein interaction to occur 
that exhibit the anticoagulant process. The effect of the type of saccharide residue, whether 
this was fucose or galactose on modifying anticoagulant activity has  been reported by Pereira 
et al., (2002). Comparisons were made between two different sulphated polysaccharides, the 
active 2-sulphated, 3-linked α-L-galactan and inactive 2-sulphated, 3-linked α-L-fucan, and 
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their ability to modify the activity from active to inactive sequence model. The position of the 
glycosidic linkage in this polysaccharide affected their activity; this was shown by comparing 
two models of sulphated galactans, the inactive 3-sulphated, 4-linked and the active 2-
sulphated, 3-linked α-L-galactans. The effect of the sulphation pattern is important in the 
structure-function relationship; increasing the sulphation content only ∼1.8-fold caused 
extensive increases in their anticoagulant activity of nearly 38-fold. This was linked to the 
occurrence of two, 4-di-sulphated of 3-linked α-L-fucans from 2-sulphated, 3-linked α-L-
fucan  (Mourão, 2004).  
Sulphated fucans have been shown to have angiogenesis inhibition activity. According to  
Koyanagi et al., (2003), some fucoidans have been extracted from Fucus vesiculosus which 
interfere with the binding of VEGF with their receptors. The same interaction between these 
molecules and FGFs with their respective receptors is also reported which causes 
angiogenesis inhibition as a consequence (Soeda et al., 2000).  
 Moreover, apoptosis and cell death due to autophagy in tumour cells was reported as a 
biological activity with some active compounds within sulphated fucans from brown algae. 
Sulphated heparin, fucoidan and Carrageenan lambda are reported to significantly inhibit 
activity toward lung adenocarcinoma in rat. This appears to be due to an interference with the 
passaging process in the tumour cells, which induces early apoptosis and leads to a 
remarkable loss of tumour cells from the lung after one hour, followed by cell death (Coombe 
et al., 1987).  Most of the bioactive compounds in algae are available commercially as an 
intact or crude compound containing sulphated polysaccharide but also contaminated with 
non-glycan compounds. Designing low molecular weight glycans with known sequences of 
saccharide remains unachieved as yet, due to the structural complexity of polysaccharide 
extracted from marine algae. In contrast, a correlation between structure and biological 
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activity is usually relatively easy to identify in marine invertebrates due to the repetitive 
nature of the backbone of disaccharide and their specific sulphation patterns.  
 
1.7.3    Therapeutic value of mammalian glycosaminoglycan in cancer 
 
Glycosaminoglycan and proteoglycans play a diverse role in cancer growth where they 
control cancer cell proliferation and growth. As reported before, GAGs control cell growth 
via cell surface HSPGs that act as co-receptors for several growth factor tyrosine kinase 
receptors. In some cases, the ligands between HSPG and growth factors cleaves by the action 
of heparanase that is known as a β-endoglucuronidase enzyme. This releases the HSPG from 
FGF-FGFR’s complex and leads to the loss of  growth signalling (Bernfield et al., 1999; 
Sanderson et al., 2004).  
Changes in the expression of ECM-degradative enzymes and the expression of cell-surface 
molecules is increasing the ability of cancer cell for invasion and metastasis. HS is degraded 
by heparanase that exists on the cell surface, this is reported to cause loss of syndecan-1 
which in turn promotes association with different host cells and increases cancer cell 
dissemination to other tissues (Ludwig et al., 2004; Ohkawa et al., 2004).  
In some studies, chondroitin sulphate proteoglycan supports cancer stem cell proliferation 
signals and provides a niche for preservation of stem cell properties in terms of DNA 
repairing capacity, apoptosis, and chemotherapy resistance. In some cases, like melanoma, 
chondroitin sulphate proteoglycans act as a specific marker for a class of epidermal stem cells 
(Legg et al., 2003). Modulating glycosaminoglycan/ proteoglycan expression in cancer stem 






1.8    Breast cancer 
 
Among cancer types, breast cancer is well known as a heterogeneous and one that accounts 
for nearly 23% of all cancer diagnoses in women. George Gey was the first to establish 
culturing of cancer cells in the laboratory over 50 years ago. This paved the way to cell 
culture as we use it today, and remains a crucial and developmental experimental tool in 
cancer research. Long after this beginning, histopathologists successfully identified 
heterogeneity in the popultions of cancer cells through morphological observations among 
breast cancer and the classification of breast cancer was based on several measures; including 
tumour grade, lymph node status, histological type and the presence of predictive markers 
such as oestrogen receptor ER and recently epidermal growth factor receptor 2(HER2). 
Breast cancer can be classified into at least five subtypes according to gene expression 
profiling and the immunohistochemically expression of ERα, progesterone receptor (PR) and 
HER2, which has been reported after molecular profiling development (Perou et al., 2000). 
Each subtype has a different response for treatment depending on the therapeutic target. ER 
has become a more powerful therapeutic target for cancer research and drug discovery. 
Therefore, the luminal A and luminal B subtypes are susceptible to hormone therapy along 
with HER2 group. The more difficult type to treat are basal tumours, due to the lack of 
expression of ERα, PR and HER2 and they are collectively known as triple-negative (Badve 
et al., 2011).  
 
1.8.1    Causes, Risk Factors, and Prevention of breast cancer 
 
Many risk factors are associated with developing breast cancer. Gender, age and other 
biological factors like mutant genes, delay in pregnancy, early age at menarche, high level of 
hormones, and late menopause are typically linked with breast cancer. For instance, females 
are more likely to develop this disease especially above age 50 (Key et al., 2001).  
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There is evidence of an increase in the possibility of developing breast cancer by 3% per one-
year delay in pregnancy while childbearing at early ages of 20 years or younger might 
significantly decrease the chance of breast cancer in women (Key et al., 2001). The risk of 
breast cancer is remarkably higher in women with high level of hormones such as oestrogen, 
also the risk might increase with exposure to exogenous hormones, especially for women on 
hormonal replacement therapy, this applies to oral contraceptives and hormonal replacement 
therapy (Chlebowski et al., 2013). Higher risks are expected for patients of combined 
oestrogen and progesterone therapy compared to oestrogen therapy alone (Gierisch et al., 
2013) . 
Carrying the mutant genes BRCA1 and BRCA2 might increase the chance of developing 
breast cancer by 45-56% especially by the age of 70. Although 85% of women identified with 
breast cancer, do not have hereditary predisposition. By contrast 85% of women with a 
familial history unnecessarily develop this disease (Antoniou et al., 2003). Environmental 
factors and life style are also considered as risk factors. High level of consumption of alcohol, 
obesity and less physical activity appear to  have significant impact on developing breast 
cancer (Key et al., 2001).  
 
1.8.2    Epidemiology of breast cancer  
 
Breast cancer is one of the most widely spread cancers especially among women. Female 
mortality and breast cancer incidence rates are variable worldwide, with a high percentage of 
incidence is reported in developed countries unlike developing countries (Boyle & Ferlay, 
2005). However, the percentage of mortality has dropped significantly in developed countries 
due to early diagnosis through implementation of screening programmes with mammography, 
improvement of adjuvant chemo and radiotherapies, decrease of hormonal replacement 
therapy and increase in awareness (Jemal et al., 2010).  
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In the UK it is estimated 1 in 8 women develop breast cancer and the percentage of incidence 
has increased by 6% in last few years, but mortality is reported to have fallen by fifth (Arasta, 
2015).  
 
1.8.3    Histology of normal breast vs histology of breast cancer 
 
The structure of normal human breast is similar in male and female before puberty, there is 
one pair of mammary glands each situated over the pectoral muscles of the chest wall one the 
left and right side of the body. Both pendent from the anterior chest wall, and some fibrous 
strands are involved to assist this called cooper ligaments. There is a conical lifted part in 
each mammary gland called the nipple, which consists tiny size pores of 0.5 mm in diameter 
and the skin surrounding this part has more melanin than other areas of the breast, this called 
areola. In female, the breast structure changes after puberty due to an increase in the 
circulatory concentrations of ovarian hormones, which leads to an increase in the growth of 
the ductal-lobular system and adipose tissue (Russo & Russo, 2004).  
There are 15 to 25 lobes that are surrounding nipple, connecting to each other by a huge 
amount of inter-lobar to produce a net of lobes each terminated in smaller lobes termed 
lobules that are open to the nipple and help with milk transport. The breast size becomes 
noticeably big during the premenstrual phase this due to size increases of ductal epithelial 
cells following the peak levels of oestrogen that happen in this phase in menstrual cycle. The 
morphological and functional changes are enormous during pregnancy and lactation due to 
the action of various hormones like oestrogen, progesterone, prolactin and human placental 




Figure 1-10: Breast anatomy. A: Histology of normal breast. B: Histology of breast 
cancer (Howard M. Reisner 2015).  
        
In breast cancer, there is typical histological morphology that helps with the classification of 
breast cancer. The majority of breast tumours are adenocarcinomas; this could be an invasive 
or non-invasive carcinomas and could diversify as ductal in-situ (DCIS) or lobular in-situ 
(LCIS) carcinomas. In cases of non-invasive carcinomas, the malignant cells remain attached 
to the myoepithelial of the ductal or lobular system, with no invasive action to the 
surrounding area.  
This kind of carcinoma might develop further if it is not treated (Stecklein et al., 2013). 
Women with lobular in-situ (LCIS) carcinomas have a greater chance to develop invasive 
carcinoma and usually they are oestrogen and progesterone receptor positive. This type of 
carcinoma is not yet transformed into the myoepithelial cells but they appear as small 
uniform solid cells filling the central part of affected lobules. Ductal in-situ (DCIS) 
carcinoma is more heterogeneous than lobular carcinoma but the most diagnosed type of non-
invasive malignancy. It could classify into many types such as comedo, cribriform, solid, and 
papillary and micropapillary. In this type, malignant cells appear in irregular shapes and 
contain a central necrosis area and large numbers of the mitotic figures. It has three different 
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morphologies, the solid sheet of cells form, called solid ductal carcinoma in situ, while it 
termed cribriform ductal carcinoma in-situ when there are spaces between cells, whereas if 
they form a finger-like structure, they are termed micropapillary ductal carcinoma in-situ 
(Viale, 2012).  
Invasive carcinoma is the term used when epithelial tumours penetrate and affect the 
surrounding tissues. This type can again be classified into two groups invasive ductal 
carcinoma and invasive lobular carcinoma. Invasive ductal carcinoma (IDC) is the most 
widespread type, with no specific macroscopic shape; they have a good chance of 
metastasising to different parts of the body via the lymphatic system or bloodstream. They 
are reported as positive express HER-2 receptor within 30% (Stecklein et al., 2013). 
Invasive lobular carcinoma (ILC) is the second most popular type of breast tumour. Unlike 
invasive ductal carcinoma, this type has more regular shaped cells with irregular ovoid nuclei 
appearance, and are usually found as oestrogen and progesterone receptor positive (Viale, 
2012).  
 
1.8.4    Molecular profiling of breast cancer 
 
Depending on the gene expression profile, breast cancer can be classified in to two essential 
groups, oestrogen receptor-positive and oestrogen receptor-negative tumours. These groups 
have further been classified into different subgroups depending on the cluster analysis of 
genome and transcriptome expression known as luminal A, luminal B, HER-2 positive, 
triple-negative or basal-like tumours, claudin-low and normal-like breast tumours (Malhotra 
et al., 2010; Perou et al., 2000).  
Luminal A tumours are reported to show a variety of gene cluster expression. They are 
positive for an oestrogen receptor expression, negative for expression of HER-2 and have a 
low expression level of Ki-67 protein (Rakha et al., 2008).  
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Luminal B tumours have positive expression for an oestrogen receptor-related gene cluster 
and HER-2. Unlike luminal A tumour, this subtype has a significant level of expression for 
Ki-67 and high proliferation rate. The third subtype of breast cancer is a HER-2 enriched 
subtype that reportedly overexpresses for HER-2 with poor prognosis and no expression for 
the oestrogen receptor-related gene cluster  (Eroles et al., 2012) 
Basal-like tumours, classified as triple-negative tumours share many common characteristics, 
such as no expression profile for oestrogen receptor, progesterone receptors or HER-2. 
However, it has been reported that 15-45% of basal-like tumours might express either 
oestrogen or progesterone receptors or HER-2, unlike triple-negative tumours. This subtype 
expresses cytokeratin five and six (CK 5/6) and epidermal growth factor receptor (Nielsen et 
al., 2004; Rakha et al., 2008). 
Triple-negative breast cancer is reported with the highest rate of mortality among other 
subtypes, particularly in black African American or British black younger women in age less 
than 50 years (Huo et al., 2009). According to Turner et al., (2010), there are several 
subtypes of triple-negative breast cancer confirmed based on gene their gene expression 
profile, which are mesenchymal, mesenchymal-stem like, immunomodulatory, a luminal 
androgen receptor-positive, and two basal-like BL1 and BL2 genes.  
A new subtype of breast cancer was recently reported known as claudin-low subgroup 
(Herschkowitz et al., 2007). This subtype shares many properties with the basal-like tumours 
regarding low gene expression profile for oestrogen, progesterone receptors or HER-2, 
luminal epithelial and also has a poor prognosis. However, it has  a high level of expression 
for some markers like epithelial to mesenchymal transition genes , also cancer stem cell-like 
features and immune response genes (Prat et al., 2010). Breast tumour gene expression 
profiles have been identified with significantly low expression of luminal epithelial cell genes 
(Parker et al., 2009). 
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1.8.5    Role of metastasis in breast cancer 
 
Metastasis is the process by which the cancer spreads to distant parts of the body, and is 
considered as a final step in the cancer progression. The mechanism of metastasis starts from 
growing primary cancer cells in the regional tissue then detachment of the cancer cells from 
the primary tumour, invasion through the myoepithelium to the nearby lymph nodes, or travel 
into blood stream and subsequent spread to other organs. Both genetic alterations and 
environmental factors are involved, with monoclonal and polyclonal expansion of the tumour 
considered as one of the main factors for formation of the premalignant lesions that turn to 
invasive tumours later on (Valastyan & Weinberg, 2011). Only a small populations of cells 
within the primary tumour have the ability to induce metastasis, which are termed circulating 
tumour cells (CTC).  Understanding the mechanism of invasion and  transition is important in 
early detection of CTC in the blood stream, which is the key point to identify early spread of 
the tumour and prevent metastasis process in the patient (Maheswaran & Haber, 2010). 
Breast cancer has a high capability to induce metastasis. The first potential recurrence site of 
breast cancer is the bone, followed by lung or liver and the central nervous system. 
Recurrence is reported between 2 to 3 years after the surgical treatment. This might be higher 





                                      Figure 1-11: Metastasis in breast cancer.  
                                           Modified from (Weigelt et al., 2005) 
 
 
1.8.6    Treatment options for breast cancer 
 
There are many therapeutic options for breast cancer treatment. The early stage of 
identification, mainly starts with surgery which could involve either a lumpectomy or 
mastectomy operation, followed by a combination of adjuvant therapies such as radiotherapy, 
chemotherapy, endocrine therapy, molecular targeted therapies such immunological therapies 
and cytotoxic chemotherapy (Vilarino-Varela et al., 2009). 
Radiotherapy might assist a patient with oestrogen receptor-positive better than oestrogen 
receptor-negative and triple-negative breast cancer. In this therapy, high energy X-rays or 
other types of irradiation are employed and delivered to the lymph nodes or chest wall 
including the surgical scar. This increases the overall survival via reduced recurrence and 
breast cancer death among the breast cancer patients (Group, 2011). 
Other treatment agents for breast cancer include systematic treatment, which is typically used 
for removing metastatic disease. It involves chemotherapy, hormonal therapy and other 
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targeted therapies. It might apply prior to surgery to shrink larger tumours or after 
lumpectomy or mastectomy. Conventional chemotherapy initially controls tumour growth by 
inducing cell death and preventing cell proliferation. However, small cell populations with 
tuomurigenic potential may express resistance to chemotherapy, the number of these cells is 
expected to increase after the treatment. Consequently, the gene expression profile in tumour-
resistant cells will be different before and after treatment, especially genes involved in cell 
cycle arrest and survival pathways (Li et al., 2008). Chemotherapy is widely applied to 
Oestrogen receptor negative or HER-2 positive patients than other subtypes breast cancer 
patients.  
In those patients with oestrogen and or the progesterone receptor positive, endocrine therapy 
is highly effective on ER+ metastatic breast cancer and improves patient survival. Like 
chemotherapy, this approach will lead to resistance over the time. The mechanism of action 
of endocrine therapy involves blocking the ER pathway, this induces deregulation within the 
ER pathway and alterations in cell survival signalling, such as increased signalling of growth 
factor receptor pathways, especially the EGFR/HER2 pathway. Therefore, a new 
combination therapy of endocrine therapy plus chemotherapy has been used in targeting both 
ER and growth factor receptor signalling which blocks the interaction between 
aforementioned pathways and reducing the possibility for creating escape-signalling routes 
(Clark et al., 1984; Osborne & Schiff, 2011). 
There are two anti-oestrogen drugs used in endocrine therapy known as Tamoxifen and 
aromatase inhibitors. Tamoxifen acts as anti-cellular proliferation agent via preventing 
oestrogen-regulated gene transcription, this could occur because of conformational changes 
in the receptor after Tamoxifen binding to oestrogen receptor. This modification in the 
receptor eventually inhibits access to one of the co-activator interaction surfaces that are 
important in cell proliferation process (Johnston & Yeo, 2014; Osborne, 1998). 
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Aromatase inhibitors act as an alternative or in a sequential order after initial tamoxifen 
therapy by reducing the level of circulating oestrogen by more than 80% in postmenopausal 
women, therefore, clinical studies have reported highly effective results on women with 
metastatic breast cancer (Brueggemeier, 1994). 
Molecular targeting therapy is another example of a breast cancer therapeutic system. It 
involves targeting molecules that play exceptional roles in cell proliferation and promoting 
cancer. This type of treatment is known as biotherapy.  
There are several examples of molecular that has been developed as biotherapy, such as 
tyrosine kinase inhibitors, which inhibit the additions of a phosphate group to the protein 
tyrosine kinase (phosphorylation) and lead to inactivation this protein, and PARP (Poly 
(ADP-ribose) polymerase) inhibitor enzyme activity, thus preventing the repair of DNA 
damage. The PARP is widely used in combined therapy for treatment of triple-negative breast 
cancer (Munagala et al., 2011). 
Some clinical data have shown sensitivity of triple-negative tumours to the above-mentioned 
therapeutic options. In addition, some resistance has reported with the new generation of 
targeted cancer therapeutics, which look similar in mechanisms of resistance to endocrine 
therapies, this due to reactivation of the signalling pathway that has not fully block at the first 
attempt.  
 
1.9    Malaria  
 
Malaria is the second disease that has been targeted by whelk GAG treatment in this study. 
Well known as a fatal tropical disease, the infection is caused by a single mosquito bite, 
through which the Plasmodium parasite that cannot survive outside the host, is transferred 
into the red blood cells. Only the female of certain species of Anopheles mosquito can 
transmit malaria when they take a blood meal for egg development. The parasite develops 
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inside the mosquito in stages, from gametocyte to sporozoite, and several factors, such as 
temperature and humidity, allow the parasite to complete its cycle in the mosquito host. The 
majority of malaria deaths are caused by a severe infection with Plasmodium falciparum, 
Plasmodium vivax being the second most common species to cause infection. Two other 
species, P. malariae and P. ovale, are responsible for a small percentage of infection across 
the world (Urbán et al., 2011). 
Symptoms appear between 7 to 18 days after infection and include fever, sweats and chills, 
headaches, vomiting, muscle pains and diarrhoea. In some cases, symptoms might not appear 
for up to a year or more after infection. According to recent estimates, approximately 300-
500 million people suffer from this disease, the majority of them in sub-Saharan Africa and 
Colombia, and 2-3 million people die of malaria every year (Vangapandu et al., 2007).  
The life cycle of the Plasmodium parasite in the human body begins when an infected female 
Anopheles mosquito takes a blood meal and inoculates sporozoites into the bloodstream. 
Having entered the liver and infected hepatocytes, the parasite proliferates into thousands of 
merozoites, which then rupture from the hepatocytes and invade the red blood cells (RBCs), 
where they develop into early trophozoites known as ring forms and then into the late form 
schizonts. The blood cycle begins again when schizonts infect RBCs and release more 
merozoites that may develop into male and female gametes. At this point the parasite can be 
transmitted to another person through the bite of a female Anopheles mosquito once it 






                                        Figure 1-12: The life cycle of malaria. 




Most of the symptoms and pathologies appear at the blood cycle infection stage, which 
makes it the main target stage for most antimalarial therapeutic agents available currently 
(Griffith et al., 2007).  
Treatment options and length of treatment depend on several factors, such as the type of 
malaria, the severity of the symptoms, the country in which the infection took place, whether 
the patient took an antimalarial to prevent the disease and whether the patient is pregnant. 
There can be serious complications from malaria, including severe anaemia, in which the red 
blood cells are unable to carry enough oxygen around the body, and cerebral malaria in which 
small blood vessels in the brain become blocked, causing brain damage and coma. Currently, 
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antimalarial drugs have many limitations, such as varying degrees of toxicity and the 
existence of certain strains of parasite that have developed resistance to antimalarial 
treatments as a result of low doses that are required to avoid the toxicity; together these 
factors create an urgent need to discover and develop new strategies and novel approaches to 
treating malaria in addition to combined therapy approaches (Wells et al., 2009).  
 
 
1.10    Aims  
 
The bioactive compounds isolated from marine organisms play a key role in many biological 
processes according to many in vivo and in vitro models. However, many bioactive molecules 
and structures from different marine species remain to be discovered. The therapeutic values 
of these bioactive polymers is increased by identifying their fine structure and using this 
information to design small molecular weight fragments. Structure elucidation of GAG’s 
from natural products is a big challenge with respect to their complexity.  
In this study, the overall aims are to elucidate the structure of a complex GAG isolated from 
whelk (marine invertebrate), and monitor their bioactivity of on several types of cancer cell 
lines in vitro. Finally, the project focused on the mechanism of action of these compounds 
and their ability to control cell growth via inducing apoptosis or cell death among triple 
negative breast cancer. These types of breast cancer require urgent action to find alternative 
therapeutic agents.  
This will be achieved in several stages; Firstly, identification of active compounds from the 
complex GAG chain mixtures isolated from whelk providing further understanding of the 
molecular composition of the whelk GAG derivative that may responsible for inhibition of 
cancer cell proliferation. Intact GAGs will then be isolated from the soft body of whelks and 
enzymatic degradation applied to produce fragments that will test for cancer cell growth 
inhibition. The fragments analysed by high performance liquid chromatography (HPLC-MS) 
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using isotopic aniline tagging, GC-MS, quantitative analysis of monosaccharides by high 
performance anionic exchange chromatography-pulse amperiometric detection HPAEC-PAD 
and an extensive structure activity study and comparison with mammalian GAGs. 
The second objective to examine the bioactivity of the intact and fragmented GAG chains on 
several cancer cells in vitro.  
Final objective to characterise the mechanism of action of the bioactive compounds from 
whelk on triple negative breast cancer cell lines, by exploring the signalling or other pathway 
involved directly, or indirectly, in cell proliferation by quantifying the total protein 
differentially expressed with and without certain GAG concentrations using label free 
proteomics approaches and pathway analysis.  
This study also aimed to determine the ability of these compounds to inhibit a small 
population within the breast cancer cells that have stem cell activity by using mammosphere 
assay on two subtypes of breast cancer.  
Finally, this study aimed to examine the activity of whelk GAGs on another fatal diseases 
such as malaria, where there is an urgency to develop a new therapeutic agent against malaria, 
especially after significant increases in developing resistance toward several 


























2.1    Materials 
 
All materials and buffer recipes listed in detail in appendix I.  
 
2.2    Methods 
2.2.1    Method of GAG isolation from soft body of Whelk. 
 
Crude GAGs were extracted as a white powder from shellfish common whelks (Buccinum 
undatum), the shell was removed and the whole soft body was defatted by incubation with 
acetone for 72 hours. The acetone was changed every day and then the whelks left to dry for 
24-48 hours. A blender was used to convert the fat-free dried whelks in to a powder. 
Following the extraction methods from (Kim et al., 1996), 4 grams of the powder was 
suspended in 40 ml of 0.05 M of sodium carbonate buffer with a pH of 9.2, then 2 ml of 
Alcalase enzyme was added to degrade protein and release GAG chains, this step takes 
approximately 48 hours at 60°C with constant agitation of 200 rpm. The mixture was cooled 
at 4 °C then 5% (w/v) trichloroacetic acid was added to the sample and mixed to precipitate 
peptides. After 10 minutes the mixture was centrifuged at 8000 rpm for 20 minutes. Three 
volumes of 5% (w/v) potassium acetate in ethanol were added to one volume of supernatant 
and the solution was stored at 4 °C overnight then centrifuged for 30 minutes at 8000 rpm. 
The precipitate, approximately 1 g, was dissolved in 40 mL of 0.2 M of NaCl solution and 
centrifuged at 8000 rpm for 30 minutes and the supernatant was discarded. Cetylpyridinium 
chloride (0.5 mL of 5% (w/v) solution) was added to the supernatant followed by 
centrifugation to recover the precipitate, which was subsequently dissolved in 10 ml of 2.5 M 
of NaCl. Finally, 5 volumes of ethanol were added and the precipitate obtained by 
centrifugation for 30 minutes at 10000 rpm. The precipitate was then dialyzed against water 
for 72 hours. The water was changed twice every day and then the sample was lyopholyzed 




                                 Figure 2-1: Whelk GAG extraction process. 
  
2.3    Enzyme Preparations  
 
Two types of enzymes were used in de-polymerisation of intact GAG chain. First, 
heparinaise fractions and second, chondroitinase ABC enzymes.  
 
2.3.1    Preparing of Hep lyase  
 
Heparanases were supplied by Grampian Enzymes. Three different subtypes of this were 
used (Heparanase I (EC 4.2.2.7), 2 IU, Heparanase II, 0.25 IU and Heparanase III (EC 
4.2.2.8), 0.5 IU). The enzyme buffer used was 50 mM sodium acetate, 0.5 mM calcium 
acetate pH 7.0.  All enzymes were adjusted to 1.0 IU/ml by adding 1X heparinase buffer 
containing 10μg/ml of BSA as stabiliser, then split into 100 μl aliquots each containing 
enzymes at 1.0 IU/ml. These stocks were stored at -80 ˚C. The working stocks are prepared 
by taking one of the above aliquots and diluting to a concentration of 200 mIU/ml by adding 
400 μl of fresh 1X hepar inase buffer without BSA to make up to a volume of 500 μl of 
enzymes to a final concentration of 200 mIU/ml and stored at -20 ˚C.  
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2.3.2    Preparation of ABC lyase 
 
Chondroitinase supplied from IBEX Pharmaceuticals Inc. (Montreal, QC). Two fractions of 
chondroitin sulphate lyase from Flavobacterium heparinum used. AC (EC Number 4.2.2.5) 
enzyme cleaves sulphated and non-sulphated polysaccharide chains containing 1-4 linkages 
between hexosamines and glucuronic acid residues. The reaction yields oligosaccharide 
products mainly disaccharides containing unsaturated uronic acids, which can be detect by 
UV spectroscopy at 232 nm. The enzyme is active on chondroitin sulphates A and C and 
hyaluronic acid, but is not active on dermatan sulphate (chondroitin sulphate B), also active at 
pH range 3.5 – 9 with chondroitin sulphate A, and 4.5 - 9 with chondroitin sulphate C. The 
enzyme Chondroitin B (E.C. 4.2.2.19) cleaves polysaccharide chains containing 1-4 linkages 
between hexosamines and iduronic acid residues in dermatan sulphate (chondroitin sulphate 
B). The reaction yields oligosaccharide products mainly disaccharides containing unsaturated 
uronic acids, which can be detected by UV, spectroscopy at 232 nm, the pH range for activity 
is 5 – 10.  The stock split into small Eppendorf tubes each containing 1.5 μl aliquots kept 
frozen at – 70 °C at 5IU/ µl concentration.  
 
2.4    Enzymatic digestion 
2.4.1    Enzymatic degradation of Heparan Sulphate (GAG-HS) 
 
The starting material for this procedure was 100µg dried, desalted GAG’s from whelk, which 
was dissolved in heparinase buffer prior to digestion of HS/Hep (50 mM sodium acetate, 
0.5mM calcium acetate pH7.0). A mixture of Heparinase I, II and III (30mIU/ ml HepI, 16 
mIU/ ml Hep II, 16 mIU/ ml Hep III) was added and the polysaccharide digested at 37 °C for 
24 hours, the reaction was terminated by heating at 100 o C for 5 minutes. The sample was 




2.4.2    Enzymatic degradation of Chondroitin Sulphate (GAG-CS)  
 
The starting material for this procedure was 100 µg dried, desalted GAG’s from whelk, 
which were dissolved in 50 mM Tris-HCl/ 50 mM sodium acetate pH 8.0 buffer. A mixture 
of Chondroitinase ABC (1.5 µl) of 5 IU/µl AC + (1.5 µl) of 5 IU/µl B was added and the 
polysaccharide was digested at 37 °C for 24 hours, the reaction was terminated by heating at 
100 o C for 5 minutes. Sample was run with gel filtration chromatography. 
 
2.5    Standard Preparation of HS and CS 
 
A standard commercial porcine intestinal mucosal heparan sulphate and chondroitin sulphate 
were provided from Celsus (Cincinnati,OH, USA). All standards were digested with 
hepinases and chondritionase lyase at 37 °C for 24 hours, the reaction was then terminated by 
heating at 100 oC for 5 minutes, the mixture was fractionated using a 10,000 MWCO filter to 
remove enzyme and undigested GAG chains, which were then used as standards in all 
analytical techniques and bioactivity screening assays.  
 
2.6    Size exclusion analysis  
 
Aliquots of 100 µl containing 100 µg of crude mixture of whelk GAG and a corresponding 
concentration of each intact HS/CS standards and digested GAG/HS, GAG/CS were applied 
to a superdex 75 10/300 GL gel filtration column from GE healthcare (Bed Volume 24 ml), 
The column was pre-equilibrated with PBS (phosphate buffered saline, 0.15 M NaCl, 20 mM 
Na2HPO4) pH 7.2, then the sample was applied and eluted from the column at a flow rate of 
1.0 ml/min, this was monitored for absorbance at 232 nm. The data was validate by using a 





                 Figure 2-2: Size exclusion analysis of GAG samples and STDs. 
  
 
2.7    Quantitative analysis of Monosaccharides by HPAEC-PAD 
 
Samples containing 1 mg of crude GAG were dissolved in 1 ml deionized water, and a 100 µl 
(10% GAG) aliquot was treated with 100 µl of 4N trifluoroacetic acid, 4N TFA (prepared by 
adding 2.375 ml deionised water to 1.00 ml of 13.5 M TFA, this provides a stock with 4N 
TFA) at 100°C for 4-6 hours to cleave all glycosidic linkages including uronic acids. 
Following hydrolysis sample tubes were removed from the heating block and allowed to cool 
to room temperature. The samples were centrifuged at 27000 rpm for 3 minutes to bring 
down any condensation on the sides and cap of the tube. Excess acid was evaporated by dry 
nitrogen flush for 10 minutes, and repeated co-evaporation with 70 µl of 50% isopropanol to 
get rid of the acids completely. Finally, the samples were dissolved in 100 µl deionised water 
and spun down, then analysed by HPAEC-PAD using a CarboPac PA-1 column 4 mm x 250 





A: Water.  
B: 100 mM sodium hydroxide (NaOH) with 5 mM (sodium acetate trihydrate) NaOAc 
(Appendix I). 
Initial conditions of 16% B at 1.0 mL/min were applied, a pulsed amperometric detector PAD 
was used in this system. In PAD applications, the electrode is automatically cleaned and 
prepared for detection by each cycle of the programmed series of potentials (i.e., the 
waveform), thereby minimizing electrode fouling by oxidation products of the analyte and 
other sample compounds, and thus maintaining consistent response. 
Monosaccharide standards were treated in parallel and used for calibration of HPAEC-PAD 
response. Table 2-1 shows the gradient settings used for monosaccharides analysis. 
 
Table 2-1: The gradient settings used for monosaccharides. 
Time/mins %A %B 
0 84 16 
20 84 16 
21 0 100 
31 0 100 
32 84 16 
50 84 16 
            
 
 
2.8    Ion exchange of intact GAG  
 
Small Polyprep column from BioRad was packed with 500 µL of DEAE Sephacel (GE-
Healthcare), the bed was calibrated with 5 mL of Diethylaminoethyl DEAE Pre-wash buffer 
(see Appendix I). 1 mg crude GAG was dissolved in 500 µl deionised water, 250 µl was 
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loaded onto the column, then the column was washed with 5 mL DEAE washing buffer (see 
Appendix I), this is called flow through buffer (more information provided in appendix IIII). 
The GAGs were eluted by adding 2.5 mL of DEAE elution buffers (1,2 and 3) (see Appendix 
I), each fraction was collected separately. All samples were de-salted using PD-10 column.  
 
2.9    PD-10 de-salting technique 
 
PD10 columns from GE-Healthcare were used for desalting and buffer exchange. samples 
preparation in the range of 1.0 to 2.5 ml by gravity flow was carried out. Desalting capacity 
was greater than 90%, the recovery was in the range of 70 to >95%. Bed dimensions were 
14.5× 50 mm and the columns were prepacked with Sephadex G-25 medium. The column 
was prepared by washing 6X with 10% ethanol, then 1 ml of sample was loaded and washed 
with 2.5 mL of 10% ethanol, the first 2.5 mL of elutant discarded as it is the void volume of 
the column.   The next 3.5 mL of 10% ethanol were collected and lyophilised. 
 





2.10    Enzymatic degradation of ion-exchange fractions  
 
The crude GAG was purified depending on the charge groups using ion exchange 
chromatography as mentioned above. Three fractions were collected, each eluted with 
different gradient of NaCl salt. Samples were coded as: 
 CK1 for1M NaCl. 
 CK2 for 2M NaCl. 
  CK3 for 3M NaCl.  
100µl (10%) of each fraction was prepared for monosaccharide quantification analysis, and 
70µl (7%) was injected in the system (more details about the calculation provided in 
appendix III). According to the amount of substrate provided in each fraction, 10 µl from 
CK1 and 62.5µl of both CK2 and CK3 were used as starting material for enzymatic 
depolymerisation.  
 
2.10.1    Degradation of HS fractions 
 
Each ion exchange fraction CK1, CK2 and CK3 was incubated with a mixture of Heparinases 
(I, II and III) in the amounts set out below for 24 hours. The same protocol was applied to 
standard porcine HS.  
CK1- 10µl Substrate + 30mU HepI + 16mU Hep II+ 16mU Hep III. 
CK2- 62.5 µl Substrate + 30mU HepI + 16mU Hep II+ 16mU Hep III. 
CK3- 62.5 µl Substrate + 30mU HepI + 16mU Hep II+ 16mU Hep III. 
HS-Std.- 10 µl Substrate + 30mU HepI + 16mU Hep II+ 16mU Hep III. 
All samples were fractionated using a 10,000 MWCO filter to remove enzyme and 
undigested GAG chains, then centrifuged at 14000Xg for 20 minutes. The flow through (the 
material in the bottom of the Eppendorf tubes) was collected as digested oligosaccharide, 
mainly disaccharide, and lyophilised for further analysis. The retained fraction of the filtrate 
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(the material on the top of the filter in the Eppendorf tubes) which is mainly undigested 
material or enzyme was also dried down for further investigations.   
 
2.10.2    Degradation of CS fractions 
 
Each sample fraction CK1, CK2 and CK3 was incubated with CS-ABC lyase for 24 hours. 
The same protocol was applied to standard CS. The amounts of enzyme used are set out 
below: 
CK1- 10µl substrate + (1.5 µl) of 5 IU/µl AC + (1.5 µl) of 5 IU/µl B. 
CK2- 62.5 µl substrate + (1.5 µl) of 5 IU/µl AC + (1.5 µl) of 5 IU/µl B. 
CK3- 62.5 µl substrate + (1.5 µl) of 5 IU/µl AC + (1.5 µl) of 5 IU/µl B. 
 CS-Std.- 10 µl substrate + (1.5 µl) of 5 IU/µl AC + (1.5 µl) of 5 IU/µl B. 
All samples were fractionated by 10,000 MWCO filter to remove enzyme and undigested 
glycosaminoglycan chains, then centrifuged 14000Xg for 20 minutes. The flow through in 
the bottom of the Eppendorf tubes was collected as digested oligosaccharide mainly 
disaccharide, and lyophilised for further purification methods. The retained fraction of the 
filtrate which is mainly undigested material or enzyme was also dried down for further 
analysis.   
 
2.11    LC/GC-MS Techniques  
 
TMS derivatisation analysis of polysaccharide by GC-MS and isotopic aniline tagging for 
GAG disaccharide analysis by mass spectrometry (GRIL-Glycan Reductive Isotope Labelling) 
were used for composition analysis and mass detection of disaccharide yield from both HS 





2.11.1    Isotopic Aniline tagging for GAG disaccharide analysis by mass spectrometry 
(GRIL-Glycan Reductive Isotope Labelling) 
 
15 µl of 12C6 aniline and 15 µl of 1 M of 95% Sodium cyanoborohydride/Sodium 
cyanotrihydridoborate (NaCNBH3) (Sigma-Aldrich) freshly prepared in dimethyl sulfoxide: 
acetic acid (65:35 v/v), and added to each GAG fractions from ion exchange chromatography 
(CK1, CK2 and CK3), each at concentration mentioned in sections (2.11.1 and 2.11.2) 8 
pmol of HS and CS standard disaccharides were used and mixed with the tagging buffer 
above. 
Reactions were carried out at 37 °C for 16 hours, and then dried in a centrifugal evaporator. 
After complete sample tagging with 12C6 aniline, 17µl of LC-MS grade water (water, 8 mM 
AcetAcid, 5 mM DBA) was added to each fraction (CK1, CK2 and CK3), mixed gently to 
produce homogenate mixture, sample spun down at 14000Xg for 7 minutes, then 5 µl was 
taken to LC-MS vials and spiked with 2 µl of 8pmol internal 13C6 aniline tag, 1 µl of 10X 
GRIL buffer and 2 µl of LC-MS water were added to bring up the mixture to the total volume 
of 10 µl, only 4 µl was injected to the system. A quaternary high-performance liquid 
chromatography pump (Thermo-Finnigan, San Jose, CA) was used for disaccharide analyses. 
Aniline isotopic disaccharide and non-isotopic disaccharides were separated on a C18 
reversed-phase column (0.46 cm x 25 cm, Vydac) with the ion pairing agent dibutylamine 
(DBA, Sigma-Aldrich). The gradient system used is shown below: 
 100% buffer A contained (8 mM acetic acid, 5 mM DBA) - 10 minutes 
 17% buffer B contained (70% methanol, 8 mM acetic acid, 5 mM DBA)- 15 minutes. 
 32% buffer B for 15 minutes.  
 40% buffer B for 15 minutes. 
 60% buffer B for 15 minutes. 
 100% buffer B for 10 minutes. 
 100% buffer A for 10 minutes. 
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Most disaccharides eluted in 60% buffer B (42% methanol), classic quadrupole ion trap mass 
spectrometer equipped with an electrospray ionization source was used, negative ion mode 
was used to observe ions of interest. The capillary temperature and spray voltage were kept at 
140 °C and 4.75 kV to decrease in-source fragmentation of sulphated disaccharides.  
 
2.11.2    Trimethyl Silyl derivative for GC-MS (TMS) 
 
GC-MS (TMS) is a powerful tool that successfully analyses methyl glycosides of neutral and 
N-acetylated amino sugars and methyl esters of uronic acids using either DB-1 or DB-5 
capillary column.  Trimethylsilyl derivatives of these sugars can be detected from their 
retention times by electron impact (EI) ionization mass spectrum comparing to standards.  
For the material used in this experiment see appendix I. The standard and sample preparation 
were as below:  
 1 M Methanolic-HCl:  1 mL of 3 M Methanolic-HCl slowly dissolved with 2 mL of 
cold Methanol on ice in a glass screw-top tube. 
 Standard Preparation:  To prepare the TMS standard 10 µg of each sugar placed 
into a glass sample tube along with 1 µg of myo-inositol, as an internal standard and 
lyophilize.  
 Sample Preparation:   100 µg of sample was taken in a glass screw cap tube and 1 
µg of myo-inositol added and lyophilize. 
PROCEDURE 
1. 200 µL of 1 M Methanolic-HCl added to the sample and tap gently to mix. The screw cap 
tightens, and incubated overnight (16-18 hr) at 80 oC. 
2. The sample cooled to room temperature, and then the Methanolic-HCl removed by dry 
nitrogen flush, and then 100 µL of methanol added to remove residual Methanolic-HCl and 
the sample brought to dryness using nitrogen flush. 
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3. Next re-N-acetylate the samples by adding 4:1:1 Methanol:Pyridine:Acetic Anhydride to a 
final volume of at least 200 µL. the tubes tightly caped and incubate at 100 oC for 1 hr. 
4. The sample cooled again to room temperature and brought to dryness using dry nitrogen 
flush. 
5. Samples derivatized with the addition of 200 µL of Tri-Sil HTP Reagent, re-caped and 
heated at 80 oC for 30 min. Samples cooled down and removeed excess Tri-Sil HTP by dry 
the samples by dry N2 flush. 
6. 1 mL of hexane added to each sample and then vortexed and sonicated to break up the 
dried sample. Next, centrifuged for 2 min at 2000 rpm. 
7. The sample filtered through a Pasteur pipette packed with glass wool. The glass wool 
prepared first by washing with a small amount of hexane. 
8. The filtrate collected and the hexane removed by dry nitrogen flush. 
9. The samples reconstitute in 100-150 µL of dichloromethane and transfer into a sample vial 
for analysis by GC-MS. 
GC-MS SETTINGS: 
Carrier Gas: Helium 
Inlet Conditions : 
Temperature: 220 oC 
Pressure : 12.897 psi 
 
GC-MS Transfer Line Temp: 280 oC 
Column: DB-5 or Equivalent, 30 m x 0.25 mm x 0.25 µm 
Column Flow: 1.1971 mL/min 
Injection Volume: 1 µL 




Table 2-2: GCMS conditions setting.  
Conditions  oC/min oC Hold Time 
(min) 
Run Time (min) 
 Initial    100  0  0 
 Ramp1  5  120  1  5 





Figure 2-4: Sugars reduction with sodium borohydride following conversion of polyols 
to polyacetate esters, then formation of TMS ethers of sugars. 
  
2.12    Periodic acid oxidation (H3IO4 or H5IO6) 
 
Periodic acid oxidation is used for polysaccharide structure elucidation and to determine the 
size of the ring by oxidation of carbon-carbon bonds between the alcohol and carbonyl group 
or adjacent diol (vicinal), each broken bond will be replaced with an OH group, in the case of 
two OH group at one carbon it will transform to a carbonyl group by losing water and no 
effects reported on ethers or acetals. Carbonyl compounds in formaldehyde might oxidize to 
formic acid or aldehydes, while ketones oxidise to carboxylic acids then to CO2. 
975 µl from CK1 was mixed with an equal volume of 2M buffer containing 0.1 M sodium 
acetate, pH 5.8, 40 µg of sodium metaperiodate, dissolved at 4 ºC for 56 hours in the dark. 
Ethylene glycol (150 µl) was added to stop the reaction, the mixture incubated for 30 mins. 
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100 µg of sodium borohydride was then added and the mixture neutralised with 25% acetic 
acid on ice. Dialysis was carried out for two days and the material dried down for further 
monosaccharide analysis and bioactivity screening.  
  
2.13    NMR spectrometry  
 
NMR spectra were recorded at Manchester Institution of Biotechnology/ NMR service using 
Brucker NMR spectrometer operating at a 1D and 2D frequency of 800 MHz at room 
temperature and 70ºC. 1H-NMR for whelk-GAG sample fractions from ion exchange 
chromatography were recorded at pharmaceutical research centre in UCSD using Brucker 
NMR for ID frequency of 600 MHz at room temperature. For NMR experiments, the total 
amount of 5mg of each fractions CK1, CK2, CK3 and crude GAG was dissolved in 500 µl 
deuterium oxide (Sigma Aldrich 151882-10X1ML). The chemical shifts from 1H-NMR 
spectra, total correlated spectroscopy TOCSY, and hetero nuclear single quantum coherence 














2.14    Cell culture 
2.14.1    Cell lines studied 
 
Several human cancer cells were used in this study and are illustrated in detail in table 2-3. 
 
Table 2-3: List of cell lines studied, classification, immune profile and complete growth 
media. 
 





1 MDA-MB-468  
Breast adenocarcinoma 
Basal ER-, PR-, 
HER2- 
DMEM +10%fetal 




Claudin-low ER-, PR-, 
HER2- 
DMEM +10%fetal 




HER2 ER-, PR-, 
HER2+ 
DMEM +10%fetal 




Luminal A ER+, PR+/-, 
HER2- 
DMEM +10%fetal 
bovine serum+2 mM 
Glutamine 
5  A549 
Lung Carcinoma 
- - DMEM +10%fetal 
bovine serum+2 mM 
Glutamine 
6 K562 
chronic myelogenous leukemia 
- - RPMI1640+10%fetal 
bovine serum+2 mM 
Glutamine 
   
 
2.14.2    Routine cell culture 
 
All adherent cell lines (MDA-MB-468, MDA-MB-231, SK-BR3, MCF-7, and A549-Lung 
Carcinoma) were cultured as monolayers while K562 were cultured as suspension cells. All 
cells were maintained at 37 oC in a humidified 5% CO2 atmosphere. The complete growth 
media used to culture adherent cells contain Dulbecco’s Modified Eagle’s Medium (DMEM-
w/1,0 g/L glucose w/o L-Glutamine/ BE12-707F) from Lonza then 10% FBS (500 mL- FB-
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1090/500) and 2 mM L-Glutamine (100 mL- XC-T1715/100) from Lab Tech (UK) were 
added. K562 also were cultured in Lonza RPMI1640 w/ 25 mM HEPES w/o Gln, 500 ml-
BE04-558F without L-glutamine, liquid, sterile-filtered, suitable for cell culture from SLS, 
then 10% FBS (500 mL- FB-1090/500) and 2 mM L-Glutamine (100 mL- XC-T1715/100) 
from Lab Tech (UK) were added. Cells were grown in tissue culture flasks T-25 (Vented 
Filter Cap, TC-Treated-Green-30 x 10- CC7682-4825) from Star lab to approximately 70-80% 
confluence then media were removed and cells washed with warm PBS pH 7.4 (10010023-
Thermo fisher scientific) prior to trypsinization. Cells were detached by incubation in 1ml of 
1x trypsin-EDTA solution at 37 °C for 5-10 minutes (Trypsin 0.25% - EDTA in HBSS w/o 
Calcium w/o Magnesium w/phenol red 100ml- CC-5012) from Lonza (UK). Cells were 
collected by centrifugation at 1500 rpm for 5 minutes and resuspended into fresh media.  
Medium was renewed 3 times per week from 24 hours after each seeding. Each cell line 
reseeded at specific dilution ratio as below: 
 
 MDA-MB-468: 1:4 seeding at 1-3 x10,000 cells/ml. 
 
 MDA-MB-231: 1:3 seeding at 1-3 x10,000 cells/ml. 
 
 SK-BR-3: 1:3 seeding at 1-3 x10,000 cells/ml. 
 
 MCF-7: 1:4 seeding at 2-4 x10,000 cells/ml. 
 
  A549: 1:6 seeding at 2-4x10,000 cells/ml. 
 
 K562: 1:6 seeding at 100,000 to 1,000,000 cells/ml. 
 
Cryopreservation of all cells performed with 90% FBS and 10% of dimethyl sulphoxide 
(DMSO) in 1.0 ml aliquots either in liquid nitrogen for long term storage, or -80 for short 
term storage.   
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2.14.3    MTT colorimetric Assay 
 
MTT assay was first described by Mosmann, (1983), who introduced a colorimetric assay for 
measuring cell viability, which therefore is used as a method for cell proliferation and a 
cytotoxicity assay. The basic principle of this assay is based on the ability of living and 
metabolically-active cells to reduce MTT (3, (4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tertrazolium bromide) salt to formazan product. MTT is soluble in water and, after being 
cleaved by the activity of mitochondrial enzymes, is converted to an insoluble crystal-form 
purple formazan by the cleavage of the tetrazolium ring. 
Healthy cells, which had been sub-cultured at least once and subsequently reached 70-80% 
confluence were used for the MTT assay.  
The first step was to count cells from culture using a haemocytometer. For adherent cell lines, 
cells have detached as per subculture (i.e. adding trypsin) then 4.5 ml media were added, then 
10 µl of cells were taken, placed on a haemocytometer for cell counting. A concentration of 
3000 cells per 100 µl per well was used. The template for the anticancer assay of the extracts 
is shown in Figure 2-5. The cells were then incubated at a temperature of 37 ˚C with 5% CO2. 
After 24 hours incubation, cells were examined microscopically to ensure that there were no 
signs of contamination and the cells were healthy. Subsequently, 100 μl extracts of whelk 
GAG, filtered by a 0.2 μm sterile filter, was added into the corresponding wells. The 
concentration of the extract was prepared in a serial dilution according to the microplate 
template, which started with a negative control in the first well (row A) until it reached the 
highest concentration in row H (Figure 2-5). The assay was performed in triplicate. Cis-
platinum, a known anticancer drug was used as a positive control. 
Afterward, the plates were incubated to allow the cell proliferation with or without the 
presence of the whelk GAG. After five days of incubation, the plates were taken out from the 
incubator and 50 μl of MTT solution at a concentration of 5 mg/ml was added into each well. 
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The plates were then kept in the incubator for the next 3-4 hours until the purple crystals of 
formazan salt were produced, followed by removing the media through gentle aspiration of 
the liquid, leaving the crystals at the bottom of the wells. Subsequently, 200 μl DMSO was 
added into each well to dissolve the formazan crystal, followed by the reading of the 
absorbance of the formazan solution in microplate reader using Sigma Plot 2000 software, at 




                                     Figure 2-5: MTT assay, plate dose pattern. 
 
 
2.14.4    Statistical approach 
 
2.14.4.1    Calculation of IC50 values  
 
The results were expressed as the value of optical density (OD) generated from OD1 
subtracted from OD2, which represented the amount of the purple formazan crystal formation 
after elimination of the background reading generated from the DMSO, remaining media or 
the microplate plastic base. The calculation of cell viability on each well of the corresponding 
column on the plate is performed by the following equation: 
Cell viability (%) = ( OD0/ ODn x 100). 
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Where OD0 is the OD from the negative control (row A) and ODn is the OD of the 
corresponding well. The mean value of viable cells from each extracts then plotted on a graph 
and used for calculation of the 50% inhibitory concentration (IC50) of each tested extract. 
The data was further analysed using Graphpad prism 5.0 (GraphPad Software, San Diego 
California USA). IC50 values were determined using non-linear regression to fit a dose 
response curve to the data after transform by the drug concentrations values to log values on 
X and the response normalised and represented as Y values.  
 
2.14.4.2    Statistical analysis 
 
All data set was analysed using Graphpad prism 5.0. Data were presented as mean ± standard 
deviation (SD). Statistical analysis was performed by two-way ANOVA test with 
Bonferroni’s multiple comparison post-test. A p-value of < 0.05 was considered statistically 
significant and R with Benjamini-Hochberg. 
 
2.14.5    Protein extraction and quantification 
 
Total protein extraction was performed on two triple negative breast cancer cell lines for 
further investigate the mechanisms of action of GAG on these cell lines by using advanced 
proteomic approaches at the Biological Mass Spectrometry Core Facility, Faculty of Life 
Sciences, University of Manchester.  
 
2.14.5.1    Cell lysates and protein concentration measurement 
 
MDA-MB-231 and MDA-MB-468 were cultured in T-25 culture flask to 80% confluence, 
then each cell line sub-cultured at an intensity of 5 ×104 cells per well in two strains of 6 well 
plate to around 90% confluence. Cells were treated with whelk GAGs at a concentration 
equivalent to their IC50 values prior to further analysis for 24 hours. The 6-well dishes were 
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placed on ice, and approximately 400 uL of 0.05% SDS with 50 mM Tris HCl pH 8 added to 
each dish. Using a scraper, cells were removed from dish into a pre-labelled Eppendorf tube 
then heated at 90°C for 10 minutes. The protein quantification was measured using Direct 
Detect® spectrometer (DDHW00010-WW) from Millipore. The protein was measured using 
the average protein concentration from sample replications to get an estimated of how much 
to digest, in this experiment 25 µg for each replicate was digested and processed by label- 
free protein quantification proteomic analysis.   
 
2.14.5.2    Proteins extraction in solution digestion technique FASP 
 
The proteins extracted underwent further sample preparation steps using filtered-aided 
sample preparation FASP. The procedure used as below: 
1. 25 µg of protein added to a spin filter tube with 200 µL of UA2 buffer (see appendix I). 
Centrifuged at 14000Xg at 20°C for 15 minutes.  
2. Next, 100 µL of UA2 buffer added and centrifuged again at 14000Xg at 20°C for 15 
minutes.  
3. To alkylate the samples which is required to ensure maximal coverage in LC/MS-MS, 50 
µL of UA1 (see appendix I) buffer with 0.05 M iodoacetamide was added to the filters and 
the samples were incubated in darkness at room temperature for 30 minutes.  
4. The solution centrifuged through and then wash the filters twice with 100 µL of UA2 
buffer followed by a further two washes of UA3 buffer.  
5.  50 µL of UA3 buffer was added to the filter and the protein was digested using 
endoproteinase LysC at protein: enzyme ratio of 1:20 at 37ºC for 2 hours and a fresh 
collection tube was used for subsequent spins. Lyophilized LysC was dissolved in ultrapure 
water. Once made, the solution is stable at least until the expiration date printed on the label 
at −80 °C.  
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6. Following this the solution was diluted to 300 µL with the addition of 250 µL of 50 mM 
Tris-HCl (pH 8.5). This brings the urea concentration down from 6M to 1M. The protein was 
further digested with trypsin at a protein: enzyme ratio of 1:20 overnight at 37ºC.  
7. After digestion peptides were collected by centrifugation at 4000Xg at 20°C for 15 minutes 
and the filtration units were washed once with 50 µL of UA1 buffer and subsequently with 
two 50 µL washes of 50 mM ammonium bicarbonate.  
8. Peptides were cleaned up with R3 beads and lyophilized and stored dry at -20ºC until 
analysis. 
Samples were de-salted prior to LC-MS/MS analysis, the de-salting procedure used here in 
96 well format is as below:  
 1 mg (100 µL of 10 mg/mL stock) of POROS R3 beads added to each well in a 
Corning 96 well plate.   
 The plate centrifuged at 200Xg (1400 rpm) for 1 minute. 
 50 µL of wet solution (50% acetonitrile) were added, the pellet re-suspended gently, 
and centrifuge at 200Xg (1400 rpm) for 1 minute. This repeated once. 
 50 µL of wash solution (0.1% formic acid) added, resuspending gently, and centrifuge 
at 200Xg (1400 rpm) for 1 minute. This repeated once.  
 The flow through was discarded.  
 The filters removed from the FASP tubes and 100 µL of the protein sample added to 
the corresponding well, resuspended gently, and centrifuge at 200Xg (1400 rpm) for 1 
minute. 
 another 100 µL of sample was added and centrifuge at 200Xg (1400 rpm) for 1 
minute. This has repeated until the entire sample was added.  
 Washed and centrifuged with wash solution (0.1% formic acid) twice.  
 The old flow through plate discarded and replaced with a fresh one.  
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 50 µL of elution solution (50% acetonitrile, 0.1% formic acid) added and centrifuged 
at 200Xg (1400 rpm) for 1 minute. This repeated once. 
 The eluted sample transfer into chromatography sample vials and dried in the Heto 
SpeedVac for 2 hours.  
 10 µL of 5% acetonitrile with 0.1% formic acid added to re-suspend the dried 
peptides. Vortex mix and ensured that the solution was at the bottom of the tube with 
no bubbles present.  
 Samples were ready for LC/MS.  
All materials, buffers and reagents used in this experiment are listed in details in Appendix I.  
 
2.15    Label-free protein quantitation proteomics  
 
Digested samples were analysed by LC-MS/MS using an UltiMate® 3000 Rapid Separation 
LC (RSLC, Dionex Corporation, Sunnyvale, CA) coupled to a QE HF (Thermo Fisher 
Scientific, Waltham, MA) mass spectrometer. Peptide mixtures were separated using a 
gradient from 93% A (0.1% Formic Acid (v/v) FA in water) and 7% B (0.1% Formic Acid 
(v/v) FA in acetonitrile) to 18% B over 57 min followed by second gradient to 27% B over 14 
min both at 300 nL per minute, using a 75 mm x 250 μm i.d. 1.7 µM CSH C18, analytical 
column (Waters).  Peptides were selected for fragmentation automatically by data dependant 
analysis on a basis of the top 12 peptides with m/z between 300 to 1600Th and a charge state 
of 2, 3 or 4.  Raw data was searched using Mascot (Matrix Science UK), against the [database 
selected] database with taxonomy of [species] selected.  Data was validated using 
PROGENESIS QI. The biological role, molecular function, and cellular localization were 
identified using PANTHER and DAVID classification system. Further pathway analysis was 




2.16    Mammosphere assay 
 
Identification of CSC renewal activity in three types of breast cancer cells, MCF-7, MDA-
MB-468 and MDA-MB-231 carried out. All buffers recipes are provided in details in 
appendix I. Non adherent plates were prepared as below:  
1. 10X poly-HEMA stock solution was prepared by dissolving 2.4 g of Poly (2-
hydroxyethyl methacrylate) in 20 ml of 95% ethanol. 
2. The mixture was steering constantly on a heated plate at 55°C overnight.  
3. To prepare 1 x poly-HEMA working solution, 1 part of 10x poly-HEMA stock 
solution was added into 9 part of 95% (v/v) ethanol and mixed well, then 200 μl added per 
well in 12 well plate.  
4. The plate was left in the sterile hood overnight without lid to dry.   
5.       When the plate dried each well was washed with sterile PBS. Mammosphere culture 
media was prepared as below: 
 DMEM/F12 (1:1). 
 10 ng/mL b-FGF. 
 20 ng/ml EGF. 
  5 µg/ml ITS. 
 1x B-27 supplement (optional) (Wang et al., 2014) .  
Cells were cultured to 70–80% confluence, according to standard protocols then detached 
using trypsin and centrifuged at 580 g for 2 minutes, media was then removed and cell pellets 
re-suspended in 1–5 ml of ice cold PBS.  Cells were passed three times through a 25G needle 
to obtain single cell suspension. A Haemocytometer was used to confirm that a single cell 
suspension was present and to determine number of cells, then 1000 cells/ml were plated in 
culture plates coated with poly-HEMA to prevent cell attachment. Cells were then incubated 
in a humidified atmosphere at 37 °C and 5% CO2 for 5 days without moving or replenishing 
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the media. After 5 days, media containing mammosphere was pipetted into a centrifuge tube 
and centrifuged at 115 g for 5 min. The supernatant was discarded and the pellet re-suspend 
in 300μl of 0.5% trypsin/0.2% EDTA then incubated at 37 °C for 2–3 minutes and the trypsin 
neutralised with double the volume of serum containing media. Again a 25 G needle was 
used to obtain single cell suspension and cells counted with haemocytometer. Cells were next 
plated in culture plates coated with poly-HEMA in triplicate and dosed with GAG in four 
different concentrations, first the IC50 of each corresponding cell, 20 µg/ml, 50 µg/ml, and 
100 µg/ml. Plates were incubated for 5 days. Finally, images of the wells were taken using 
Zeiss Axio Microscope (Axio Imager 2) equipped with camera for advanced imaging. 
 
2.17    General material and methods for in vitro culturing of malaria 
2.17.1    Culture of Plasmodium falciparum 
 
Parasite culture procedures were carried out in the collaboration with pathogen laboratory 
researchers (University of Salford) using a sterile hood (ESCO class II Biological safety 
cabinet) and pre-sterilised equipment. Routine culture methods were optimised from (Read & 
Hyde, 1993). Disinfection of waste material was carried out using Virkon (Antec 
International, UK) before autoclaving and disposal. Media used comprised of RPMI 1640 1x 
(+) L-Glutamine (+) 25 mM HEPES (4-(2-Hydroxyethyl) piperazine-1-ethanesulfonic acid) 
(Gibco, Life Technologies, UK). Then 2.5 g Albumin bovine serum fraction V (Sigma, UK), 
2.5 ml 1mg/ml hypoxanthine (Sigma, UK) in phosphate buffered saline (PBS) (Fisher 
Chemical,UK), 2.5 ml 40% glucose (Dextrose Anhydrous, Fisher Scientific, UK) in sterile 
water and 0.5 ml  of 50 mg/ml gentamycin (Sigma, UK) in PBS were transferred to a 50 ml 
falcon tube. Then approximately 20 ml RPMI 1640 from a newly opened bottle was added 
and the mixture passed through a 0.22 µm filter directly into the 500 ml bottle of RPMI 1640 
medium using a 20 ml syringe, the mixture gentle mixed and the complete medium was 
stored at 2-8 o C. The washing media used was contain RPMI 1640 1x (+) L-Glutamine (+) 
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25mM Hepes (Gibco,Life Technologies, UK) without additives and was stored at 2-8 oC for 
up to 2 weeks.  
The human blood (O+ whole blood obtained from the human blood bank) was prepared for 
culture of Plasmodium falciparum by washing the blood immediately to remove leukocytes 
before use. The whole blood was centrifuged for 5 minutes at 3400 rpm using 50ml falcon 
tubes then blood plasma and the pale layer (the buffy coat-containing white blood cells) that 
forms on top of the red blood cells was removed then re-suspended in an equal volume of 
washing medium and following centrifugation (as described previously) the supernatant 
along with the buffy coat, was discarded. The washing process was carried out 3X then the 
haematocrit was re-suspended in complete medium and stored at 2-8 oC until further use.  
In vitro culture of plasmodium falciparum was started by mixing 10 ml of complete medium 
and 0.5 ml of washed blood in 50 ml culture flask, warmed to 37 oC prior to the addition of 
the parasites, then 0.5 ml of parasitised blood (predominantly ring stage culture retrieved 
from liquid nitrogen) was then added and the parasite culture was gassed with a 5 % CO2, 5 % 
O2 and 90 % N2 gas mixture (BOC Limited, UK) and placed in the incubator (Leec culture 
safe touch 190 CO2, Leec Limited, Uk) at 37oC. In this experiment, smaller flasks (12.5 cm3) 
with a final culture volume of 5 ml were used, for every 10 ml of complete medium 1 ml of 
50 % haematocrit blood was added and the media was changed every 48 or 72 hours. Routine 
maintenance of a Plasmodium falciparum culture included removing and discarding the old 
medium from the flask without disturbing the parasitized blood layer at the bottom of the 
flask, then the estimation of parasitaemia calculated by transferring a single drop of 
concentrated parasitised blood on to a microscope slide, thin blood smear used to obtain 
monolayer cells, then the slide dried in open air and fixed by rinsing in 100% methanol. The 
slide was immersed in Giemsa stain at room temperature for ~20 minutes (Gurr’s Giemsa 
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stain solution (BDH/VWR international limited, UK) diluted at ratio1:10 with Giemsa buffer), 
the buffer recipe is shown in appendix I. 
The slide was gently washed with tap water, dried and viewed under oil immersion (X100) 
using a Leica DM 500 compound microscope. Estimation of parasitaemia was calculated as 
an average percentage of at least 3 fields of view and the estimated parasitaemia determined 
by counting the total number of red blood cells per field of view (approx. 100-200) and 
noting those containing parasites. Next the culture was diluted to 1 % parasitaemia with 
washed blood (50 % haematocrit) and new fresh complete medium was added to bring it to 
final haematocrit concentration of 5 %.  
In order to obtain a predominantly ring stage parasite culture, the sorbitol synchronisation 
technique was used by adding sorbitol (5 % w/v) solution at 9 ml to 1 ml of culture pellet and 
incubated for 5 mins then centrifuged at 3400 rpm for 5 minutes and the supernatant was 
discarded. The parasite pellet then washed 3X with complete medium, eventually re-
suspension in complete medium at 50 % haematocrit. 
 
2.17.2    Drug susceptibility assays 
 
To evaluate antimalarial activity of the whelk-GAG samples, a stock solution at 
concentration of 25µg/ml was prepared by dissolving 25 µg of the GAG in 1ml complete 
medium, the solutions were passed through a 0.22 μm filter then the infected blood treated   
by serial dilution of GAG stock solution from highest 25 µg/ml to lowest of 3.13 µg/ml for 
48h and 72 hours respectively in black bottom 96 well plates (Nunc, Denmark). Untreated 
infected blood (positive control) and uninfected blood (negative control) samples were 
suspended at final volume of 100 μl of complete medium and a haematocrit of 5 %.  
At time point of 48h and 72 hours of GAG treatment, a 100 μl of each replicate from serial 
concentration was transferred into separate Eppendorf tubes and washed once with PBS and 
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centrifuged for 90 seconds at 140000 rpm, the pellet was then re-suspended in 1 ml 5 x 
SYBR Green 1 solution (in PBS) and incubated in the dark for 20 minutes at room 
temperature followed by centrifugation for 90 seconds at 14,000 rpm. The samples were 
fixed by re-suspending the pellet in 250 μl of 0.37 % formaldehyde solution in PBS 
(formaldehyde solution for molecular biology 36.5 %, Sigma, UK), followed by incubation 
for 10-15 minutes at 4 ºC. The fixed sample was washed 3X in PBS and re-suspended in 1 ml 
of PBS, flow cytometry method was used, the FITC channel of the BD FACs Verse flow 
cytometer system used to record fifty thousand events per sample and the IC50 values 
calculated using nonlinear regression Gaphpad prism 5.0. Data was normalised and the log-
transformed drug concentrations were then plotted against the dose response, the data 
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3.1    Introduction 
 
Natural products have been extensively studied over a period of many years. A diverse class 
of compounds that are associated with many desirable therapeutic properties, including anti-
inflammatory, anti-oxidant and anticancer activity.  
While there are many examples of therapeutic natural products that have been identified, 
most are not effective as drugs when introduced to biological systems. Maintaining activity 
can be problematic for a variety of natural compounds due to poor pharmacology linked to 
their being excreted, being destroyed by enzymes, or being too large to cross the cell 
membrane independently (Jamieson et al., 2013).  
The nature of GAGs and their role in cells may ultimately allow their development as 
effective therapeutic agents once the molecular structure that is responsible for their 
biological and pharmacological interaction is determined. 
Researchers have identified bioactive molecules from marine organisms that are considered 
to be drugs and have been approved for human use in different parts of the world. These 
include chemical compounds isolated from sponge-derived microorganisms known as 
Sorbicillactone A which have been found to be effective against leukaemia cells without 
showing notable cytotoxicity (Bringmann et al., 2007). Another example is Didemnin B, a 
compound isolated from the Caribbean tunicate Ecteinascidia turbinate, which showed 
antitumour activity against a variety of cancer cell lines including breast, ovarian, cervical, 
myeloma, glioblastoma/astrocytoma and lung cancers (Rinehart Jr et al., 1981). This was the 
first marine extraction to be investigated and developed specifically for its anticancer activity 
(Nuijen et al., 2000).  
Although several studies have been conducted on marine algae, many bioactive extractions 
from invertebrates such as whelk (a type of mollusc) have received little attention. A few 
compounds have been characterised in this phylum although heterogenic, heavy sulphated 
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GAGs and extremely modified HS/CS are described in various species of molluscs (Dietrich 
et al., 1989).  
Despite several limitations in the discovery of bioactive lead compounds, many studies have 
been undertaken to find a new, interesting molecular species with potential to be developed 
as a therapeutic agent for certain diseases such as cancer. Some of these are cytotoxic agents 
against cancerous cells, target cell division and proliferation, damaging DNA, leading to cell 
death and evading apoptosis, depending on their overexpression and dysfunction or, for 
instance, deregulated signal transduction in cell cycle pathways (Fabbro & Garcia-Echeverria, 
2002). 
Natural products are lead compounds in drug discovery, especially for the development of 
new therapeutic agents. Some plant-derived products such as terpenes, phenolics and 
alkaloids have revealed anti-parasitic properties with high efficacy and selectivity. Quinine is 
a subtype of alkaloid, which has been reported to have antiplasmodial and anti-parasitic 
activity. Terpenes also has been reported to show some activity against protozoan parasites 
and the potential of tetrahydroyfuran lignans such as grandisin, a phenolic subtype, to prevent 
the transmission of T. cruzi by blood transfusion has been reported (Christensen & Kharazmi, 
2001; Kayser et al., 2003).  
This chapter focuses initially on screening the bioactivity of crude whelk GAG extracts on 
cell proliferation of several types of cancer, including lung carcinoma, two subtypes of 
positive breast cancer, liver cancer and leukaemia. The aim is to determine any selectivity of 
whelk GAG crude extracts toward specific types of cancerous cells. The second part of this 
chapter demonstrates the potential antimalarial activity of crude whelk GAG extraction, using 
SYBR Green dye and flow cytometry in drug susceptibility assays’ as described in detail in 
Chapter 2 (section 2.16).                                  
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3.2    Results 
3.2.1    Cytotoxicity assay on lung carcinoma  
 
Uncontrolled cell growth in the lung tissue is known as lung carcinoma. Most primary lung 
carcinomas cells are classified histologically into two main types: small-cell lung carcinoma 
(SCLC) and non-small-cell lung carcinoma (NSCLC). The latter includes several subtypes, 
including squamous cell carcinoma, large cell carcinoma and adenocarcinoma. Small-cell 
lung carcinomas grow more quickly and thus are more likely to be discovered when they 
have spread outside of the lung. The majority of lung cancer cases are correlated with a 
patient history of smoking cigarettes, although non-smokers can develop lung cancer due to 
other factors such as genetic predisposition or environmental hazards. Adenocarcinoma is the 
most common lung cancer, especially among non-smokers. Although there are several 
treatment options for lung cancer, including surgical removal combined with adjuvant 
radiation and chemotherapy, this particular cancer is associated with poor outcomes and high 
mortality rates (Bender, 2014; Dong et al., 2016).  
However, the treatment of lung cancer has improved following investigation of the molecular 
mechanisms involved in tumorigenesis that enable multiple oncogenic alterations to be 
determined. Epidermal growth factor receptor (EGFR) plays a remarkable role in treating 
refractory lung cancer in the patients carrying EGFR mutations. Such patients respond to the 
EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, achieving outcomes that could 
not be observed from traditional chemotherapy (Lynch et al., 2004).  
Identifying alternative treatment options for lung cancer that appear to be more effective and 
less toxic is crucial. Thus, the effect of whelk GAG crude extracts on pulmonary 
adenocarcinoma A549 cell line has been examined. The results shown in Figure 3.1 
demonstrate the percentage of estimated cell viability over a five-day incubation period with 
whelk GAG intact extraction. A range of concentrations from 100 µg/ml to 1.5625 µg/ml was 
used, and the cells were cultured in monolayer per well and treated with serial dilution of 
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whelk-GAG concentrations and treated with serial dilution of whelk-GAG concentrations 
ranging from 100µg/ml to 1.5625µg/ml. Cell viability was determined by MTT colorimetric 
assay (purple formazan crystals absorbance) and the data was validated using GraphPad 
software to calculate the inhibition concentration value (IC50), as shown in Table 3.1. The 
results show significant inhibition activity of intact crude whelk-GAG on the A549 cell line 




Figure 3-1: Cytotoxic effects of different concentrations of whelk GAG crude extracts 
on pulmonary adenocarcinoma A549 cells. 
The data is represented as the percentage of viable cells for sample size (n=3) as mean ± SD. 
Cells were cultured in monolayers and maintained at 37 °C in a humidified 5% CO2 
atmosphere. Cytotoxicity assay was performed using MTT colorimetric assay. The IC50 













3.2.2    Cytotoxicity assay on two subtypes of positive breast cancer 
 
The heterogeneity of breast cancer was demonstrated in Chapter 1. Each subtype of breast 
cancer has a specific immune profile and other characteristics, such as low or high expression 
of the proliferation marker Ki67, lack or over expression of ERα, PR and HER2 or 
enrichment for markers associated with mammary cancer stem cells (CSCs) (for example, 
CD44+ CD24-/low phenotype). Each subtype also has a different treatment response. Some 
are amenable to hormone therapy due to ER expression, others subtypes could subject for 
trastuzumab therapy, which involves the use of a monoclonal antibody to target cancer cells 
that are overexpressing the protein HER2 (human epidermal growth factor receptor 2). 
Another subtype, known as triple negative breast cancer, nonresponsive for endocrine therapy 
but often responsive to chemotherapy (Holliday & Speirs, 2011).  
Here we aimed to investigate the anti-proliferation activity of intact crude whelk-GAG on 
different subtypes of positive breast cancer. The activity on triple negative breast cancer is 
extensively studied in Chapter 5. 
Intact Whelk-GAG extracts were incubated with MCF-7 and SKBR3 cell lines. Both cell 
lines often are responsive to chemotherapy. However, MCF-7 is known to be endocrine 
responsive and low expression of the proliferation marker Ki67, unlike SKBR3 cell line. The 
other treatment option for this cell line is trastuzumab therapy, as SKBR3 is not responsive to 
endocrine therapy and is known for high expression of the proliferation marker Ki67.  
The results shown in Figure 3.2 demonstrate the percentage of viable cells over a five-day 
incubation period treated with serial dilution of whelk GAG concentrations ranging from 100 
µg/ml to 1.5625 µg/ml. Cell viability was determined by MTT colorimetric assay (purple 
formazan crystals absorbance) and the data validated using GraphPad software to calculate 
the inhibition concentration (IC50) value, as shown in Table 3.1. 
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The results illustrate significant inhibition activity of intact whelk-GAG extracts on both cell 




Figure 3-2: Cytotoxic activity of whelk GAG extracts on two subtypes of breast cancer. 
Panel A: MCF-7. Panel B: SKBR3. 
The data is represented as the percentage of viable cells for sample size (n=3) as mean ± SD. 
Cells were cultured in monolayers and maintained at 37 °C in a humidified 5% CO2 
atmosphere. Cytotoxicity assay was performed using MTT colorimetric assay. The IC50 









3.2.3    Cytotoxicity assay of intact whelk GAG extracts on hepatoblastoma-derived cell 
line Hep G2 
 
Hepatoblastoma is a primary human liver carcinoma and widespread childhood tumour 
among other type of cancer. It is considered a rare tumour and is less responsive to 
chemotherapy. This cell line has been used to study a wide variety of biological processes, 
including liver metabolism, hepatotoxicity and oncogenesis. Another type of liver cancer, 
known as secondary liver cancer, develops when the original cancer metastasises and spreads 
throughout the body, as is especially common in the case of lung, breast, pancreatic and 
stomach cancers. Metastasis begins when the cancer cells manage to enter the bloodstream 
and are allocated in other organs. Because the liver works as a filter for the blood, there is a 
high risk that cancer nodes will form in it, causing secondary liver carcinoma (López-Terrada 
et al., 2009). 
Treatment options for this type of cancer are very complicated. Some of these options are 
available for only primary human liver carcinoma. The options available to treat secondary 
liver carcinoma depend on the origin or source of the primary tumour, the stage and location 
of the cancer cells within the liver and the general health of the patient. Treatment may 
involve surgery, liver transplantation in rare cases, chemotherapy, radiotherapy and other 
biological therapies. Because all these options have serious consequences in terms of the 
extensive damage they do to the liver, there is an urgent need to discover an alternative 
therapeutic agent with less toxic properties.  
The aim of this experiment is to examine the inhibition activity of crude whelk GAG extracts 
on this cell line and thereby gaining some idea of the hepatotoxicity of the crude whelk 
GAGs. The result obtained from MTT experiments are illustrated in Figure 3.3 and show that 
the percentage of viable cells drops off dramatically after the cancer cells are treated with 
serial dilution of crude whelk GAG extracts at a range of concentrations varying in dosage 
from 100 µg/ml to 1.5625 µg/ml over a five-day incubation period. The IC50 value obtained 
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was 0.85±0.01 µg/ml, which is very small compared to the activity of crude whelk GAG 
samples on other cell lines. This suggests a kind of specific toxicity of the crude extracts 
toward liver cells. 
 
Figure 3-3: Cytotoxic activity of whelk GAG extracts on HepG2 cell line. 
The data is represented as the percentage of viable cells for sample size (n=3) as mean ± SD. 
Cells were cultured in monolayers and maintained at 37 °C in a humidified 5% CO2 
atmosphere. Cytotoxicity assay was performed using MTT colorimetric assay. The IC50 
values were calculated using nonlinear regression analysis (GraphPad Prism 5.0).  




3.2.4    Cytotoxic assay of crude whelk GAG extracts on chronic myelogenous leukaemia 
 
The K562 cell line is a type of chronic myelogenous leukaemia (CML), which is diagnosed 
as a clonal myeloproliferative disorder in the stem cells that form the primitive hematopoietic 
resulting cancer of the marrow and blood. This type of cancer is heterogenic among patients, 
has two or three phases and is characterised by the presence of a chromosomal marker, the 
Philadelphia chromosome (Ph) in the leukaemia. The three phases of chronic myelogenous 
leukaemia (CML) comprise an initial phase or chronic phase, which is more likely to be 
controlled by therapy than the other phases, which is followed by an accelerated phase and 
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finally the blast crisis phase, resulting in the patient’s death within 3 to 6 months. Some 
patients die from complications arising during the accelerated phase; others might develop 
blast phase CML without transferring from initial to accelerated phase (Kantarjian et al., 
1993).  
Chronic myelogenous leukaemia is less severe than acute leukaemia as the CML does not 
overlap with the mature red cells, white cells and platelets. The most reliable treatment option 
is tyrosine-kinase inhibitors (TKI). Chemotherapy drugs, including protein synthesis inhibitor 
therapy, is another treatment option that is effective for chronic and accelerated phase CML 
patients in addition to many other therapies such as stem cell transplantation.  
The aim of this experiment is to identify the inhibitory activity of crude whelk GAG extracts 
on this particular cancer type that is known for its multidrug resistance. Promising results 
with a half inhibition concentration value IC50 was achieved (see Table 3.1), as was a 
decrease in the cell survival. The percentage of viable cells shown in Figure 3.4. 
 
Figure 3-4: Cytotoxic activity of crude whelk GAG extracts on K562 cell line. 
The data is represented as the percentage of viable cells for sample size (n=3) as mean ± SD. 
Cells were cultured in monolayers and maintained at 37 °C in a humidified 5% CO2 
atmosphere. Cytotoxicity assay has performed using MTT colorimetric assay. The IC50 





Table 3-1: IC50 Values represented in (µg/ml) of different cancer cell lines over 5 day’s 




3.2.5    Crude Whelk GAG extracts as an antimalarial therapeutic agent 
3.2.5.1    Blood smear of parasite 
 
A thin blood smear was used to obtain monolayer cells the estimation parasitaemia according 
to the procedure described in Chapter 2. The same method was used to microscopically 
monitor the effect of different concentrations of crude whelk GAG extracts on the infected 
blood. This experiment was done using serial dilution of whelk GAG samples over a range of 
concentrations from 1 mg/ml to 0.015 mg/ml. The results shown in Figure 3.5 demonstrate 
the blood films of single slides at single concentration. Interestingly, the red blood cells begin 
to undergo lysis at 0.25 mg/ml; complete blood lysis is observed at 0.5 and 1 mg/ml, while 
the level of parasite appears to be reduced at a concentration of 0.0156 mg/ml. By increasing 
the concentration of GAG to 0.0312, 0.0615 and 0.125 mg/ml, the infection appears to be 
eliminated from the RBC. This preliminary data shows a potential toxicity effect of whelk 
GAG crude extraction on infected RBC at particular concentrations. All the experiments 
 82 
 
performed subsequently were designed according to the apparent toxicity, and the whelk 
GAG concentrations used were below the doses that cause RBC lysis.   
 
Figure 3-5: Thin blood smear for untreated and treated infected blood. 
The microscopic monitoring of blood smear shows clean RBC at doses of 0.0312 mg/ml and 




3.2.5.2     Cytotoxic activity of whelk GAG samples toward the malaria parasite using 
fluorescence-based drug susceptibility assay 
 
Over the years, a variety of drug screening techniques and assays have become available. 
However, because of the importance of the erythrocyte stages of the parasite life cycle as 
noted previously, most of these assays target screening drug activity on this particular stage. 
This includes the fluorescence-based drug susceptibility assays that utilise relatively simple, 
quick and high sensitive DNA-binding fluorescent dyes such as SYBR Green which depend 
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on the fact that the parasite’s host cells (human RBC) are free from DNA. This mean that the 
fluorescence observed in the sample can be attributed to parasite double stranded DNA only.  
Here, the uninfected blood, infected blood and the sample treated with different 
concentrations of whelk GAG extracts were stained in accordance with the methods 
described in Chapter 2. Using synchronised culture at ring stage revealed only one population 
of fluorescence intensity on the cytometer output, showing good labelling of the parasites at 
this stage. The BD-FACSVerse software was used to accurately determine parasitaemia by 
recording the percentage of infected cells relative to the total number of events recorded (red 
blood cells). The gating strategy was adapted from (Karl et al., 2009). 
The IC50 values were calculated using nonlinear regression analysis (GraphPad Prism 5.0). 
The percentage of parasitaemia plotted against drug concentration in µg/ml and the graphs of 
the two parasite stages (ring and schizonts) are presented in Figure 3-6. The serial dilution of 
whelk-GAG used in this experiment ranged in dosage from 25 µg/ml to 3.13 µg/ml. Output 
data was produced from technical triplicate tests on each dose. Interestingly, the results 
showed significant inhibition activity of whelk-GAG intact compound toward Plasmodium 
falciparum proliferation at both aforementioned stages. The IC50 values generated from the 
ring and schizonts phases of the parasite life cycle after 48 and 72 hours of incubation with 
whelk-GAG intact extraction were 12 µg/ml and 10 µg/ml respectively.  
Comparison of negative control (uninfected blood), positive control (infected blood without 
whelk GAG treatment) and infected blood that treated with whelk GAG crude extracts shown 
in Figure 3-7. Dot plot of forward light scatter (FSC) versus side scatter in BD flowcytometry 
has been used to determine the overall population of RBC. Scatterplots based on forward 
scatter (FSC-A) and SYBR Green dye fluorescence (FITC-A) at 494/521 nm was used to 
monitor negative control, positive control and the effect of whelk GAG on parasite viability 




Figure 3-6: IC50 values of crude whelk GAG extracts on two mononuclear parasite 
stages. 
Panel A: The percentage of viable parasitaemia (trophozoites stage) against drug 
concentration after 48 hours of incubation. Panel B: The percentage of viable parasitaemia 
(ring stage) against drug concentration after 72 hours of incubation. The IC50 values were 








Figure 3-7: Comparison of uninfected blood (negative control), infected blood (positive 
control) and sample treated with crude whelk GAG extracts. 
Panel A: Dot plot of forward light scatter (FSC) versus side scatter. Panel B: Scatterplots 
based on forward scatter (FSC-A) and SYBR Green dye fluorescence (FITC-A) (494/521) 
representing uninfected blood (negative control). Panel C:  Example of infected blood 
sample in P2. Panel D: Reduced number of mononuclear parasite level due to whelk GAG 
treatment. The gating strategy was employed to distinguish between the RBC population (P1) 





















The aim of this chapter has been to evaluate the biological activity of whelk GAG crude 
extraction on a variety of cancer cells and on malaria. The main finding of this chapter is that 
whelk GAG crude extracts expressed significant inhibition activity toward all cancer cells 
and toward malaria. 
Cancer is defined as uncontrolled growth of mutant cells among normal tissue. Multiple 
oncogenic alterations may occur in the cells, including mutations in some genes. These 
mutations are responsible for clear modifications in cell function, which offer potential 
targets in cancer therapy.  
Over the last few decades, treating and understanding cancer has become the main aim of 
many studies, especially in the developed countries where cancer is one of the major causes 
of mortality. Different cancer types have different immune profiles and their response to the 
treatment options available vary depending on the tissue type and other histological 
properties, cancer stage, degree of metastasis and multiple oncogenic alterations. Regardless 
of the cancer type, the treatment options available for cancer patients generally begin with 
surgery and is often followed by chemotherapy, radiotherapy and in some cases hormone 
therapy. Conventional cancer treatments do not always have a desirable result. In fact, they 
can make cancer more malignant. For instance, chemotherapy and radiotherapy have been 
used as powerful tools to destroy the DNA of the cancer cells in the hope of causing more 
harm to them than to the normal cells. However, this is not the case most the time. Very 
significant side effects have been observed from these treatment options; moreover, even 
after treatment, there is a very high risk that cancer will recur and even develop drug 
resistance. In some cases, treating particular type of cancer with chemo agents ends with 
more deadly type of cancer like liver cancer.  
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As with chemotherapy, the risk of inducing secondary cancers with self-renewing capacity is 
high, especially for some cancers such as breast cancer. With these concerns in mind, specific 
biological approaches to treating cancer have been developed, including target therapies that 
employ purified molecules such as monoclonal antibodies (MABs), cancer vaccines, cell 
growth factors, cancer growth blockers, drugs that block cancer blood vessel growth for i.e. 
angiogenesis inhibitors such as interferon and interleukin 2 (immunotherapy) and gene 
therapy (Oldham, 1984).  
This study demonstrates that whelk GAG crude extracts inhibits the growth of HepG2 cells 
and A549 cells. The results are broadly consistent with those of a study that investigated the 
biological activity of brown seaweed extraction, known as Sargassum pallidum, which 
reported significant cytotoxic activity on HepG2 cells and A549 cells. The cytotoxicity effect 
was explained by the correlation between the activity and their molecular weight and 
sulphation pattern (Ye et al., 2008). Another study has reported antituomur activity from 
brown algae (U. pinnatifida), which inhibited proliferation of prostate cancer PC-3, cervical 
cancer HeLa, alveolar carcinoma A549, and hepatocellular carcinoma HepG2 cells in a 
similar pattern to the commercial fucoidan from F. vesiculosus as reported by Synytsya et al., 
(2010). However, the molecular structure of these active compounds seems to be different 
from that of crude whelk GAG extracts, which contains marine non- GAG material. The 
chemical structures of marine sulphated GAGs are very unique and distinct from GAG 
structures. Although they bear sulphation and are sometimes composed of disaccharide 
repeating units like GAGs, they are much more homogeneous and regular in terms of 
backbone composition and sulphation patterns than mammalian derived GAGs (Pomin, 
2012a, 2012b, 2015; Pomin & Mourão, 2008). Over-sulphated fucoidans is another type of 
sulphated glycan from marine organisms that inhibit tumour-induced angiogenesis by 
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preventing the binding of VEGF165 to its cell surface receptor and inhibiting the VEGF-
mediated signalling transduction (Narazaki et al., 2008).  
The results of this study describe for the first time a strong cytotoxic activity of whelk GAG 
crude extracts against two subtypes of breast cancer cell, MCF-7 and SKBR-3. The most 
likely explanation for this finding is that whelk GAG extract acts as an anti-proliferation 
agent. This process is an important part of cancer development, as many proteins and signal 
transduction pathways resulting from mutations that favour proliferation is involved in 
stimulating cell growth. Administration of exogenous GAGs from whelk with active 
structural features may lead to a competitive process, with the functional endothelial GAGs 
binding to the growth factors that are commonly seen during the cell differentiation event, 
thereby giving rise to an anti-proliferation outcome.  
Dose-response bioassays usually involve one assessment, which takes place at the end of a 
defined exposure period. More information is needed on the effect of whelk GAGs on each 
cell line generated by adapting cell cycle analysis and apoptosis assay, which could carry on 
using flow cytometry. Although it was not possible to cover this aspect in the present study, 
an earlier study by our group using a similar compound isolated from whelk toward breast 
cancer (MDA-MB468-NQ01 and MDA-MB-468), leukaemia (MOLT-4 and K562) and 
ovarian (HeLa) cell lines demonstrated significant perturbations in the cancer cell cycle, 
showing cell cycle arrests at different stages. Similarly, significant apoptosis inductions were 
induced by whelk GAGs on the cancer cells (Ogundipe, 2015).  
The anticancer activity of sulphated polysaccharides isolated from marine animals such as sea 
cucumbers is well established. The secondary metabolites characterised from this species 
suppress the proliferation of various human tumour cell lines in vitro. The molecular 
mechanisms of these glycosides include cell apoptosis through the activation of intracellular 
caspase cell death pathways, arrest of the cell cycle at S or G2/M phases and dysregulation of 
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certain cellular receptors and enzymes participating in cancerogenesis, such as epidermal 
growth factor receptor (EGFR), extracellular signal-regulated kinases (ERK) and others. 
Administration of some glycosides leads to many cellular changes including reduction of 
cancer cell adhesion, suppression of cell migration and tube formation in those cells, 
suppression of angiogenesis, inhibition of cell proliferation and tumour invasion. As a result, 
growth inhibition of tumours occurs in vitro and in vivo (Aminin et al., 2015).  
Targeting molecules such as receptors, signalling molecules etc., based on alterations in their 
expression and/or function that promote proliferation in many different human cancers may 
block tumour maintenance. Targeting cell cycle proteins in sustained proliferative signalling 
especially at the G1 phase of the cell cycle when the progression depends on the balance of 
proliferative and anti-proliferative signals is important. It is believed that cancer cells ignore 
the signals to stop proceeding into the S phase and arrests in G1, here resulting in excessive 
DNA replication and induced mutations (Malumbres & Barbacid, 2009).  
Moreover, this is the first study, to our knowledge, to examine the activity of whelk GAG 
crude extracts against plasmodia growth. From the output data presented in this chapter, 
intact whelk GAGs can be considered as a highly antiplasmodial agent with respective IC50 
values of 10 and 12 µg/ml at the ring (trophozoites) and schizont stages. This finding is in 
line with those reported from marine sea cucumbers Ludwigothurea grisea and Isostichopus 
badionotus, from the red alga Botryocladia occidentalis and from the marine sponge 
Desmapsamma anchorata, which exhibited significant antimalarial activity in vitro model that 
inhibit Plasmodium falciparum growth at low-anticoagulant concentrations. The mechanism 
of action of the active compounds from these marine organisms has been indicated by the 
inhibition of erythrocyte invasion by Plasmodium through coating of the parasite. Heparin-
related polysaccharides of low anticoagulating activity could play a crucial role as potentiates 
of immune responses, such as invasion of human RBC mediated by sulphated 
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polysaccharides is followed by prolonged exposure of Plasmodium to the immune system 
(Marques et al., 2016).  
Interestingly, the important role of high negatively charged sulphated glycol-conjugates such 
as dextran sulphate 500K, dextran sulphate 5K, sulphatides, fucoidan and heparin in 
inhibiting the invasion of erythrocytes by merozoites and the cytoadherence of parasitized 
erythrocytes PRBC to endothelial cells, especially by highly negatively charged proteoglycan, 
has been reported. The mode of action of these compounds in inhibiting the invasion of 
erythrocytes by Plasmodium falciparum merozoites is unclear, but it has been confirmed that 
it was not mediated by killing the parasites.  
Furthermore, the correlation between the inhibition activity and the highly negatively charged 
glycol-conjugate is critical. Both invasion and cytoadherence are inhibited by highly 
sulphated dextran sulphate 500K, while un-sulphated dextran 500K and hyaluronic acid have 
no significant inhibition effects. In fact, the positively charged protamine sulphate could 
promote cytoadherence.  
Sulphated proteoglycans are involved in the binding of sporozoites of malaria parasites to 
hepatocytes (Xiao et al., 1996). Adherence is important for parasite development as parasites 
use specific protein for adherence to specific receptors on host cells surfaces. This increases 
the potential of utilising such properties to identify malaria vaccine candidates.  
The possibility of targeting plasmodial invasion proteins for antimalarial drug development 
has been demonstrated by numerous studies. Among the major surface proteins of the 
sporozoites of the various Plasmodium species such as P. yoelii is circumsporozoite (CS), 
which selectively binds to heparin, fucoidan and dextran sulphate Sepharose, but binds with 
lower affinity to chondroitin sulphate A and C-Sepharose. This illustrates the capability of 
GAGs to block merozoite and sporozoite invasion (Pancake et al., 1993). An indispensable 
antigen MSP-1, which plays an important role in invasion and is localized in abundance on 
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the merozoite surface, is another example of targeting invasion proteins for the development 
of novel antimalarial drugs. This protein was targeted by heparin, which binds to the specific 
domain of MSP-1 (termed MSP-133) and prevents secondary proteolytic processing (Boyle 
et al., 2010).  
The above result does not enable us to determine the exact mechanism of action of whelk 
GAGs toward malaria. However, the findings suggest a strong anti-proliferation effect from 
whelk GAG, which would also be beneficial in the treatment of certain other diseases such 
malaria. 
These findings can contribute to the development of anticancer and antimalarial agents. 
Further studies are required to investigate their mode of action, given the urgent need to 
develop new therapeutic agents following a significant increase in the development of 
resistance toward several of the available chemotherapeutic approaches (Mita et al., 2009; 

















 : Isolation 
and structural analysis 




































4.1    Introduction 
 
The structure elucidation is the most important process for understanding the biological 
function of the GAGs isolated from whelk. Whelk GAGs have potentially powerful 
therapeutic effects as proven by their activity as anticancer agents (chapter 3 and 5).  
The extraction methods of crude GAGs from whelk, as mentioned in previous chapter, 
included de-fatting the soft body with acetone wash, followed by pronase treatment to break 
down the protein part and precipitate by addition of TCA, ammonium sulphate or ammonium 
bicarbonate. These methods are often used in carbohydrate extraction because conjugates 
have been found with protein or lipids in the majority of biological samples. GAGs were then 
further purified using step elution anion exchange chromatography and their biological 
activities assessed. The ion exchange chromatography helps to remove non GAG 
contamination and enables the desirable sugar to be eluted at void volume of the column. 
GAG chains are then desalted using either PD-10 column or extensive dialysis against 
deionized water. 
The complex sulphate-rich polysaccharides produced in this procedure contain repetitive 
units of certain monosaccharides. The monosaccharide composition analysis performed in 
this study utilised HPAEC-PAD (High pH anion exchange chromatography coupled with 
pulsed amperometric detector), which characterised the types and amounts of 
monosaccharide in the crude whelk GAGs and the purified fractions. Monosaccharide 
identification was achieved in comparison with authentic standards (Willför et al., 2009). In 
addition, GC-MS was used as an additional technique to further verify the results obtained 
from monosaccharide composition HPAEC-PAD analysis.   
A variety of  additional analytical techniques and methods can also be used to help further 
understand the structure- function relationship of the GAGs (Pomin & Mourão, 2008), such 
as chemical and enzymatical degradations of complex polysaccharides. Glycan chains maybe 
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further processed by enzymatic degradation to remove impurities such as proteins or lipids. 
This is important in two aspects, firstly, to improve their detection and secondly, it facilitates 
their separation. 
Gel filtration chromatography is a useful technique for carbohydrate purification, especially 
after enzymatical degradation of conjugated glycan chains.  Stable isotopes labelling through 
reductive amination of the derivative sugar has been used in GAGs analysis, followed by 
revere phase HPLC coupled with MS (Lawrence, Olson, et al., 2008). 
The aim of this chapter is to analyse the structure of crude biologically active GAGs isolated 
from whelk. To address this a variety of analytical techniques, such as HPAEC-PAD, gel 
filtration chromatography, enzymatic digestion and GRIL-LC-MS methods have been used. 
Further investigation was carried out by 1D/2D-NMR experiments, and finally all ion 
exchange GAG fractions were transferred to bioactivity screening assay, to investigate their 
biological activity toward cancer cells, which is demonstrated in chapter 5. 
 
4.2    Results 
4.2.1    Monosaccharides analysis of intact GAG by HPAEC-PAD 
 
To understand the fine structure and backbone chain composition of unknown 
polysaccharides from whelk-GAG sample, it is required to breakdown the complex 
polysaccharide into constituent monosaccharide units. A simple and sensitive method has 
been used to quantify and identify the monosaccharide composition in whelk GAG using 
high-performance anion exchange chromatography (HPAEC) with electrochemical detection 
by pulsed amperometric detection (PAD). This method has previously been applied to  
sulphated glycans from different human tissues at low-picomole level (Adamo et al., 2009).  
This method is a powerful and sensitive procedure to identify monosaccharide composition 
and total carbohydrate present in the sample. Based on the weakly acidic properties of 
carbohydrates that allows selective separation of carbohydrate using strong ion-exchange at 
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high pH. This provide simple and direct quantification of non-derivatized monosaccharides at 
low-picomole concentrations. The HPAEC is coupled with pulsed amperometry detection 
that uniquely detects the oxidizable function groups at specific voltages used within the 
detection.  
The column used for monosaccharide analysis of whelk-GAG sample was CarboPac PA1, 
which is designated specially to analyse mono-, di- or oligosaccharides. These columns are 
classified under type one (nonporous pellicular resin) and have excellent mechanical stability 
that can tolerate back pressures of more than 4000 psi, and wide stable range of pH (0-14).  
The theory behind pulsed amperometry detection is that the pulse sequences are typically 
recorded in less than one second from the measured potentials on the working gold electrode 
surface. The first potential measure on the working electrode surface is recorded as a pulse 
electrical current generated from oxidation of hydroxyl groups in the carbohydrates, followed 
by reduction that effectively cleans it of unwanted products from the carbohydrate oxidation. 
The final potential step completely reduces the gold oxide on the electrodes surface back to 
gold, which renews the electrode surface after removal of the bound analyte. 
Monosaccharides from neutral and amino sugar are routinely separated by HPAEC-PAD and 






Figure 4-1: Monosaccharide composition analysis. 
Panel (A)- Monosaccharide profile of GAG isolated from whelk species. The hydrolyzed 
sample was dissolved in water and injected on Dionex-ICS3000 HPAEC-PAD, the column 
used for monosaccharide profiling was Carbopac PA-1 (4mm x 250mm). The solvents used 
for HPAEC was 100mM NaOH and 100mM NaOH + 250mM NaOAc. The amount injected 
for monosaccharide analysis of intact GAG was 5µg/ml. Panel (B)- Standard 
monosaccharides were dissolved in water and injected on Dionex-ICS3000 HPAEC-PAD, 
the column used for monosaccharide profiling was Carbopac PA-1 (4mm x 250mm). The 
solvents used for HPAEC was 100mM NaOH and 100mM NaOH + 250mM NaOAc. The 




The monosaccharide profile in whelk GAG, as shown in figure (4-1 panel A), was compared 
to the MonoUA-Standards figure (4-1 panel B), the results show the crude GAG mixtures 
contain a mixture of glycoproteins in relatively high amounts, most of these sugars are 
generally present in different glycoconjugates found in eukaryotic system such as various 
glycoproteins and proteoglycans. GalNH2 can be a component of O-glycans, chondroitin 
sulphate and dermatan sulphate; likewise, GlcNH2 and Glu are components of N-linked 
glycan, heparin/heparan sulphate, hyaluronan and keratan sulphate (Wiederschain, 2009). 
The presence of GlcA along with the amino-sugars GlcNH2 and GalNH2 indicates the 
presence of a significant quantity of GAG in whelk extracts. A noticeable absence of IdoA 
might indicate the absence of any dermatan sulphate in this sample. Or an unusual heparan 
sulphate structure. The amount of each monosaccharide units in the whelk sample are 
represented in µg/ml in the table below.  
  










4.2.2    Enzymatic digestion and Gel filtration chromatography of Intact GAG 
4.2.2.1    Enzymatic digestion and gel filtration chromatography of digested GAG with 
Heparinase Lyase 
 
The enzymatic de-polymerisation is a powerful tool for fragmentation of long chain of 
complex polysaccharide into smaller oligosaccharides as part of a structure study. The 
enzymes act on specific substrates sequences, within the GAG chains. The complete 
digestion provides a range of simple known sequences of repetitive disaccharides or 
oligosaccharides. The whelk GAG and standard commercial porcine intestinal mucosal 
heparan sulphate was subjected to enzymatic digestion.  
Size exclusion chromatography has been used to purify carbohydrates following enzymatic 
digestion. The chromatogram of digested GAG was compared to undigested GAG sample 
(figure 4-2). However, the results obtained demonstrated a low-resolution profile.  In 
undigested GAG, a broad peak was observed, which indicates a complex mixture of glycan, 
that may still be conjugated to some contamination peptides.  
Heparinase enzyme has been used to release the glycan from the conjugated glycan chains 
and the disaccharide released could eluted in column total volume. The elution profiles 
observed with all hep lyase fractions showed more asymmetrical peaks, that eluted at total 
column volume as expected. This compared favourably to the elution profile of disaccharide 
units from commercial HS. Complete de-polymerisation was expected after using mixture of 
three heparin lyase enzymes. However, the possibility of a small proportion incompletely 
digested chains cannot be ruled out. Longer incubations with increasing amount of enzymes 















         
 
   
 











Figure 4-2: Gel filtration chromatography of intact GAG, digested GAG with HEP 
lyase and commercial HS. 
Panel A- size exclusion profile of intact GAG from whelk. 100µl aliquot containing 100µg 
of crude mixture of whelk GAG is prepared and 50µl injected in HPLC system, sample 
separated using superdex 75 10/300 GL gel filtration column. Column pre-equilibrated with 
PBS-pH7.0, UV detection is used at 280nm and result recorded per second for maximum 
2000 seconds. Panel B- size exclusion profile of standard commercial Porcine intestinal 
mucosal heparan sulphate digested with HEP lyase fractions for 24hours at 37 °C, 50µl 
applied to superdex 75 10/300 GL gel filtration column, UV detection is used at 232nm and 
result recorded per second for maximum 2000 seconds. B-1, is commercial HS digested with 
HepI. B-2, is commercial HS digested with HepII. B-3, is commercial HS digested with 
HepIII. Panel C- size exclusion profile of whelk-GAG sample. 100µl aliquot containing 
100µg of crude mixture of whelk GAG is digested by Hep lyase fractions for 24hours at 
37 °C, 50µl applied to superdex 75 10/300 GL gel filtration column, UV detection is used at 
232nm and results recorded per second for maximum 2000 seconds. C-1, is crude sample 
digested with Hep I. C-2, is crude sample digested with Hep II. C-3, is crude sample digested 












4.2.2.2    Enzymatic digestion and gel filtration chromatography of digested GAG with 
ABC Lyase 
 
To investigate the presence of chondroitin sulphate in whelk-GAG, the crude GAG was 
digested with ABC lyase to release CS disaccharides. The results in figure (4-3) show the 
elution profile of whelk GAG along with the elution profile from standard porcine intestinal 
mucosal chondroitin sulphate digested with ABC-chondroitin lyases. 
 
 
          
              
 103 
 
         
Figure 4-3: Gel filtration chromatography of digested GAG with ABC lyase and 
commercial CS. 
Panel A- size exclusion profile of standard commercial Porcine intestinal mucosal 
chondroitin sulphate digested with ABC lyase fractions for 24hours at 37 °C, 50µl applied to 
superdex 75 10/300 GL gel filtration column, UV detection is used at 232nm and results 
recorded per second for maximum 4000 seconds. Panel B- size exclusion profile of digested 
whelk-GAG sample. 100µl aliquot containing 100µg of crude mixture of whelk GAG was 
digested by ABC lyase fractions for 24hours at 37 °C, 50µl applied to superdex 75 10/300 
GL gel filtration column, UV detection is used at 232nm and result recorded per second for 
maximum 4000 seconds. Panel C: Elution profile of whelk-GAG intact sample.  
 
 
4.2.3    Ion exchange chromatography and PD-10 de-salting techniques  
 
Whelk GAG was separated according to the GAG charged group using anion exchange 
chromatography prior to structural analysis and assessment of biological activities. The 
DEAE-Sepharose was used to fractionate the GAG mixture according to net negative charge. 
The whelk-GAG sample was fractionated into three fractions by step-wise addition of buffer 
with increasing chloride ion concentrations from 1.0 to 3.0 M. Each fractions were then de-
salted using a PD-10 column and GAG containing fractions were pooled, lyophilized and 





4.2.4    Quantitative analysis of monosaccharides on different –GAG fractions obtained 
from DEAE-fragmentation by HPAEC-PAD   
 
The three fractions of dry de-salted GAG eluted from ionic exchange chromatography were 
labelled as follows: CK1 (sample eluted at 1M NaCl), CK2 (sample eluted at 2M NaCl), and 
CK3 (sample eluted at 3M NaCl). These fractions were then subjected to, a monosaccharide 
analysis and quantification. Results in figure 4-4 panel A, B, C illustrate the types of 
monosaccharide found in each sample with the quantities being listed in the table (4-2), while 
panel D and E represent spectra of MonoUA-Std and CS- Std.  











Figure 4-4: The monosaccharide analysis form HPAEC-PAD system for ionic exchange 
chromatography fractions. 
Panel A- is spectra of monosaccharide analysis of 7% injected material of fraction CK1- 
eluted from ionic exchange chromatography in gradient of 1M NaCl. Panel B- is spectra of 
monosaccharide analysis of 7% injected material of fraction CK2- eluted from ionic 
exchange chromatography in gradient of 2M NaCl. Panel C- is spectra of monosaccharide 
analysis of 7% injected material of fraction CK3- eluted from ionic exchange 
chromatography in gradient of 3M NaCl. Panel D- is spectra of MonoUA-Std at 1nmole 
injected value. Panel E- is monosaccharide analysis of CS- Std from HPAEC-PAD. 
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Briefly, monosaccharides were produced by subjecting 10% of dry GAG material from each 
fraction to acid hydrolysis for 4 hours with TFA, and then each fraction was injected in 
HPAEC-PAD system. Typically, common monosaccharides were found in all three fractions. 
The results demonstrated the types of monosaccharide that exists in fractions CK1, CK2, 
CK3 and CS-Std and their relative amounts. A peak indicated with (*) is unknown compound 
and is potentially of huge interest in relating the relative biological activity of the whelk GAG 
chains. The unknown peak was found in all samples, in differing amounts, as well as in the 
standard CS. In order to identify this unknown peak, Fraction CK1 was further analysed 
using GC-MS after conversion of sugars into their volatile derivatives by TMS. The mass of 
the unknown peak in fraction CK1 was identified and it has a mass of 226.97 (M-H) (see 
Appendix II). The samples were hydrolysed using 2N TFA at 100ºC for 4h and acid removed, 
followed by LCNH2 cartridge purification to remove all neutral components. The bound 
fractions were eluted by 0.1M ammonium format dried and re-suspended in 50% methanol 
and injected directly on MS. The spectra are acquired in negative mode. We can see uronic 
acid as an ion of 193 (M-H) and the 226.97 (M-H) ion which is not present in the blank or 
GlcA std, and only present in CS-std and CK1(Appendix II).  
The GalNH2 monosaccharide was most abundant in all samples, which could be a result of 
O-glycans. TFA cleavage conditions with O-glycan units increase the chance of producing 
sugar moiety, as using TFA broadly not recommended especially with acid instable glyosidic 








4.2.5    GC-MS spectrum of fraction CK-1 GAG as trimethyl silyl derivative 
 
GC analysis of carbohydrate was an alternate method to verify monosaccharide composition 
of the crude and fractionated whelk GAG. Application of GC  requires volatile stable 
derivatives, this what introduce us to trimethyl silyl derivatives methods which is first 
described by Sweeley et al., (1963).  
Nowadays, GC-MS is a well established  techniques for use in carbohydrate analysis. Three 
main steps are involved in this methods, first each species is converted into a derivative,  by 
converting the hydroxyl groups of free monosaccharides generated by glycan hydrolysis to 
trimethylsilyl ethers, then the sample is run with GC-MS, which give qualitative and some 
limited quantitative data on the whelk GAGs structural composition.  
Poor solubility of some sugar can sometimes be seen with the TMS derivatives, along with a 
variations in the sensitivities of different linkages toward hydrolysis especially O-glycan 
linkage. Multiple peaks of same monosaccharide can also be presents for some TMS 
derivative as the ring forms of the sugar can adopt different anomeric configurations. The 
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combination with trimethylsilylation (TMS) allows the GC-MS separation of the D and L 
pair of isomers, thus it helps to identify the absolute configuration of single monosaccharide 
that might difficult to confirm their formation by TFA hydrolysis of the glycan (Varki et al., 
2009).  
The result from GC-MS of fraction CK-1 shown in figure (4-5), multiple peaks of  the same 
monosaccharide are present in TMS derivative produced from this fraction. High abundance 
of GlcNAc and GalNAc was also reconfirmed. The peaks were matched with the 
fragmentation pattern in two prepared TMS standards, in order to confim the peak 
assignments. The TMS standards used contained 1 mg/mL solution of standard sugars: 
rhamnose, fucose ribose, arabinose, xylose, mannose, galactose, glucose, N-acetyl 
glucosamine, N-acteyl galactosamine, N-acetyl mannosamine, glucuronic acid and 
galacturonic acid along with 1 µg of myo-inositol, as an internal standard were prepared, 
lyophilize and used as standared. 
This result confirms that the unknown peak present in all active fractions may be due to a 
modification in one of the composition, which turned the single monosaccharide to be more 
acidic and it is very high in most CS containing samples hence in this sample is highly 








Figure 4-5: Composition analysis of CK1- GAG fraction and standards by GC-MS. 
Panels A and B- are standard 1and 2- TMS. Panel C- composition analysis of fraction CK1 
by GC-MS as TMS derivative. Multiple peaks of same monosaccharide are presents for TMS 
derivative as the ring forms of the sugar can adopt different anomeric configurations of D and 
L forms.   
 
 
4.2.6    Disaccharide analysis by enzymatic digestions of GAG fractions from ion-
exchange chromatography 
 
The amount of each fractions (CK1, CK2 and CK3) required for enzymatic digestion was 
determined as in in table (4-2). 10µl of CK1, 62.5µl of both CK2 and CK3 were digested 
with a mixture of Heparinase enzymes and CS-ABC lyase for 24 hours at 37 ºC, samples 
were next fractionated with 10K MWCO filter to remove enzyme and undigested GAG 
chains, then the flow throw fractions, containing the disaccharide produced by the digestion, 
were tagged with Aniline isotopic label for future quantitative analysis by Glycan Reductive 





4.2.7    Glycan Reductive Isotope Labelling (GRIL) LC-MS analysis of Isotopic Aniline 
tagging for GAG disaccharide 
 
The fundamental idea of isotopic labelling is to replace a single atom by one of its isotopes, 
thus the single atom can be detected and localised in the molecule structure in the products by 
detecting the isotopes. In biochemistry there are several types of isotopes such as 2H 
(deuterium), 3H (tritium), 13C, 14C, 15N, and 18O, but not all of them yield structural 
information. Different isotopes can be classified into different groups, some of them are 
known as radioactive isotopes such as 3H and 14C, others are not radioactive but stable 
isotopes like 2H, 13C, 15N, and 18O and easy to detect by analytical methods such as NMR 
especially 13C and 15N. Here we use aniline-containing stable isotopes (12C6 and 13C6) in 
Glycan Reductive Isotope Labelling (GRIL) LC-MS as very sensitive and reliable methods to 
identify the disaccharide even rare type such as D2A0. The (GRIL) LC-MS method can be 
applied for any type of GAG sourced from human or invertebrate tissues. This technique is 
much sensitive than UV or fluorescent derivatisation to analyse the disaccharide following 
enzymatic degradation (Kinoshita et al., 1997).  
It provides accurate peak retention time, absolute mass and fragment ion analysis of each 
disaccharide. The only limitation of analysing carbohydrate by LC-MS methods is the solvent 
effects on disaccharide ionization that produces variation in the ionization efficiency, which 
in turn leads to incomplete quantification of disaccharide. However, to overcome this 
problem the concentration of disaccharide correlated with the detection of a molecular 
standard. This addressed by applying linear best fit equations (Saad & Leary, 2003), or by 
tagging techniques using different isotopic tags (Yuan et al., 2005).  
The procedure of sample preparation and tagging methods used in this study have described 
in details in sections (2.9.1, 2.9.2 and 2.10.1).  
The results shown in Figure 4-6 demonstrate the types and % molar quantities of disaccharide 
composition identified in flow through FT fraction (the part of material that digested with 
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Hep lyase and ABC lyase and passed through the 10K filter) of whelk GAG from GRIL-LC-










D0H0 ▲UA-GlcNH2 D0a0 ▲UA-GalNAc 
D0H6 ▲UA-GlcNH2-6S D0a4 ▲UA-GalNAc4s 
D2H0 ▲UA-2S-GlcNH2 D2a0 ▲UA2S-GalNAc 
D2H6 ▲UA2S-GlcNH26S D0a6 ▲UA-GalNAc6S 
D0A0 ▲UA-GlcNAc D2a4 ▲UA2S-GalNAc4S 
D0A6 ▲UA-GlcNAc6S D2a6 ▲UA2s-GalNAc6s 
D2A0 ▲UA2S-GlcNAc D0a10 ▲UA-GalNAc4S6S 
D2A6 ▲UA2S-GlcNAc6S D2a10 ▲UA2S-GalNAc4S6S 
D0S0 ▲UA-GlcNS   
D0S6 ▲UA-GlcNS6S   
D0S3 ▲UA-GlcNS3S   
D2S0 ▲UA2S-GlcNS   
D2S6 ▲UA2S-GlcNS6S   
D2S3 ▲UA2S-GlcNS3S   
D0S9 ▲UA-GlcNS3S6S   












Figure 4-6: Disaccharide yield from whelk-GAG sample using GRIL-LC-MS. 
Panel A- bar graph shows 12 HS disaccharides, (**) indicate most abundant disaccharide in 
all fractions, (*) indicated second highest amount of disaccharide type in all flow through FT 
part in all fractions. Panel B- bar graph of 7 CS disaccharides yield from enzymatic 
degradation of intact whelk-GAG sample identified and quantified by GRIL-LC-MS after 
tagging with 12C6 and 13C6. (**) indicate most abundant disaccharide in flow through FT 
fraction in fraction CK3, (*) indicate highest amount of disaccharide found in all flow 
through FT fraction in fraction CK1 and CK2.   
 
 
The results show that there is a significantly high amount of DS20 (ΔHexA2S-GlcNS) in 
whelk GAG fractions (43.15%) relative to commercial porcine HS (10.4%) as identified by 
Gill et al., (2013) and porcine heparin (0.9%) as detected by Saad et al., (2005). The second 
noticeable disaccharide detected in all whelk GAG fractions CK1, CK2 and CK3 was D2S6 
(ΔHexA2S-GlcNS6S), in contrast, this disaccharide is representing most abundant 
disaccharide in commercial porcine heparin and HS. Types of CS-disaccharide found within 
whelk GAG fractions are also significantly different from commercial porcine CS, the 
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amount of specific disaccharide between each fraction are clearly various. In fraction CK1 
and CK2, D0a10 (ΔHexA-GalN4S6S) disaccharide was the highest at 57.60% and 71.22% 
respectively, while in fraction CK3 it was 4.42%, comparing to the commercial porcine 
which is represent the least amount 1.39%. The remarkable amount of D2a6 (ΔHexA2s-
GalN6S) is found only in fraction CK3 at 77.74%, while it was 0.59%, 1.43% and 0.04% in 
CK1, CK2 and CS-Std respectively. The percentage of molarity of each HS disaccharide 
characterised in fractions CK1, CK2, and CK3 illustrated in details in table (4-4).   The 
percentage of N, 2-O, 6-O-sulfation patterns in HS disaccharide has been calculated in each 
fraction and the average number of SO3 per disaccharide quantified. The results show high 
amounts of N-SO3 at about 90.23% average for all GAG sample fractions comparing to other 
type of sulphating pattern.  In addition, the percentage 2-O, 4-O, 6-O-sulfation pattern and 
average SO3 per disaccharide has clearly identified in CS disaccharide yield in all fractions in 
table (4-5). A high amount of 6-O-SO3 sulphating pattern (72.82%) found in all CS 
disaccharide fractions, almost twice as much as the amount found in CS-Std (36.24%). This 
has followed by 2-SO3 sulphating pattern (an average of 26.59% of all fractions) which is 
represent 0.30% of the total compound sulphating pattern in CS-Std. The 2-SO3 pattern, 
representing 77.74% of all suphating types, found mostly in fraction CK3, which was eluted 
in the highest salt strength of 3M NaCl. The amount of 4-O-sulfation in CS disaccharide in 
whelk GAG fractions found very similar to the amount in the CS-standard, as represent at an 








Table 4-4: Disaccharide quantities of fractions CK1, CK2 and CK3 in percentage mole. 
A: percentage mole of HS disaccharide for all whelk-GAG sample fractions. B: Percentage 
mole of CS-Std and CS disaccharide for all whelk-GAG sample fractions. (*) indicates most 























Table 4-5: Type of sulphating in HS and CS derivatives of each whelk-GAG fractions. 
A: represent the type of sulphating in each HS fractions and the average concentration of 
sulphates per HS disaccharide. B: represent the type of sulphating in each CS fractions and 
average concentration of sulphates per CS disaccharide. (*) indicates most abundant HS/CS 









HS-CK3 HS-Std Average of all 
fractions 
%Unsulphated 1.70 1.91 10.10 28.35 
 
4.57 
%N-SO3 90.44* 92.26* 88.01* 58.21 
 
90.23 
%2-O-SO3 85.31 76.15 64.96 37.37 
 
75.47 





   






Type of sulphating CS-CK1 CS-CK2 CS-CK3 CS-Std Average of 
all fractions 
%Unsulphated 4.43 4.02 4.95 3.83 4.46 
%2-SO3 0.61 1.43 77.74* 0.30 26.59 
%4-O-SO3 92.98* 91.74* 16.63 61.42 67.11 
%6-O-SO3 60.18 75.45 82.84 36.24 72.82 
Average SO3 per 
disaccharide  
1.54 1.69 1.77 0.98 1.66 
 
 
A LCQ classic quadrupole ion trap mass spectrometer equipped with an electrospray 
ionization source, and a quaternary high-performance liquid chromatography pump (Thermo-
Finnigan, San Jose, CA) was used for disaccharide analyses. Derivative and non-derivative 
disaccharide residues were separated on a C18 reversed-phase column (0.46 x 25 cm, Vydac) 
with the ion pairing agent dibutylamine (DBA, Sigma-Aldrich). Ions of interest were 
monitored in negative ion mode. To minimize in-source fragmentation of sulphated 
disaccharides, the capillary temperature and spray voltage were kept at 140 °C and 4.75 kV, 
respectively (Katajamaa & Orešič, 2005). 
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Samples were treated with Heparinases I, II, and III, similar amounts digested separately with 
ABC lyase to yield derivatives, the reducing form of each GAG disaccharide can form a 
Schiff base with the amine group of aniline. The resulting imine is then reduced with sodium 




Figure 4-7: The interaction of amino group in the aniline tag with the reducing sugar 
form.   
 
 
The LC-MS spectra of the flow through (FT) fraction from nanosep centrifugal devices with 
omega membrane of all fractions CK1, CK2, CK3, HS-Std and CS-Std shown in appendix II. 
Disaccharides and standards produced by treatment with CS-ABC/ Hep lyase, tagged with 
12C-aniline and spiked with known amount of 13C-aniline tag as an internal standard. Ions of 
interest were monitored in negative ion mode. The 13C6 aniline-derivative forms of 
commercially provide HS and CS were used for quantitative analysis by GRIL-LC/MS.  
The m/z values of the 13C6 aniline-derivative standards differ from the 12C6 aniline derivatives 
by + 6 atomic mass units, more illustration found in appendix II. 
The GRIL-LC-MS is applied to all flow through (FT) of the whelk-GAG fractions CK1, CK2 
and CK3, the FT is the material that has been completely digested by Hep lyase or ABC lyase 
into di or oligosaccharide of (2-6 disaccharide) that passed through the 10K filter (Nanosep 
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centrifugal devices with omega membrane) (Figure 4-8), the filter media contain omega 
membrane that has low protein-binding, modified polyethersulfone on polyethylene substrate, 
the filtrate receiver is polypropylene, for rapid purification, separation of mixture and sample 
fractionation, the membrane pore size is less than 5nm and able to fractionate biomolecule 
with rang of 30K-90K molecular weight. Any material longer in size than the membrane pore 
size will remain on the top of the filter as retained fraction, this could include buffers, 
enzymes, and incomplete digested substrates. The retained fraction of all sample fractions 
were subjected for monosaccharide analysis to determine the monosaccharide in the mixture, 
using HPAEC-PAD. The results in figure 4-9 confirmed the monosaccharide composition of 
the retained fraction from all fractions, which is clearly suggest incomplete digestion of the 
whelk GAG with both Hep lyases and condroitinases ABC. 
 
 




















Figure 4-9: Monosaccharide analysis of retained fraction of the mixture in all sample 
fractions. 
Panels A1, B1 and C1: Represent the monosaccharide that exist in the retained fraction of 10% 
CK1, CK2 and CK3 fractions respectively that digested by HS lyase. Panels A2, B2 and C2: 
Represent the monosaccharide that exist in the retained fraction of 10% CK1, CK2 and CK3 






4.2.8    Monosaccharides analysis by HPAEC-PAD technique of whelk-GAG sample 
oxidised by periodic acid.  
 
Periodic acid (HIO4) oxidation cleaves the vicinal diol group on a carbohydrate molecule to 
generate an aldehyde groups. This oxidation is often applied to polysaccharides that have 
vicinal hydroxide groups to generate oligosaccharide for structural elucidation. The 
monosaccharide residues of a polymer containing hydroxyl groups which are involved in an 
ester or glycosidic linkage are found to be resistant to periodic acid oxidation.  
Most of neutral sugars are considered to be reactive monosaccharides, such as mannose, 
fucose, glucose and galactose. It has been reported that periodic acid might not produce 
aldehydes in uronic acid and highly sulphated hexosamines in the glycol-conjugated or 
proteoglycan due to electrostatic repulsion condition (Leblond et al., 1957).   
The aim of this experiment is to determine the sugar ring structure and in addition, to 
examine the possibility glycose are oxidised to aldehydes in the whelk-GAG samples, which 
might then in turn lose their bioactivity on cancer cells. To validate the results from the 
periodic acid oxidation treatment, all whelk-GAG sample underwent monosaccharide 
compositional analysis to provide a clear evidence of whether the mixture of intact whelk-
GAG is completely oxidised or that the ring form of the monosaccharide remained intact. The 
results shown in figure 4-10 demonstrated the monosaccharide composition analysis of 
whelk-GAG fractions (CK1, CK2 and CK3) after the oxidation process by periodic acid 
treatments. It is obvious that the respective amounts of monosaccharide remained non-
oxidised and the chains are still highly polymerised. This was expected, as such compounds 
show no sign of aldehyded formation by oxidation process with periodic acid due to the 
strong negative charge pass on by ionised carboxylate groups of the glucouronic acid and the 
sulphated groups of hexosamine that cause electrostatic repulsion with the negatively charged 
periodate ions, which inhibit the oxidation of acidic polysaccharide (Bancroft & Gamble, 
2008). However, no uronic acid was detected after the oxidation reaction in all fractions, 
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whilst high abundance of neutral sugars is observed. Prolonged periodic acid treatment might 
affect uronic acid in the GAG sample fractions and hence make it positive for periodic 
oxidation treatment  (Kiviranta et al., 1985).  
According to Scott & Harbinson, (1969), targeting the uronic acid moiety in chondroitin 
sulphates A, B and C, and seaweed with oxidation reaction by medium containing 0.2 M 
sodium perchlorate to avoid electrostatic field effect,  showed that polymer-bound uronic 
acids whether this was iduronic or guluronic are more quickly oxidised than their glucuronic 










Figure 4-10: Monosaccharide composition analysis by HPAEC-PAD of whelk-GAG 
sample fractions oxidised with periodic acid. 
Panel A: Monosaccharide composition of fraction CK1 after treating with periodic acid to 
oxidise the sugar rings. Panel B: Monosaccharide composition of fraction CK2 after treating 
with periodic acid to oxidise the sugar rings. Panel C: Monosaccharide composition of 








4.2.9    NMR spectra analysis  
 
Nuclear Magnetic Resonance Spectroscopy (NMR) is considered as a powerful analytical 
method for a variety analytical applications. First observation is back to1940s. All elements 
can be usefully studied using NMR. However, some elements are difficult to observe due to 
their nuclear properties such as oxygen and aluminium.  
This technique could be defined as “the absorption and emission of electromagnetic radiation 
by the nuclei of certain atoms when they are placed in magnetic field”. During the last decade 
NMR has become increasingly attractive for use in’ biology and medicine applications 
including studies of bio-macromolecular structure and function.  
It believes that both standards (the proton 1H and carbon 13C) along with other spectroscopic 
can provide confirmation of the structure of drug substances. In case of  1H NMR could find a 
a wide range of protons in different chemical groups can be found. Chemical shift 
measurements are formally based on the resonance position of the bare proton nucleus as the 
primary standard; therefore, we could define the chemical shift in terms of the difference in 
resonance frequencies between the nucleus of interest (i.e. 1H) and a reference nucleus (i.e.1H 
of TMS) by means of a dimensionless parameter (Earl & VanderHart, 1982).  
 Some atoms have no overall spin as they spin are paired and cancel each other such as 12C, 
16O, 32S atoms, while others like 1H,13C, 31P, 15N, 19F have nucleus with an overall spin. There 
is a correlation between overall spin and the number of neutrons and protons, if they both 
balanced then the nucleus has no spin. But if the number of neutrons and the number of 
protons are disproportionate then the nucleus has a half-integer spin, or it has an integer spin 
if there is  not appropriate number of neutrons or protons (Edwards, 2009).  
In drug discovery, NMR has an important role in structure elucidation of unknown bioactive 
macromolecular compounds from first identification to optimisation steps. It is an efficient 
and accurate tool to successfully screen the compounds with powerful action as drugs for 
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curing diseases. All the structure information of the compounds can be monitored and 
extracted based on the chemical shift.         
 
4.2.10    1D (1H-NMR) and 2D (HSQC-NMR) experiments   
 
Two types of NMR experiments (1D and 2D) were run in order to identify the structure of the 
whelk-GAG samples, using Brucker NMR spectrometer operating at a 1D and 2D frequency 
of 800MHz. AVIII NMR spectrometer with TCI cryoprobe equipped with Z gradients at 
70ºC. Also 600MHz to operate 1H-NMR at room temperature was used to monitor all whelk-
GAG fractions from ion exchange chromatography CK1, CK2 and CK3 using Deuterium 
Oxide (D2O) as the solvent. 
 The data in one dimensional NMR (1D) is usually presented with x axis corresponding to the 
frequency axis which is the chemical shifts measured in ppm and the Y axis corresponds to 
the intensity, while in 2D-NMR there are two frequency axes and the intensities present in 
third axis, therefore, it is present as plots.  
The aim of this experiment was to identify the structure of the complex compounds on the 
atomic level and their interactions with other compounds.  Sample preparation and solvent 
exchange used in this experiment is as shown in section (2.12).  
Figure (4-11) shows the signal in both 1D/2D-NMR of intact whelk-GAG samples. Broad 
peaks were observed from 1H-NMR of intact whelk-GAG and CK1, CK2, and CK3 fractions.  
Measurement of multiple coupling constants directly was not possible from all spectra signals 
due to peaks overlap. Unfortunately, the complexity of the mixtures in each sample made it 
impossible to make unambiguous assignments of the glycan constituents within the samples. 













Figure 4-11: Brucker NMR spectrometer at 1D and 2D, frequency of 800MHz at 70 °C and 600MHz at 37 °C. 
Panel A: 1H spectrum of CK1 extracts at frequency of 800MHz at 70 °C. Panel B: HSQC spectrum of crude GAG extracts at frequency of 







4.3 Discussion  
 
The aim of this chapter was to analyse the structure of GAGs isolated from whelks and to 
begin to link biological activity with structural fine detail. This is important in the 
progression of designing bioactive compounds from natural products and to ultimately move 
towards the development of potential therapeutic approaches.  
The main finding of this chapter were that the structure of the whelk GAG is significantly 
different from the structure of mammalian GAGs, which lies mainly in the abundance of 
different disaccharide units and the sulphation patterns presents in these molecules.   
Initially, the monosaccharide composition of the whelk GAG was investigated. The amount, 
and type, of monosaccharides was determined using highly sensitive techniques, most of the 
monosaccharides found in the whelk GAG samples are also typically present in different 
glycoconjugates such as glycoproteins and proteoglycans from other organisms. 
The monosaccharide composition analysis is an important method used to identify the 
structure of  complex GAGs, this methods has been adopted in several studies (Gao et al., 
2011). Monosaccharide composition analysis by HPAEC-PAD suggests the presence of 
specific non-GAG related oligosaccharide classes such as N-glycans or O-glycans within the 
crude GAG samples. 
High abundance of glucose, fucose and galactose monosaccharide are seen in  the whelk 
GAG samples, this in agreement with the finding by Tanoue & Handa, (1987). According to   
KerheRvé et al., (1995),  monosaccharide composition analysis of different marine species 
revealed a high abundance of glucosamine, mannose, ribose, rhamnose, fucose, and xylose.   
Most of these monosaccharides are also detected in the crude whelk GAG samples in this 
study.  
The results showed lower amounts of uronic acid distributed among whelk GAGs chain. This 
finding has been confirmed by the result obtained from GC-MS. Some marine organisms 
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have been  reported to express small amounts or uronic acid whether iduronic or glucourinc 
acid comparing to the amount of other monosaccharides found in mammalian GAG chains 
(Jiao et al., 2011). This finding concurs with another study that showed the chemical 
composition of green and red seaweeds Codium fragile and Chondrus crispus, which are 
reported to have 31% neutral sugars within their structure compared to only 0.6% uronic acid 
(Kulshreshtha et al., 2015).  
The most likely explanation of the unclear findings from the size exclusion 
chromatography experiments is the incomplete digestion of GAG substrate by the enzymes. 
This resulted in the presence of broad peaks observed from elution profiles. Unfortunately, 
an extensive period of sample incubation with lyases showed no further degradation, 
which might indicate that whelk GAGs are unfavourable substrate of either enzyme. Many 
factors should be taken into consideration when broad peaks are observed from size 
exclusion chromatography, such as sample impurities. This makes purification of 
heterogeneous GAG samples even more difficult and increases the complexity within the 
samples elution profile. In addition, the main limitation of this technique is the low 
resolution profile with carbohydrate comparing to proteins. As carbohydrate is 
heterogeneous and larger than other macromolecules.  
The above analysis does not enable us to determine comprehensively the fine structure of 
Whelk GAG chains but the disaccharides or oligosaccharides generated from enzymatical 
degradation does give us an insight into the reasons why the biological properties of 
Whelk GAGs differ so significantly from mammalian GAG chains.  
Ion exchange chromatography enabled the fractionation the GAG sample according to 
their net negatively charged groups using stepwise adding of sodium chloride with three 
different buffer strengths. The result show that the fraction eluted with 1 M NaCl yielded 
approximately 90% of total sample applied to the column, followed by smaller amounts of 
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fractions eluted with 2M or 3M NaCl salt concentrations. This indicates that most pure 
polysaccharide of the hexuronic acid and neutral sugars composition of whelk GAG is 
elute at low salt concentrations according to their net charge at the selected pH. The above 
finding was confirmed by monosaccharide composition analysis of each fractions. In 
addition, monosaccharide quantification for all fractions (1M, 2M and 3M NaCl) enabled 
the calculation of the corresponding amounts of each enzyme required per substrate for 
complete enzyme digestion for further structure elucidation process.  
The results in this chapter show for the first time the abundance of different disaccharide 
units presents in whelk GAGs along with their sulphation patterns differ significantly from 
mammalian GAGs, using the GRIL-LC/MS technique. The results are broadly consistent 
with some reports in the literature, such as the structural analysis of compound with 
reduced anti-coagulant activity isolated from the shrimp L. vannamei by Brito et al., 
(2008), suggesting that some GAG isolated from marine organisms differ in their chemical 
composition than mammalian GAGs. The finding is in line with another study that shows 
the content of unique markers for the antithrombin-binding region of heparin isolated from 
the two marine clam species Anomalocardia brasiliana and Tivela mactroides are present 
in large amounts (up to 25-30%) of the total disaccharide units. This also demonstrated the 
occurrence of a novel saccharide sequence identified as (-GlcNSO3)-IdA-GlcNSO3(3,6-
di-OSO3), that has not previously been found in heparin or related polysaccharides in 
mammalian GAGs.  
This finding might explain, at least in part the incomplete digestion of the whelk GAGs by 
heparinase enzymes. Since each heparinase enzyme is known to act on specific substrate, 
changes in the amount of specific disaccharide, sulphation pattern and/or their 
configuration within the intact chain might result in resistance toward enzymes activity.  
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Reasonable amounts of GAGs detected from the retained fraction of the Nanosep 
centrifugal devices contain omega membrane (10K filter Eppendorf tube), which again 
could be the result of incomplete digestion by heparinase enzymes. This fraction has 
proven biological activity toward cancer unlike the flow throw fractions, which 
demonstrated no activity toward cancer cells (further explained in chapter 5). This finding 
was unexpected and suggests that retained fragments contained the key heparinase 
resistant sequences that may be responsible for the biological activity and as such their 
structure is going to important for future studies.   
This study has a number of possible limitations, including the main factor, which is the 
degree of complexity of whelk GAG structure that will take an extensive study to identify 
biologically active sequences within the whelk GAG chains.  
These findings contribute considerably to the evaluation and plans for further structure 
analysis of whelk GAG in the development of potential therapeutic approaches, which may 
have an important role as future anticancer and antimalarial agents.  
Further studies are required to further analyse the structure of whelk GAGs in particular 
the bioactive compounds detected in the retained fractions. More research in this area is 
necessary to answer several questions that remained unresolved in terms of structure-
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5.1    Introduction 
 
Recent concerns about triple negative breast cancer (TNBC) have generated a considerable 
body of research. Triple negative breast cancer is an aggressive disease subtype that has the 
poorest outcomes and accounts for as many as one in five cases. Compared to positive breast 
cancer, TNBC is a faster growing type of breast cancer. Treatment options for patients with 
TNBC are limited to the use of conventional medicine, including a combination of therapies 
such as surgery, radiotherapy and chemotherapy. Hormone-based therapies cannot be used to 
treat TNBC as these cells do not have receptors for oestrogen, progesterone or HER2 proteins. 
Chemotherapy or radiotherapy is more toxic to the body’s immune system and in most cases 
creates resistive cancer cells. In addition, there is a high potential for reoccurrence of cancer 
and metastasis. Many studies have been conducted to expand our understanding of TNBC 
and to find alternative treatment options; as a consequence, many inhibitors are currently 
under development to treat TNBC (Cleator et al., 2007). 
Treatment directed against proliferative pathways such as cytokines and growth factors that 
activate receptors are promising therapeutic options for TNBC. Many compounds in these 
pathways are either overexpressed or mutated in cancer cells which provide potential 
therapeutic targets in the treatment of cancer (Adjei & Hidalgo, 2005).  
Recently, there has been growing interest in developing potential drugs and biomaterials from 
marine organisms for their particular physical and chemical properties. Researchers have 
identified a wide variety of active compounds including GAGs, which have the potential to 
inhibit the growth of human tumour cells in vitro and in vivo.  
Many marine polysaccharides are subjected to chemical modifications to yield derivatives 
that are degraded, semi-synthetic and smaller in size, which have been found to exhibit 
extensive and diverse biological action, such as treating and even preventing cancer.  
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In addition to their ability to induce programmed cell death (apoptosis) or anti-proliferation, 
as small molecules they have industrial value because they can increase drug design and drug 
discovery, since large fragments are unlikely to be good drug candidates. Their availability, 
lower toxicity and suitability for human application must also be taken into account.  
A study by Saravanan & Shanmugam, (2010), characterised crude GAGs extracted from the 
bivalve mollusc Amussium pleuronectus, which were fractionated by ion exchange 
chromatography to a low molecular weight, resulting in derivative exposed anticoagulant 
activity. This study suggested that GAG from bivalve molluscs could be an alternative source 
of heparin.  
Research has suggested that applying diverse extraction methods might yield different 
compounds that vary not only in their structural composition but also in their biological 
composition. For example, using two different methods for isolating brown seaweed 
Adenocystis utricularis at room temperature and 70 °C yielded two different compounds, 
each with totally different activities against herpes simplex virus 1 and 2 (Ponce et al., 2003). 
Another study by Ye et al., (2008), suggested that the biological activity of polysaccharide 
isolated from Sargassum pallidum was significantly increased by reducing the chain size and 
increasing the sulphation pattern.   
Several studies have investigated the biological activity of marine GAG extracts. Researchers 
have identified GAGs with anticoagulant, antibacterial, antiviral and anticancer properties. 
However, these studies have not addressed the treatment of aggressive cancers such as TNBC. 
Furthermore, while a few attempts have been made to characterise active GAGs from marine 
animal bodies, whelk has received little attention 
This chapter focuses on four objectives, the first of which is to examine the biological activity 
of crude whelk GAG extraction. Secondly, examine the biological activity of whelk GAG 
derivatives from different analytical techniques on two subtypes of TNBC, in order to 
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identify the most significant active fraction. The third objective is to evaluate the anti-
proliferation activity of whelk GAGs on cancer stem cell. Finally, determine the mechanism 
of action of whelk GAG on TNBC cell lines using label-free proteomic approaches.  
There are two types of proteomic, labelling approaches. The first is simply to label the 
peptides with isotopes; the second is to floresce labels then mix and analyse all the samples 
together in a single LC-MS/MS run. The peptides originating from different samples can then 
be distinguished in a mass spectrometer.  
By contrast, label-free approaches simply compare the peptides originating from different 
samples in different LC-MS/MS runs. Recently this approach has been widely used, 
especially as the sensitivity and resolution of LC-MS/MS has increased and with advances in 
computational algorithms (Nahnsen et al., 2013). Moreover, label-free quantitative 
proteomics is a powerful tool with which to estimate overall changes in protein abundances 
among a variety of different samples (Megger et al., 2013).  
One of the most effective tools for drug target identification is based on the comparison of 
protein expression between drug-treated and untreated tumour cells. This promising approach 
helps to characterise proteins enriched or isolated due to interacting or binding to bioactive 
molecules, causing what are called drug–protein interactions (Drewes, 2012). In 
pharmacology, proteomics is a promising tool for determining the specificity of drugs and for 
identifying new targets for interaction with known drugs or those that are sensitive to newly 
designed drugs. Proteomics also can provide direct information about side effects and 
toxicities to minimize failure in clinical trials (Sutton, 2012).     
It is important to examine the capability of whelk GAGs to induce cell death among small 
populations of cells known as cancer stem cells (CSC), and this chapter addresses this aspect 
of the current study. Initial bio screening of the whelk GAG crude extraction was carried out 
on mammosphere generated from MDA-MB-468, MDA-MB-231 and MCF-7. Promising 
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results were reported from all cell lines, further suggesting the importance of whelk GAGs in 
treating cells with cancer and stem cell properties among TNBC cells. 
 
5.2    Results 
5.2.1    Effect of intact GAG on triple negative breast cancer 
 
Both triple negative breast cancer cells (MDA-MB-468 and MDA-MB-231) were plated at a 
density of 3×103 in 96 well plates. Cells were incubated for 24 hours to allow confluent 
monolayer formation then washed and withdrawn from the effects of trypsin. Cells were 
incubated in the presence and absence of whelk GAG crude extractions. Serial dilution of 
whelk GAG extraction was used to treat the cells then incubated for 5 days, each condition 
was in triplicate. Cell proliferation was evaluated by measuring the absorbance of MTT dye 
(purple formazan crystals) using a plate reader. The percentage of viable cells was 
represented as mean ±SD, and IC50 was calculated for each cell line using GraphPad Prism 
5.0 software. The effect of crude whelk GAG extracts on both cell lines is illustrated in 
Figure 5-1. In the presence of whelk GAG, cell proliferation significantly decreased in both 
cell lines as the dosage increased. IC50 values of 3.48±0.02 µg/ml and 2.76±0.01 µg/ml were 








Figure 5-1: Inhibition activity of intact whelk GAG sample on negative breast cancer 
cells. 
Panel A: Cell proliferation inhibition of whelk GAG on MDA-MB-468. Panel B: Cell 
proliferation inhibition of whelk GAG on MDA-MB-231. Data represent the percentage of 
viable cells for sample size (n=3) as mean ± SD. Cells were cultured in monolayers and 
maintained at 37 °C in a humidified 5% CO2 atmosphere. Cytotoxicity assay were performed 
using an MTT colorimetric assay. The IC50 values were calculated using nonlinear 




5.2.2    Effect of HS/CS-disaccharide observed from digestion of whelk GAG and 
commercial porcine HS/CS on triple negative breast cancer 
 
To compare the bioactivity of whelk GAG extracts and commercial porcine HS/CS on triple 
negative breast cancer, both cell lines MDA-MB-468 and MDA-MB-231 were cultured in a 
monolayer in 96 well plates and dosed with a serial dilution of all compounds over a 5-day 
incubation at 37 ºC and 5% CO2, and each condition was in triplicate. In addition, whelk 
GAG extraction and commercial porcine HS/CD were subjected to enzyme de-
polymerisation using a mixture of Hep I, II, III and ABC lyase. The results from this 
experiment demonstrate the effect of whelk GAG extraction and the whelk GAG fragments 
library generated by Hep I, II, III/ABC lyase depolymerisations on both cell lines. This 
experiment has been repeated for commercial porcine HS/CS and its depolymerisation 
derivatives on TNBC.  
The results clearly suggest significant activity of crude extraction and fractions yielded from 
enzymatic digestion of Hep I, II, III and a combination of all Hep lyase. In addition, the 
results from the fragments generated by ABC lyase showed a dramatic anti-proliferation 
activity. However, the anti-proliferation activity reported from Hep depolymerisation 
fragments is slightly different from the anti-proliferation activity shown with fragments 
generated from ABC lyase. A noticeable resistance has been shown from TNBC cells toward 
whelk GAG fragments generated by Hep lyases, whereas a similar inhibition profile is 









Table 5-1: IC50 values of whelk GAG fragments libraries from Hep lyase and ABC 
lyase on TNBC cell lines.   
 






+ Hep I 
IC50 µg/ml 
whelk  GAG 
+ Hep II 
IC50 µg/ml 
whelk  GAG 














2.61 42.32 37.89 33.15 3.03 
2 MDA-MB-
231 
3.48 13.97 24.92 26.03 27.61 4.60 
 
Commercial porcine HS/CS have no inhibition activity on the MDA-MB-468 and MDA-MB-
231 cell line either before or after enzymatic degradation compared to the activity of whelk 
GAG crude extraction.  
The results shown in Figure 5-2 indicates the inhibition activity of whelk GAG crude 
extraction on the MDA-MB-468 and MDA-MB-231 cell line, in comparison to mammalian 
GAGs and their fragments generated by Hep lyase and ABC lyase degradation. This leads to 
conclude that mammalian GAG has no inhibition activity on TNBC cell lines, as compared to 



















Figure 5-2: Anti-proliferation activity of crude whelk GAG extracts compared to the 
activity of commercial mammalian HS/CS before and after enzymatic depolymerisation. 
Panel A1 and B1: Shown the effect toward MDA-MB-231 cell line. Panel A2 and B2: 
Shown the effect toward MDA-MB-468 cell line. The data represent the percentage of viable 
cells for sample size (n=3) as mean ± SD. Cells were cultured in monolayers and maintained 
at 37 °C in a humidified 5% CO2 atmosphere. Cytotoxicity assay were performed using an 




5.2.3    Cytotoxic effect of ion-exchange chromatography fractions of whelk GAG before 
and after oxidation with periodic acid on triple negative breast cancer cell lines 
 
Whelk GAG crude extraction was fractionated by ion exchange chromatography. The sample 
was eluted in a salt (ionic strength) gradient in order to group the GAG according to charge. 
As described in detail in Chapter 4, three fractions were obtained and examined for their 
activity on TNBC cells, MDA-MB-231 and MDA-MB-468. The results were compared with 
the activity obtained from GAG sample fractions that had been oxidised with periodic acid. 
The results shown in Figure 5-3 compare the percentage of viable cells (±SD) for each cell 
line after dosing the cells with 100 µg/ml fractions of CK1, CK2 and CK3 in both conditions 
(oxidised and non-oxidised with periodic acid) over a 5-day incubation period, with each 
condition performed in triplicate. The results shown in Panel A indicate highly significant 
inhibition activity of whelk GAG fragments CK1, CK2 and CK3 toward the MDA-MB-231 
cell line compared with untreated cells (negative control). However, the activity of these 
fractions on the same cell line varies after oxidation carried out by periodic acid. Treating the 
cell lines with an equal amount of whelk GAG fragments that is oxidised by periodic acid 
over the same period of time results in a high level of significant activity of fragments CK1 
and CK2, whereas fraction CK3 was found to be less significant. In addition, the percentage 
of viable cells obtained was higher from CK3 than from other fractions. This experiment was 
repeated with the MDA-MB-468 cell line. As shown in Figure 5-3 (Panel B), the activity of 
whelk GAG fractions oxidised with periodic acid remained similar to that of the non-oxidised 
GAG, with a significant level of activity being obtained from both conditions toward this cell 















                
 
Figure 5-3: Inhibition activity of whelk GAG fractions (CK1, CK2, and CK3) from 
anion-exchange comparing with the biological activity of fractions oxidised with 
periodic acid on triple negative breast cancer cells. 
Panel A shows highly significant activity of whelk GAG fractions CK1, CK2, and CK3 on 
MDA-MB-231 breast cancer cells from all fragments. This compares to the data shown in the 
second graph, which illustrates the activity of whelk GAG fragments CK1, CK2, and CK3 
treated with periodic acid oxidation (P), which shows a slightly different effect from each 
fragment CK2, CK2 and CK3. 
Panel B shows high significant activity of whelk GAG fragments CK1, CK2 and CK3 treated 
and untreated with periodic acid oxidation on MDA-MB-468 breast cancer cells. Data 
represent the percentage of viable cells for sample size (n=3) as mean ± SD. Cells were 
cultured in monolayers and maintained at 37 °C in a humidified 5% CO2 atmosphere. 





5.2.4    Cytotoxic activity of whelk GAG fractions CK1, CK2 and CK3 before and after 
enzymatic degradation on triple negative breast cancer cell lines 
 
Whelk GAG crude extraction was analysed using a variety of analytical techniques in order 
to identify the structure of the GAG in relation to the active part of the polymer responsible 
for their activity toward many cancer cell lines, including triple negative breast cancer. The 
inhibition activity remained for the retained fraction (R) which did not pass through the 
centrifuge filtration device following enzymatic degradation of all fragments obtained from 
whelk GAG by ion exchange chromatography.  
The aim of this experiment was to determine the activity of whelk GAGs that has been 
fractionated by ion-exchange chromatography and de-polymerised by enzymes. As described 
in detail in chapter 4, these compounds are passed through a 10K filter (Nanosep centrifugal 
devices with omega membrane). The monosaccharide and disaccharide composition of both 
the flow-through (FT) and the retained fractions (R) was then thoroughly analysed. After 
determining the molecules involved in the structural backbone of these two fractions (FT and 
R), the dried material was examined for its biological activity on the MDA-MB-231 and 
MDA-MB-468 breast cancer cell lines.  
An equal amount (100 µg/ml) of each fraction of FT and R of all fragments (CK1, CK2 and 
CK3) were incubated with both cell lines for five days at 37 ºC and 5% CO2. The cells were 
cultured in monolayer in 96 well plates and incubated for 24 hours, then the medium was 
changed and a fresh medium was added to all wells then dosed with 100 µg/ml of each 
fraction (FT and R) in triplicate. The cytotoxic activity was obtained using an MTT assay. 
The data were validated using GraphPad Prism 5.0 software. The results shown in Figure 5-4 
demonstrate the activity of whelk GAG which has been depolymerised by Hep lyase or ABC 
lyases and which has passed through the filter. This flow through (FT) is more likely to 
contain di or oligosaccharide that is smaller in size than the pore size of the filter and 
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therefore is capable of passing through the device. The other fraction, which is often larger in 
size than the filter and unable to pass through it, is called the retained fraction (R). The results 
shown in panel A1 and panel B1 indicate no activity of the FT fractions from Hep lyase on 
either the MDA-MB-231 or MDA-MB-468 cell line. Moreover, no inhibition activity was 
seen for the FT fraction of ABC lyase fragments against either cell line, as shown in Panels 
A3 and B3. On the other hand, highly significant inhibition activity was observed from the 






















Figure 5-4: Anti-proliferation activity of whelk GAG fractions CK1, CK2 and CK3 
before and after enzymatic degradation on triple negative breast cancer. 
 
Panel A: Inhibition activity of FT and R from Hep lyase and ABC lyase fragments on 
the MDA-MB-231 cell line. A1 shows the activity of FT fraction from a 10K filter of Hep 
lyase degradation of whelk GAG. A2 shows the activity of R fraction from a 10K filter of 
Hep lyase degradation of whelk GAG. A3 shows the activity of FT fraction from a 10K filter 
of ABC lyase degradation of whelk GAG. A4 shows the activity of R fraction from a 10K 
filter of ABC lyase degradation of whelk GAG for each fragments CK1, CK2 and CK3 from 
anion exchange chromatography.  
Panel B: Inhibition activity of FT and R from Hep lyase and ABC lyase on the MDA-
MB-468 cell line. B1 shows the inhibition activity of FT fraction from a 10K filter of Hep 
lyase degradation of whelk GAG. B2 shows the inhibition activity of R fraction from a 10K 
filter of Hep lyase degradation of whelk GAG. B3 shows the inhibition activity of FT fraction 
from a 10K filter of ABC lyase degradation of whelk GAG. B4 shows the inhibition activity 
of R fraction from a 10K filter of ABC lyase degradation of whelk GAG for each fragments 
CK1, CK2 and CK3 from anion exchange chromatography. Data represent the percentage of 
viable cells for sample size (n=3) as mean ± SD. Cells were cultured in monolayers and 
maintained at 37 °C in a humidified 5% CO2 atmosphere. Cytotoxicity assay were performed 





5.2.5     Cytotoxic effect of crude whelk GAG extracts on mammosphere formation in 
breast cancer 
 
It is critical to examine the capability of the new therapeutic candidate to induce cell death 
even among small populations of cells that has self-renewable properties. Herein, we 
examined the cytotoxic effect of crude whelk GAG extraction on mammosphere formation in 
three breast cancer cell lines’. Culture methods and materials are described in detail in 
chapter 2 (section 2.15).  
This experiment aimed first to determine the ability of different subtypes of breast cancer to 
induce mammosphere formation and then to highlight the potential inhibition activity of 
whelk GAG extraction on the tumourspheres formed in each cell line. Cells were plated in 
culture plates coated with poly-HEMA in triplicate and dosed with ideal IC50 values of 
whelk GAG crude extraction corresponding to each cell line, in serial concentrations of 20 µg, 
50 µg, and 100 µg/ ml. Plates were incubated for 5 days at 37 °C and 5 % CO2. In designing 
this experiment with different concentrations of whelk GAG alone in addition to the IC50 
values corresponding to each cell line, the aim was to compare the cytotoxic effect from each 
concentration on the mammosphere formation as these populations of cells usually are known 
for their resistance, which raises the possibility of inducing inhibition among them using 
different concentrations from the IC50 values of whelk GAGs used for primary breast cancer 
cells. 
The results obtained from culturing mammospheres clearly indicate that the capability of 
MCF-7 to form mammosphere is greater than that of either MDA-MB-231 or MDA-MB-468.  
Figure 5-5 (Panel A) illustrates the mammosphere formation in the MCF-7 cell line. Image A 
depicts the untreated mammosphere; images B, C, D and E show clusters of cells clumped 
together with no obvious signs of mammosphere formation. However, TNBC cell lines 
survived the non-adherent culture conditions and were able to grow a high number of cells in 
the suspension form, which confirms the ability of all subtypes of breast cancer cells to 
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develop malignancy and the high risk of metastasis. The mammosphere and clumped cells 
decreased when the cells treated with the IC50 values corresponded to each cell line. The 
images show that increasing the dose from 20 µg/ml to 50 µg/ml and 100 µg/ml induced 
significant cell death. Given that CSC possess the cell-surface phenotype CD44+/CD24−/low 
cells, further investigation is necessary into the CD44+/CD24−/low cell subpopulation on the 
mammosphere formation in MCF-7, MDA-MB-231 and MDA-MB-468 using fluorescence-
















Figure 5-5: Mammosphere formation in three breast cancer cell lines. 
Panel A: Mammosphere formation in the MCF-7 cell line. Image A (untreated) shows clear 
mammosphere formation; image B depicts cells treated with the desirable IC50 value; images 
C, D and E show the results of treatment for 5 days with 20 µg/ml, 50 µg/ml and 100 µg/ml 
GAG respectively. Panel B: Mammosphere formation in the MDA-MB-468 cell line. Image 
A (untreated) shows clumped cell formation; image B shows the results of treatment with 
desirable IC50 value; images C, D, and E depict cells treated for 5 days with 20 µg/ml, 50 
µg/ml and 100 µg/ml GAG respectively. Panel C: Mammosphere formation in the MDA-
MB-231 cell line. Cells survived and grew in suspension condition (image A, untreated); 
image B shows the result of treatment with desirable IC50 value; images C, D, and E depict 




5.2.6    Label free protein quantification  
5.2.6.1    Quantitative proteomics analysis 
 
Quantitative proteomics is one of the most powerful methods for identifying the regulation or 
dysregulation of biological systems that can result from changes in protein levels, changes in 
subcellular localization or changes in post-translational modifications (PTMs), which cause 
changes in protein-protein interactions. There are two types of quantitative analysis: relative 
quantification and absolute quantification. Relative quantification identifies changes in the 
expression level of protein between samples conditions, while absolute quantification 
determines the number of copies of the protein per cell and measures the expression level of 
different proteins within a single sample or between different samples. This approach is used 
in the pharmaceutical and biomedical industries for quality control, therapeutic analysis and 
drug testing purposes.  
Both relative and absolute quantification can be performed using one of two methods, 
labelling or label-free. In the labelling approach, a sample is labelled with either a metabolic 
label such as SILAC or 15N while in culture, or a chemical label such as like iTRAQ, ICAT, 
TMT and dimethyl after extraction and digestion of the protein from the cells or tissue. In the 
label-free approach, protein quantification usually is done by counting the spectra or ion 
intensities of individual samples run separately and the expression levels or protein 
abundance is calculated by comparison between different samples runs (Zhu et al., 2009). 
Here, the complex peptide mixture from triple negative breast cancer (TNBC) replicates were 
analysed. Digested samples were analysed by LC-MS/MS using an UltiMate® 3000 Rapid 
Separation LC (RSLC, Dionex Corporation, Sunnyvale, CA) coupled to a QE HF (Thermo 
Fisher Scientific, Waltham, MA) mass spectrometer. The complex spectra were further 
analysed using PROGENESIS Qi software, which performed the peak identification, 
followed by protein identification and protein quantification by searching with the web-based 
UniProt mapping tool. Two different conditions of the total proteome of breast tumours was 
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analysed in each cell line: untreated cells (control) and cells treated with whelk GAG crude 
extraction over 24 hours.  
The cut-off parameters used were p-value < 0.05 for determining the significant difference, 
and maximum fold ≥ 1.5 of the increase/decrease in protein levels. Analysis of the MS data 
identified 846 distinct proteins differentially expressed between treated and untreated samples 
in the MDA-MB-468 cell line. A total of 553 proteins were identified and were differentially 
expressed between treated and untreated sample in the MDA-MB-231 cell line.  
Normalised abundance is calculated as the sum of the normalised area under the curve for all 
the quantitative peptides for each sample, whereas raw abundance is the sum of the raw (real) 
area under the curve for all the quantitative peptides for each sample. A comparison of all 
data is shown in Figure 5-6. Principal component analysis (PCA), which was performed to 
obtain a simplified data visualisation, shows that sample groups cluster reasonably well and 
that the greatest variation in the data is attributable to the cell line when followed by the 
treatment. The data clusters for each individual cell line, which are also shown, indicate that 
the greatest change is most likely caused by the treatment applied to the cells. In these cases, 
the p-value obtained from statistical analysis of the samples most likely accounts for the 










Figure 5-6: Principal Component Analysis PCA of Triple Negative Breast Cancer 
TNBC cells proteome at protein level. 
PCA of both cell lines shown in colour variation as follows: control (blue) and Whelk GAG 
treated (purple) in MDA-MB-468, and control (orange) and whelk GAG treated (green) in 




5.2.6.2    Mapping identified proteins to functional clusters in two triple negative breast 
cancer cell lines  
 
Gene ontology analysis of all the proteins identified from two cell lines was obtained by 
Protein ANalysis THrough Evolutionary Relationships (PANTHER version 11.1) (Mi et al., 
2013). Firstly, existing ANOVA p-values were extracted from the data from the two label-
free proteomic analyses and imported into R. Benjamini-Hochberg, p-values then were 
derived from the existing p-values for each analysis using the ‘p.adjust’ method and volcano 
plot images were obtained using R (Figure 5-7). Protein groups which were under the 5% 
significance threshold were selected for further analysis.  
The functional classification was summarised using PANTHER biological process (BP) gene 
ontologies, molecular function (MF) gene ontology and cellular component (CC) gene 
ontology, using the list of all identified proteins from each cell line as data input. Proteins 




Gene ontology (GO) molecular function categories according to the PANTHER database in 
both TNBC cell lines (Figures 5-8 (A) and 5-9 (A)) showed that the majority of the identified 
proteins are categorised being catalytically active and protein having binding properties. The 
percentage of each functionally overrepresented cluster varies between cell lines. For instance, 
metabolic activity represents the majority of molecular function in MDA-MB-468 for 
GTPase activity and pyrophosphatase activity (39%), followed by protein binding (37%) and 
structural molecular activity (10%), while the majority of molecular function in MDA-MB-
231 is categorised as protein binding (47%), metabolic activity (21%) and structural 
molecular activity (15%). The majority of protein binding is related to cytoskeletal protein 
binding, for example actin binding and microtubule binding, followed by receptor binding 
such as growth factor activity and hormone activity.   
The remaining identified proteins in both cell lines contributed to transporter activity, signal 
transduction activity and receptor activity. A closer look at the BP ontologies of these 
proteins (Figure 5-8 (B) and 5-9 (B)) showed 29% and 28% of the identified proteins were 
related to the cellular process in MDA-MB-468 and MDA-MB-231 respectively, while 27% 
in MDA-MB-468 and 18% in MDA-MB-231 related to the metabolic process.  
The distribution of protein localisation in MDA-MB-468 (Figure 5-8 (C)) showed that the 
majority of the identified platelet proteins were located in parts of the cell, including 
cytoplasmic proteins (43%), organelles (32%) and the macromolecular complexes (16%). 
The remaining proteins contributed to the membrane (7%) and extracellular region (1%) 
respectively. The distribution of protein localisation in MDA-MB-231 (Figure 5-9 (C)) was 
restricted to the parts of the cell (33%) and cell organelle (29%); the remainder of the 
identified proteins were mapped to the macromolecular complex (16%), membrane (8%), 
extracellular region (8%) and extracellular matrix (6%). 
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Furthermore, gene functional annotation in a network context was performed using online 
tools including Database for Annotation, Visualization and Integrated Discovery (DAVID). 
This tool has developed functions to cluster related GO terms or genes, an approach that 
allows the enrichment analysis to progress from gene-centric to biological module-centric 
analysis. These methods take into account the networked nature of biological annotation 
content in order to concentrate on building the larger biological picture from gene group-
based analysis rather than focusing on an individual term or gene. Like other methods, this 
method has obvious limitations, as genes that have a weak relationship with other genes or 
terms will not be included in the analysis.  
Proteomic data were analysed to generate biological functional clusters, which were verified 
by the significant enrichment of the online tool, DAVID v6.8 (https://david.ncifcrf.gov). For 
both MDA-MB-468 and MDA-MB-231, experiments with proteins with adjusted p-values of 
less than 0.05 generated functional annotation clustering. The ontologies were ranked by the 
significance of enrichment calculated using the DAVID online tool. A false discovery rate 
(FDR) corrected p-value was calculated for each protein for multiple hypothesis comparisons 
by the Benjamini-Hochberg method (Benjamini & Hochberg, 1995). Briefly, this uses a 
strategy to identify groups of genes with high connectivity; these groups contain genes 
defined by similar functional properties and can be considered as functional clusters.  Lists of 





Figure 5-7: Volcano plot images were produced using R, for each analysis, for corrected 
p-values. 
Panel A presents data for whelk GAG treated vs control samples in the MDA-MB-468 cell 
line. Panel B presents data for treated vs control samples in the MDA-MB-231 cell line. High 
values on the y-axis of a volcano plot indicate low p-values, so higher –log10 (p-values) are 
the most significant. The x-axis (fold change) is log2-scaled, so a value of 0 indicates no ‘fold 
change’. The fold change corresponds to the ratio of C / T (control / treated) for each protein 
(group). Points are coloured as follows: absolute fold changes larger than 1 is orange, a p-
value less than 0.05 is red, if the p-values is less than 0.05 and the absolute fold change is 

























Figure 5-8: Function classification from PANTHER online tool analysis of differential 
proteins expressed in the MDA-MB-468 cell line upon GAG treatment. 
Panel A: Functionally enriched GO: Molecular function categories. Panel B: Functionally 
























Figure 5-9: Function classification from PANTHER online tool analysis of differential 
proteins expressed in the MDA-MB-231 cell line upon GAG treatment. 
Panel A: Functionally enriched GO: Molecular function categories. Panel B: Functionally 





For every functional category from a number of sources (e.g. GO, KEGG, INTERPRO) there 
are associated proteins, counts in experimental/reference data, fold enrichment values, p-
values and Bonferroni/Benjamini/FDR corrected p-values. Here the most enriched functional 
categories in the experimental data are visualised. However, the functional categories are 
clustered together based on the proteins/genes annotated in each functional category. An 
enrichment score is given for each cluster. Based on the results of this analysis shown in 
Tables 5-2 and 5-3, highest enrichment scores were obtained for cadherin binding involved in 
cell-cell adhesion, and the cell-cell adherent’s junction and extracellular matrix in both 
TNBC cell lines. Cell adhesion is an important process on the tissue level for maintaining 
morphologies and their functions in an integrated manner. It is known as an interaction 
between a cell and a surface, substrate or another cell that occurs from the action of 
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transmembrane glycoproteins, called cell adhesion molecules, such as receptors. Such 
processes have a crucial role in tumour progression, in particular during invasion and 
metastasis (Cavallaro & Christofori, 2004).  
Cadherins (calcium-dependent adhesion) are defined as any cadherin binding that occurs as 
part of the process of cell-cell adhesion. A class of type-1 transmembrane protein, they play 
important roles in cell adhesion, forming adherens junctions to bind cells within tissues 
together, and therefore play a critical role during tissue differentiation. They are dependent on 
calcium (Ca2+) ions to function. There are 18 proteins involved in this biological function in 
the human proteome and the cytosol-facing domains of these proteins are usually connected 
to elements of the cytoskeleton (Lodish et al., 1995).  
This finding is in line with the data generated from PANTHER. The molecular function and 
biological process annotations were enriched in both TNBC cell lines for protein binding, 
which involved cytoskeletal protein binding, receptor binding and calcium ion binding.  
Another annotation cluster shown in Table 5-2 relates to the MAPK cascade signalling 
pathway. This is probably the most important in instigating the cellular response to the whelk 
GAG. Mitogen-activated protein kinases (MAPKs) are a highly conserved family of 
serine/threonine protein kinases involved in a variety of fundamental cellular processes such 
as proliferation, differentiation, motility, stress response, apoptosis and survival. Other 
proteins that are enriched contribute to cellular processes such as signal transduction/cell 
communication that initiate by binding to cell receptors (Seger & Krebs, 1995). However, the 
proteins related to nucleic acid binding transcription factor activity appeared to be less 
important during cell growth inhibition by whelk GAG.  
The finding indicated that whelk GAG contributed to the interaction of the protein with an 
integrin and growth factor. Neuregulin (NRG) is an example of a specific growth factor that 
has a unique heparin-binding domain; binding to their receptors leads to rapid receptor-
 168 
 
tyrosine phosphorylation and activation of downstream signalling pathways. The heparin-
binding domain binds specific sulphate groups on negatively charged HSPGs, leading to a 
highly specific tissue distribution of NRG (Pankonin et al., 2005).   
Other proteins that were found to be enriched in the MDA-MB-231 cell line are involved in 
important pathways, such as PI3K-Akt signalling pathway. It is known to contribute to the 
biology of various types of cancer including proliferation, adhesion, angiogenesis and 
metastasis. These findings suggest the influence of whelk GAG to downregulate crucial 
pathways such as proliferation, adhesion, migration and metastasis of breast cancer cells 






     
Table 5-2: Adjusted functional annotation clustering of significant proteins from DAVID online analysis of label--free proteomic data 
from the MDA-MB-468 cell line. 
Functional annotation clustering was conducted using DAVID analysis tool using subset data from quantitative proteomics analysis. Fold 
enrichment measures the magnitude of enrichment compared to human genome. Fold enrichment > 2 was considered as significant. The 
population percentage is the total number of proteins involved in a given term divided by the total number of input proteins. P-values examine 
the significance of gene-term enrichment. P-value <0.05 was considered significant. Existing ANOVA p-values were extracted from the two 
label-free proteomic analyses and imported into R. Benjamini-Hochberg p-values and were derived from the existing p-values for each analysis 
using the ‘p. adjust’ method. Protein groups which were under the 5% significance threshold for corrected p-values were selected for further 
analysis. False discovery rate (FDR) is the corrected over-representation probability, helps estimating the false positives and it is calculated 
using the Benjamini-Hochberg approach. 
 










 Category Term % pValue Fold 
Enrichment 
Bonferroni Benjamini FDR 
 GOTERM_MF_DIRECT GO:0098641~cadherin 
binding involved in cell-
cell adhesion 
8.95 1.57E-13 5.33 8.84E-11 2.95E-11 2.30E-10 
 GOTERM_CC_DIRECT GO:0005913~cell-cell 
adherens junction 
8.95 5.24E-13 5.11 2.36E-10 7.85E-11 7.43E-10 
 GOTERM_BP_DIRECT GO:0098609~cell-cell 
adhesion 



















 Category Term % pValue Fold 
Enrichment 





4.62 3.18E-11 10.27 5.87E-08 2.94E-08 5.41E-08 
 GOTERM_BP_DIRECT GO:0006521~regulation 
of cellular amino acid 
metabolic process 




2.31 1.09E-07 19.02 6.12E-05 1.53E-05 1.59E-04 
 GOTERM_BP_DIRECT GO:0033209~tuomur 
necrosis factor-mediated 
signaling pathway 
3.46 2.11E-05 5.15 0.03 0.002 0.03 
 GOTERM_BP_DIRECT GO:0002223~stimulatory 
C-type lectin receptor 
signaling pathway 
3.17 4.15E-05 5.31 0.07 0.004 0.07 
 GOTERM_BP_DIRECT GO:0050852~T cell 
receptor signaling 
pathway 
3.17 6.97E-04 3.77 0.72 0.052 1.18 
 GOTERM_BP_DIRECT GO:0000165~MAPK 
cascade 
4.33 7.09E-04 2.90 0.73 0.051 1.20 
 GOTERM_CC_DIRECT GO:0000932~cytoplasmic 
mRNA processing body 























 Category Term % pValue Fold 
Enrichment 
Bonferroni Benjamini FDR 
 UP_KEYWORDS mRNA processing 6.93 1.10E-08 4.29 3.66E-06 4.57E-07 1.49E-05 
 UP_KEYWORDS mRNA splicing 5.78 9.24E-08 4.57 3.09E-05 2.81E-06 1.26E-04 
 GOTERM_BP_DIRECT GO:0000398~mRNA 
splicing, via spliceosome 
5.20 1.96E-06 4.11 0.003 3.01E-04 0.003 
 UP_KEYWORDS Spliceosome 3.46 9.86E-06 5.62 0.003 1.94E-04 0.013 
 GOTERM_CC_DIRECT GO:0005681~spliceosomal 
complex 
3.17 1.04E-05 6.23 0.004 3.59E-04 0.014 
 GOTERM_CC_DIRECT GO:0071013~catalytic step 
2 spliceosome 
2.60 3.29E-04 5.21 0.13 0.007 0.465 
 GOTERM_BP_DIRECT GO:0008380~RNA 
splicing 
3.17 0.001 3.36 0.95 0.09 2.807 
 KEGG_PATHWAY hsa03040:Spliceosome 3.17 0.003 2.97 0.56 0.09 4.562 
 GOTERM_BP_DIRECT GO:0006397~mRNA 
processing 





Table 5-3: Adjusted functional annotation clustering of significant proteins from DAVID online analysis of label-free proteomic data 
from MDA-MB-231 cell line. 
Functional annotation clustering was conducted using DAVID analysis tool using subset data from quantitative proteomics analysis. Fold 
enrichment measures the magnitude of enrichment compared to human genome. Fold enrichment > 2 was considered as significant. The 
population percentage is the total number of proteins involved in a given term divided by the total number of input proteins. P-values examine 
the significance of gene-term enrichment. P-value <0.05 was considered significant. Existing ANOVA p-values were extracted from the two 
label-free proteomic analyses and imported into R. Benjamini-Hochberg p-values and were derived from the existing p-values for each analysis 
using the ‘p.adjust’ method. Protein groups which were under the 5% significance threshold for corrected p-values were selected for further 
analysis. False discovery rate (FDR) is the corrected over-representation probability, helps estimating the false positives and it is calculated 
using the Benjamini-Hochberg approach. 
 










 Category Term % pValue Fold 
Enrichment 
Bonferroni Benjamini FDR 
 GOTERM_CC_DIRECT GO:0031012~extracellular 
matrix 
10.14 8.21E-04 6.24 0.13 0.04 1.00 
 GOTERM_BP_DIRECT GO:0007155~cell 
adhesion 
10.14 0.009 3.76 0.99 0.35 14.00 
 GOTERM_BP_DIRECT GO:0010811~positive 
regulation of cell-substrate 
adhesion 



















 Category Term % pValue Fold 
Enrichment 
Bonferroni Benjamini FDR 
 GOTERM_MF_DIRECT GO:0031072~heat 
shock protein binding 
5.79 6.14E-04 23.64 0.10 0.02 0.75 
 GOTERM_BP_DIRECT GO:0006457~protein 
folding 
7.24 0.005 6.85 0.98 0.26 8.44 
 GOTERM_MF_DIRECT GO:0051082~unfolded 
protein binding 
5.79 0.009 9.02 0.81 0.16 11.07 





Annotation Cluster 3 Enrichment Score: 2.21    
 Category Term % PValue Fold 
Enrichment 
Bonferroni Benjamini FDR 
 UP_SEQ_FEATURE region of interest:Heparin-
binding 
5.79 4.07E-05 58.15 0.01 0.01 0.05 
 GOTERM_MF_DIRECT GO:0005178~integrin 
binding 
8.69 6.01E-05 14.18 0.01 0.01 0.07 
 UP_KEYWORDS Heparin-binding 7.24 2.06E-04 16.94 0.03 0.007 0.25 
 GOTERM_BP_DIRECT GO:0030198~extracellular 
matrix organization 
8.69 0.001 7.55 0.55 0.15 1.66 
 GOTERM_BP_DIRECT GO:0033627~cell adhesion 
mediated by integrin 
4.34 0.001 49.38 0.69 0.15 2.39 
 UP_SEQ_FEATURE domain:VWFC 4.34 0.001 48.46 0.39 0.22 2.21 
 KEGG_PATHWAY hsa04145:Phagosome 8.69 0.002 6.30 0.25 0.25 2.52 
 GOTERM_MF_DIRECT GO:0008201~heparin 
binding 
7.24 0.003 7.75 0.48 0.10 4.49 
 GOTERM_MF_DIRECT GO:0050840~extracellular 
matrix binding 
4.34 0.004 28.64 0.56 0.09 5.66 
 GOTERM_BP_DIRECT GO:0007160~cell-matrix 
adhesion 
5.79 0.005 10.97 0.98 0.27 8.13 
 SMART SM00214:VWC 4.34 0.006 23.29 0.31 0.31 6.57 
 GOTERM_BP_DIRECT GO:0007155~cell adhesion 10.14 0.009 3.76 0.99 0.35 14.00 
 INTERPRO IPR001007:von Willebrand 
factor, type C 
4.34 0.009 19.68 0.89 0.42 11.92 






 UP_KEYWORDS Cell adhesion 8.69 0.021 3.73 0.97 0.24 22.92 
 INTERPRO IPR000884:Thrombospondin, 
type 1 repeat 
4.34 0.023 12.41 0.99 0.66 26.41 
 KEGG_PATHWAY hsa05205:Proteoglycans in 
cancer 
7.24 0.032 4.01 0.98 0.88 31.88 
 KEGG_PATHWAY hsa04512:ECM-receptor 
interaction 
4.34 0.097 5.54 0.99 0.89 69.87 
 KEGG_PATHWAY hsa04510:Focal adhesion 5.79 0.128 3.12 0.99 0.86 80.03 
 KEGG_PATHWAY hsa04151:PI3K-Akt signaling 
pathway 
7.24 0.155 2.32 1 0.86 86.15 
 GOTERM_CC_DIRECT GO:0009897~external side of 
plasma membrane 




5.2.6.3    Cell signalling pathway analysis 
 
The online PANTHER tool makes it possible to identify components of functional pathways 
from lists of dysregulated proteins. This allows candidate dysregulated pathways to be 
selected for more detailed investigation. PANTHER uses binomial statistics tools to compare 
a given gene list to a reference list (NCBI: Homo sapiens genes) to determine statistically 
significant overrepresentation of functional groups of genes. The approach employed in this 
chapter uses the quantitative proteomic data derived from label-free quantitative proteomic 
analysis from two triple negative breast cancer cell lines, MDA-MB-468 and MDA-MB-231. 
Each identified protein was automatically annotated according to the pathways in which it is 
involved. The respective pathways were then statistically analysed for their over-
representation, and a list of the possible pathways through which whelk GAG inhibits cancer 
growth was generated. The resulting list was then filtered using a minimum 3-fold 
enrichment and p-value < 0.05 for the enrichment of data output. The pathways enriched in 
both cell lines are listed in tables 5-4 and 5-5. When subset data from the MDA-MB-468 cell 
line was used as data input, the result showed five pathways are significantly involved in the 
whelk GAG modes of action. Four pathways were significantly enriched in MDA-MB-231 
cell line. 
Table 5-4: Pathways enriched in MDA-MB-468 from PANTHER online analysis. 








Glycolysis 22      8 14.98 1.54E-05 
DNA replication 35     12 14.13 1.90E-08 
Ubiquitin proteasome pathway 66     11 6.87 1.51E-04 
EGF receptor signaling pathway 139     14 4.15 1.78E-03 





Table 5-5: Pathways enriched in MDA-MD-231 from PANTHER online analysis. 








De novo pyrimidine deoxyribonucleotide 
biosynthesis 
13 4 19.04 1.07E-02 
DNA replication 35 7 12.37 3.37E-04 
Cytoskeletal regulation by Rho GTPase 83 10 7.45 2.21E-04 
Integrin signalling pathway 192 12 3.87 1.38E-02 
 
According to the results observed from PANTHER and REACTOME from MDA-MB-468 
cell line, whelk GAG have an impact on EGF receptor signalling pathway and FGF signalling 
pathway. Whelk GAG might bind to EGFR and block RAS signalling which eventually 
inhibit phosphatidylinositol 3-kinase PI3K-AKT- mTOR, this further leads to cell arrest and 
anti-proliferation. RAS is a chain of proteins in the cell that communicates a signal from a 
receptor on the surface of the cell to the DNA in the nucleus of the cell. It is normally 
activated in response to the binding of extracellular ligands to various receptors such as 
epidermal growth factor (EGF) binding to its cognate receptor EGFR, Upon EGF binding to 
the extracellular domain of EGFR, the intracellular domain of EGFR forms an asymmetric 
dimer in the cytosol. EGFR and its ERBB receptor family members can form homo- or 
hetero-dimers. Downstream signalling proceeds through Ras in the Raf-MEK-ERK which is 
a key Ras effector pathway, known as the mitogen-activated protein kinase (MAPK), Raf-
MEK- ERK pathway, and/or PI3K-Akt-mTOR pathways. The signalling is involved in 
numerous cellular functions, including cell proliferation, apoptosis, migration, and 




PANTHER pathway analysis suggests that DNA replication signalling pathways are affected 
in MDA-MB-468 and MDA-MB-231 as a consequence of GAG treatment. This pathway is a 
complex network of interacting proteins and enzymes that are required for DNA replication. 
The role for DNA replication stress in human tumourigensis has been extensively studied. 
The early stages of cancer development, before genomic instability and malignant conversion 
commonly express markers of an activated DNA damage response to delay cancer. These 
include phosphorylated kinases ATM and Chk2, phosphorylated histone H2AX and p53. 
However, mutations in some pathways such as ATM or p53 might allow cell proliferation 
(Bartkova et al., 2005).  
REACTOME (http://reactome.org) is a free bioinformatics online tool for visualisation and 
analysis of pathways to support genome analysis of large gene lists derived from high-
throughput genomic, proteomic approaches. Pathway analysis is a powerful tool for 
extracting meaning from a long list of differentially expressed genes and proteins. 
REACTOME offers a set of pathway analysis tools which aim to deal with the large size of 
the data samples, and provides reliable and accurate results as well as additional information. 
The analysis algorithm conducted in REACTOME is comprised of four steps. The first 
involves finding matches between the protein/gene identifiers in the user’s sample and the 
background data contained in REACTOME. The second step involves grouping the identified 
proteins in sets or species projections. This is followed by aggregating the found identifiers in 
the pathways and finally, performing statistical testing to calculate the likelihood that the 
association between the sample identifiers and the found pathway is due to random chance 
(Fabregat et al., 2017).  
According to García-Campos et al., (2015), the simple hypothesis in an over-representation 
analysis is that relevant pathways can be detected if the proportion of differentially expressed 
genes within a given pathway exceeds the proportion of genes that could be randomly 
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expected. The method used by Reactome to calculate statistical significance is the Binomial 
Test. Together with the p-value, the false discovery rate (FDR) helps to estimate false 
positives and is calculated using the Benjamini-Hochberg approach (Benjamini & Hochberg, 
1995).  
Here, a set of protein IDs from proteomic data for each cell line was uploaded in 
REACTOME, which served as an additional tool with which to verify the previous pathway 
analysis results from PANTHER and functional annotation clustering from DAVID. The 
output was filtered by searching for pathways with an entities p-value < 0.05. The over-























Pathway name Entities 
pValue 
Entities FDR 
R-HSA-216083 Integrin cell surface interactions < 0.01 < 1% 
R-HSA-
1474244 
Extracellular matrix organization < 0.01 < 1% 
R-HSA-
5687128 
MAPK6/MAPK4 signalling < 0.01 < 1% 
R-HSA-70171 Glycolysis < 0.01 < 1% 
R-HSA-
8866910 
TFAP2 (AP-2) family regulates 
transcription of growth factors and 
their receptors 
< 0.01 < 1% 
R-HSA-
3371497 
HSP90 chaperone cycle for steroid 
hormone receptors (SHR) 
< 0.01 < 1% 
R-HSA-140342 Apoptosis induced DNA fragmentation < 0.01 < 1% 
R-HSA-211227 Activation of DNA fragmentation 
factor 
< 0.01 < 1% 
R-HSA-179419 APC:Cdc20 mediated degradation of 
cell cycle proteins prior to satisfation 
of the cell cycle checkpoint 
< 0.01 < 1% 
R-HSA-392517 Rap1 signalling (cell cycle) < 0.01 < 1% 
R-HSA-
8866911 
TFAP2 (AP-2) family regulates 
transcription of cell cycle factors 
< 0.01 < 1% 
R-HSA-69473 G2/M DNA damage checkpoint < 0.05 < 1% 
R-HSA-351906 Apoptotic cleavage of cell adhesion  
proteins 
< 0.05 < 1% 
R-HSA-70326 Glucose metabolism < 0.05 < 1% 
R-HSA-
5626467 
RHO GTPases activate IQGAPs < 0.05 < 1% 
R-HSA-351906 Apoptotic cleavage of cell adhesion  
proteins 
< 0.05 < 1% 
R-HSA-
2262752 
Cellular responses to stress < 0.05 < 1% 
R-HSA-
5638302 
Signalling by Overexpressed Wild-
Type EGFR in Cancer 
< 0.05 < 1% 
R-HSA-
5638303 
Inhibition of Signalling by 
Overexpressed EGFR 
< 0.05 < 1% 
R-HSA-
5637812 
Signalling by EGFRvIII in Cancer < 0.05 < 1% 
R-HSA-
5673001 








Pathway name Entities 
pValue 
Entities FDR 
R-HSA-216083 Integrin cell surface interactions < 0.01 < 1% 
R-HSA-
1474244 
Extracellular matrix organization < 0.01 < 1% 
R-HSA-
5683057 
MAPK family signalling cascades < 0.01 < 1% 
R-HSA-
5625900 
RHO GTPases activate CIT < 0.01 < 1% 
R-HSA-351906 Apoptotic cleavage of cell adhesion  
proteins 
< 0.01 < 1% 
R-HSA-351906 Apoptotic cleavage of cell adhesion  
proteins 
< 0.01 < 1% 
R-HSA-
2644603 
Signalling by NOTCH1 in Cancer < 0.01 < 1% 
R-HSA-
5626467 
RHO GTPases activate IQGAPs < 0.05 < 1% 
R-HSA-69205 G1/S-Specific Transcription < 0.05 < 1% 
R-HSA-68886 M Phase < 0.05 < 1% 
R-HSA-
8956320 
Nucleobase biosynthesis < 0.05 < 1% 
R-HSA-170834 Signalling by TGF-beta Receptor 
Complex 
< 0.05 < 1% 
R-HSA-176814 Activation of APC/C and 
APC/C:Cdc20 mediated degradation of 
mitotic proteins 
< 0.05 < 1% 
R-HSA-176408 Regulation of APC/C activators 
between G1/S and early anaphase 
< 0.05 < 1% 
R-HSA-
8875878 
MET promotes cell motility < 0.05 < 1% 
R-HSA-
8852276 
The role of GTSE1 in G2/M 
progression after G2 checkpoint 
< 0.05 < 1% 
R-HSA-174143 APC/C-mediated degradation of cell 
cycle proteins 
< 0.05 < 1% 
R-HSA-453276 Regulation of mitotic cell cycle < 0.05 < 1% 
R-HSA-
8874081 
MET activates PTK2 signalling < 0.05 < 1% 






The analysis revealed several pathways and sub-pathways, of which the integrin cell surface 
interactions pathway was the most overrepresented.  
Integrins are the receptors that mediate cell adhesion to the extracellular matrix ECM. 
Integrins consists of one alpha and one beta subunit forming a non-covalently bound 
heterodimer. Eighteen alpha and eight beta subunits have been identified in humans that 
combine to form 24 different receptors. The control of integrin function occurs via regulatory 
signals that originate within the cell cytoplasm and are then transmitted to the external ligand-
binding domain of the receptor. As previously indicated by DAVID annotation analysis, 
REACTOME pathway analysis showed that whelk GAG demonstrated a direct inhibition 
towards the signalling of these integrins through their receptors.  
ECM composition is highly heterogeneous and dynamic, modulated largely by matrix 
metalloproteinases (MMPs) and growth factors. Collagen is the most abundant fibrous 
protein within the ECM, constituting up to 30% of total protein in multicellular animals. It 
provides tensile strength and the ability to recover after stretching (Daley et al., 2008). Whelk 
GAG affected the collagen through their signalling events in both cell lines. 
ECM performs many functions such as proliferation, adhesion and migration, and regulates 
cell differentiation and death (Hynes, 2009). Within the pathways related to extracellular 
matrix organization, whelk GAG was found to influence deregulated cell proliferation and 
invasion, potentially attributed to the inhibition of the epidermal growth factor (EGF) 
signalling cascade. Thus suggesting that whelk GAG specifically influence cell proliferation 
and adhesion, as also was shown by the data obtained from PANTHER.  
As described in the previous section, our study has demonstrated that whelk GAG reduced 
the level of glycolysis in the MDA-MB-468 cell line following 24 hours of treatment. In line 
with this finding, REACTOME pathway analysis showed that whelk GAG interfered with the 
glycolysis metabolic complex signalling cascade that converts glucose 6-phosphate to 
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pyruvate, which then controls rearrangement of cancer cells metabolism. Glucose via 
glycolysis provides the carbon skeletons, NADPH and ATP, to build new cancer cells, which 
persist in hypoxia that in turn rewires metabolic pathways for cell growth and survival (Dang, 
2012).  
Interestingly, this effect has not been reported from MDA-MB-231.  This cell line looks to 
have been effected less by the GAG treatment (figure 5-5). It may be the glycolysis effects 
are a later effect of whelk GAG treatment as the cells begin to die.  
Moreover, pathway analysis using subset data from the MDA-MB-468 and MDA-MB-231 
cells showed direct effect of whelk GAG on Rho GTPase (guanine-nucleotide-exchange 
factors (GEFs) or GTPases). The latest are molecular switches that control a wide variety of 
signal transduction pathways in all cells. They are known principally for their pivotal role in 
regulating the actin cytoskeleton, but their ability to influence cell polarity, microtubule 
dynamics, membrane transport pathways and cell cycle progression is probably just as 
significant (Bremm et al., 2008; Mateus et al., 2007). Specific members of the Rho family 
and their downstream targets contribute to the regulation of key elements from the core cell 
cycle machinery, mostly involved in the G1/S transition (Villalonga et al., 2006). 
Moreover, pathway analysis using subset data from the MDA-MB-231 cell line showed 
selective effect of whelk GAG on Notch signalling pathway. Notch signalling is a highly 
conserved signal transduction pathway that regulates stem cell maintenance and 
differentiation in several organ systems. Upon activation, the Notch receptor is 
proteolytically processed, its intracellular domain (NICD) translocates into the nucleus and 
activates expression of target genes. A crosstalk with other conserved signalling pathways 
such as the Wnt, Hedgehog, hypoxia and TGFβ/BMP pathways can affect Notch signalling 
output (Borggrefe et al., 2016).  
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This regulation can happen by regulation of ligand, receptor or transcription factor 
expression, regulation of protein stability of intracellular key components, usage of the same 
cofactors or coregulation of the same key target genes (Borggrefe et al., 2016). Since 
carcinogenesis is often dependent on at least two of these pathways, a better understanding of 
their molecular crosstalk is pivotal. There are various examples of elevated Notch signalling 
being associated with a particular subtype of breast cancer and response to targeted therapy. 
For example, elevated Notch1 expression is found in HER2 +ve (Zardawi et al., 2010)  and 
triple negative/basal breast tumours (Reedijk et al., 2008). Recently, a study has identified a 
series of activating mutations within the PEST domain of Notch1, Notch2, and Notch3, these 
mutations were enriched in triple negative breast cancers (Wang et al., 2015).  
Notch signalling is known to regulate many cellular processes of breast cancer including 
proliferation by upregulating cyclinA, cyclinB, and cyclinD1 expression (Rizzo et al., 2008), 
angiogenesis, by activate Notch signalling in neighbouring endothelial cells to promote 
angiogenesis (Dufraine et al., 2008; Zeng et al., 2005), metastasis, as shown by Sethi et al., 
(2011), the breast cancer cell line MDA-MB-231 was forced to express the Notch ligand 
Jagged1, and this was found to significantly increase bone metastasis.  
Finally, Notch signalling was found to regulate cancer stem cell activity, by regulating the 
self-renewal of breast cancer stem cells (Harrison et al., 2010; Harrison et al., 2013).  
Altogether, it is very clear that activation of Notch plays a key role in breast cancer. 
Therefore it represents a very attractive therapeutic target for many breast cancer subtypes, 
such as ER-positive tumours, as they frequently develop resistance to endocrine treatments. 
Several recent studies have suggested that ER mutations may occur during endocrine 
treatment (Robinson et al., 2013).  More recently, pharmacologic and genetic inhibition of 
the Notch signalling was found to reduce breast CSC activity in vitro and tumour formation 

























Figure 5-10: The integrin cell surface interactions pathway. 
Downregulation (showing in a dark blue) in the majority of integrin signalling events in the cytosol in the MDA-MB-468 cell line (Panel A1, B1, 
C1 and D1) and MDA-MB-231 cell line (Panel A2, B2, C2 and D2).  
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5.3    Discussion 
 
This chapter set out to assess the impact of the crude whelk GAG extracts and their fragments 
on TNBC cell proliferation and to investigate their mode of action on TNBC using label-free 
proteomic approaches. In addition, this chapter has described the results from experiments 
designed to examine the activity of whelk GAGs toward cancer stem cells by using 
mammosphere assays on different breast cancer subtypes.  
The main finding of this chapter is that whelk GAG crude extracts have significant inhibitory 
activity on the triple negative breast cancer cell lines MDA-MB-231 and MDA-MB-468. 
Remarkable IC50 values were reported from both cell lines, with nearly 3.48±0.02 µg/ml and 
2.76±0.01 µg/ml observed from MDA-MB-231 and MDA-MB-468 respectively.  
A comparison between the bioactivity of whelk GAG extracts and commercial mammalian 
HS/CS on triple negative breast cancer has been reported under two conditions, before and 
after enzymatic degradation of each source of GAG (whelk and commercial mammalian 
HS/CS). The results indicated no growth inhibitory activity from commercial mammalian 
HS/CS either before or after enzymatic degradation on TNBC cell lines. By contrast, 
significant inhibition was observed following treatment with whelk GAG extracts before and 
after enzymatic degradation with HS and CS lyases. 
The results reported in Chapter 3 suggested incomplete enzymatic digestion of whelk GAG, 
according to the elution profile from size exclusion chromatography. On the evidence from 
high-performance liquid chromatography, neither ABC nor Hep lyases completely 
broakdown the whelk GAG chain, as evidenced by the overlapping peaks that were obtained 
after enzymatic depolymerisation, which revealed partially depolymerised compounds.  
In line with these results, the biological activity of the fragments generated from Heparinase 
lyase has slightly reduced. This could be as a result of losing fraction of the Hep/HS unit 
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from the chain that might play an important role in cell growth inhibition. The activity from 
fragments generated by ABC enzyme seemed to be similar to the crude whelk GAG extracts. 
This study has shown that whelk GAG fractions from high performance anion exchange 
chromatography (HPAEC) exhibit significant inhibition activity toward TNBC cell lines. 
These fragments were oxidised by periodic acid, which acts on glycoside bonds. The aim was 
to break down the sugar rings and evaluate the structure-function activity. Remarkably, the 
biological activity remained in these fragments and fucose units were the only 
monosaccharide that have been oxidised by periodic acid as indicated in previous chapter. 
This finding was unexpected and suggests that the substrate undergoes partial oxidation 
process even after a long-term oxidation period. In addition, losing of fucose units did not 
affect the biological activity of whelk GAGs. This indicates that fucose units that attached to 
the GAG chain in whelk extracts seem less important in the biological activity.  
Nevertheless, a study has shown that the C-2-C-3 glycol group in the uronic acid moiety of 
the GAGs has low reactivity towards periodic acid oxidation. The reactivity of D-glucuronic 
acid in chondroitin 4-sulphate and 6-sulphate was reported to be relatively low, which might 
oxidize 100 fold more slowly compared to the fast oxidation of the C-5 epimer L-iduronic 
acid in heparan sulphate (Scott & Tigwell, 1978). This might explain the incomplete 
oxidation process. 
Fragments CK1, CK2 and CK3 from ion exchange chromatography were degraded by 
enzymatic action. Each fragment was then separated by a 10K filter into two fractions, a 
flow-through fraction (FT) and a retained fraction (R). Each fraction from each fragment 
(CK1, CK2 and CK3) was tested in vitro. No inhibition activity toward either the MDA-MB-
231 or MDA-MB-468 cell line was obtained from the FT fraction after Hep and ABC lyase 
degradation. This result clearly suggests that fragments with a size equal to or smaller than 
10K tended to be weaker and their anti-proliferative effects were lost. 
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However, massive inhibition activity on both cell lines was reported from the retained 
fraction of all fragments. These results indicate that the active fragments are bigger in size 
than 10K (the size of the filter pores), and therefore could not pass through the filter.  
These findings concur with other studies that show different sizes of marine GAG fragments 
seem to exhibit different biological activity. Many polysaccharides isolated from marine 
organisms have been chemically modified or degraded and are involved directly or indirectly 
in inhibiting cancer growth or influence different stages of carcinogenesis (Stonik & Fedorov, 
2011).  
Fragments with different molecular weight of fucosylated chondroitin sulphate are reported 
to exhibit anticoagulant activity, but this activity has been shown to reduce with the decrease 
in molecular size of the polysaccharide obtained, and a molecular size above 6 kDa is 
required to achieve thrombin inhibition (Wu et al., 2010).  
The results are broadly consistent with those of another study of unfractionated chains of 
Fucoidans which is isolated from many marine organisms. These are reported to exhibit 
activity in several aspects, such as inducing apoptosis in human colon cancer cells as well as 
breast adenocarcinoma MCF-7 (Hyun et al., 2009; Kim et al., 2010; Yamasaki-Miyamoto et 
al., 2009).   
Other studies reported that naturally over-sulphated and high molecular weight fucoidans 
from U. pinnatifida exhibit significant activity as anticancer agents and prevent angiogenesis 
due to their molecular size (Cho et al., 2010; Narazaki et al., 2008).   
In contrast, some reports in the literature indicate that low molecular weight oligosaccharides 
isolated and prepared from Chondrus ocellatus may be more promising as anticancer agents 
than high molecular forms of the same polysaccharide (Lins et al., 2009). 
This is the first study, to our knowledge, to examine the bioactivity of crude whelk GAG 
crude extracts on mammospheres formation in MCF-7, MDA-MB-468 and MDA-MB-231, 
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although the mammospheres formed from MDA-MB-468 and MDA-MB-231 were not as 
clear as those obtained from MCF-7. However, it is clear that some population of each cell 
line survived the conditions of undetected culture and proliferated over a 5-day incubation 
period. The crude whelk GAG extracts reduced the number of mammospheres in all cell lines 
after treatment with the IC50 values corresponding to each cell line but did not completely 
inhibit mammosphere growth. The inhibition activity was increased by increasing the dose of 
whelk GAG. This important finding shows the capability of crude whelk GAG extracts to 
induce cell death among fewer cell populations from different subtypes of breast cancer 
which have the ability to develop metastasis or act as cancer stem cells (CSC).   
In order to gain a better understanding of the mechanism of action of the whelk GAG extracts 
and highlight potential targets for the active compounds from whelk GAG in TNBC, this 
study has employed a label-free proteomic approach.  
The results from these experiments suggested many pathways that might be involved in the 
whelk GAG inhibition mechanisms on both cell lines. The integrin cell surface interaction 
pathway was identified by REACTOME as the first route of whelk GAG to induce growth 
inhibition. The further downstream signalling transduction of this pathway leads to cell cycle 
arrest and anti-proliferation.  
The results demonstrated that whelk GAG impedes FGF and FGFRs pathways in MDA-MB-
468 cells, which eventually inhibit cell proliferation and tumour progression. The results also 
suggested the ability of whelk GAG to bind to EGFR which may block or inhibit RAS 
signalling which eventually inhibit PI3K-AKT- mTOR, this further leads to cell arrest and 
anti-proliferation in MDA-MB-468 cells.  
The results showed that whelk GAGs affected the extracellular organization in both cell lines. 
The pathways related to extracellular matrix organization consist of several proteins that are 
responsible for many cellular functions such as cell proliferation, cell differentiation and cell 
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adhesion. Each protein has several domains, and each domain has its own specific structure 
and function. For example, the extracellular domain of E-cadherin that was significantly 
enriched in both cell lines upon whelk GAG treatment, is essential for cell-to-cell adhesion. 
The cytoplasmic domain of E-cadherin interacts with the catenins (α-, β-, γ- and p120 catenin) 
anchored to the actin cytoskeleton, establishing cadherin-catenin complexes (Gumbiner & 
McCrea, 1993).  
It has been reported that the conformation of E-cadherin is only stable upon Ca2+ binding to 
its highly conserved, negatively charged extracellular motifs. E-cadherin forms an adherens 
junction with its binding partner β-catenin and actin filaments. This complex is critical to 
inhibiting individual epithelial cell motility and to providing homeostatic tissue architecture 
(Cavallaro & Christofori, 2004; Kemler & Ozawa, 1989; Wen et al., 2015). E-cadherin is 
also involved in a number of signalling pathways in carcinogenesis. One of the pathways that 
is frequently overexpressed in breast cancer involves Rho GTPases, among which Rho A, 
Rac1 and Cdc42 have been extensively studied (Chen et al., 2014; Li et al., 2014; Menezes et 
al., 2014). They contribute to the regulation of key elements from the core cell cycle 
machinery, mostly involved in the G1/S transition. This pathway was significsantly affected 
by whelk GAG treatment in MDA-MB-231 cells.    
The results demonstrate downregulation in the glycolysis metabolism pathway in MDA-MB-
468, which is important in cancer survival. It may be the glycolysis effects are a later effect 
of whelk GAG treatment as the cells begin to die. This pathway seems to be less important in 
whelk GAG modes of action on the MDA-MB-231 cell line. 
However, selective effect of whelk GAG on Notch signalling pathway has been reported 
from MDA-MB-231 cell line. Recently, a study has identified a series of activating mutations 
within the PEST domain of Notch1, Notch2, and Notch3, these mutations were enriched in 
triple negative breast cancers including MDA-MB-231 cell. Notch signalling is known to 
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regulate many cellular processes of breast cancer including proliferation, metastasis, cancer 
stem cells, angiogenesis. Therefore, this result describes a strong potential target for whelk 
GAG and demonstrates one of the most important mechanisms of action on this cell line.  
In conclusion, the crude whelk GAG extracts were extensively active on both cell lines, 
whereas no activity was reported from commercial mammalian HS or CS on either cell line. 
In this study, a library of fragments was generated from whelk GAG using ion-exchange 
chromatography, Heparinase lyase, and ABC lyase. Incomplete enzymatic digestion of whelk 
GAG was suggested by the elution profile of size exclusion chromatography. The results 
from MTT assays from both cell lines show an obvious resistance from both TNBC cell lines 
towards fragments generated from Hep lyase. This could be as a result of losing some 
Hep/HS units from the chain sequence that may play an important role in inhibiting the 
growth of TNBC cells. The results from fragments generated from ABC lyases showed high 
inhibition activity toward both cell lines with no resistance as previously noticed with Hep 
fragments.  
Moreover, fragments from ion-exchange chromatography have shown significant inhibition 
activity on both cell lines. The oxidised form of these fractions showed noticeable inhibition 
activity on both cell lines. Generally, D-glucuronic acid moiety of the GAG shows low 
reactivity towards periodic acid oxidation, hence the whelk GAG sample is reported to have a 
high abundance of glucuronic acid, which might explain the resistance to the oxidation 
process. In addition, losing of fucose units because of oxidation process did not affect the 
biological activity of whelk GAG. This suggests that fucose is less important in the whelk 
GAG function against cancer growth.  
Each fraction (FT and R) from each fragment (CK1, CK2 and CK3) was monitored for its 
biological activity. No inhibition activity on TNBC cell lines was obtained from the FT 
fraction of Heparinase lyase and ABC lyase degradation. However, significant inhibition 
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activity on both cell lines was observed from the retained fractions from all fragments. The 
inhibition activity of the obtained purified GAG (FT fraction) on TNBC cell lines tended to 
be weaker and its anti-proliferative effects were lost to some extent. This strongly suggests 
that the active fragment is clearly longer in size than 10K. 
In addition, crude whelk GAG extracts have shown a remarkable inhibition activity on 
mammospheres obtained from MCF-7, MDA-MB-468 and MDA-MB-23 cell lines. This 
important finding shows the capability of whelk GAGs to induce cell death among cells that 
might develop metastasis or act as CSC. 
An overall understanding of the mechanism of action of whelk GAG toward TNBC cell lines 
has emerged from this study. An important finding demonstrated that whelk GAG selectively 
impedes specific pathways in each cell line studied, such as FGF and FGFRs pathways in 
MDA-MB-468 cells, leading to the inhibition of cell growth, cell arrest and decreased cell 
survival. In addition to their selective activity on Notch signalling pathway that has been 
reported from MDA-MB-231 cell line. Furthermore, whelk GAG affected the extracellular 
organisation, which is important in cell proliferation and survival. In addition to their 
influence on glycolysis metabolism in MDA-MB-468 and their potential attribute in 
downregulating the DNA replication process, whelk GAGs induce cell arrest and anti-
proliferation among cells. Taken together, the results of this study have confirmed the anti-
proliferation activity of whelk GAG and explained its coherent modes of action, which 
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This study has evaluated the role of whelk GAGs in the growth inhibition of several cancers 
and malaria in vitro. An additional aim was to investigate the structure of whelk GAGs and to 
highlight the key differences between these GAGs and mammalian GAGs, and to associate 
structural differences with their biological activity. 
Many naturally derived active compounds have been discovered because of intensive 
research by pharmaceutical companies and academia. Studies have addressed the contribution 
of marine GAGs in the development of new bioactive candidates with anti-proliferation 
activity toward different cancers and malaria. However, despite great interest in the 
investigation of natural products from marine organisms, many marine species and their 
constituents remain undiscovered. 
Data from advanced analytical techniques has enabled significant new insights to be gained 
into the role that sulphation patterns and the organisation/abundance of different disaccharide 
units in molecules may play in influencing oligosaccharide conformation and, more 
importantly, function. These have been shown to be significant factors and to play a major 
role in biological functions, with differences identified between inactive and active 
oligosaccharides in whelk GAGs in comparison to mammalian GAGs.  
For the first time, this study has shown that crude whelk GAG extracts inhibit the growth of 
HepG2 cells, MCF-7, SKBR-3, K562, A549 cells and plasmodial growth. Although the exact 
mechanism of action of whelk GAG toward these cancers and towards malaria is not fully 
understood, the most likely explanation for this finding is that whelk GAG extracts act as an 
anti-proliferation agent. Administration of exogenous GAGs from whelk with active 
structural features in effective doses may lead to a competition process in which the 
functional endothelial GAGs bind to the growth factors that are commonly seen in the cell 
differentiation event. This could therefore give rise to an anti-proliferation outcome. 
Administration of some marine GAGs led to many cellular changes such as reduction of 
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cancer cell adhesion, suppression of cell migration and tube formation in those cells, 
suppression of angiogenesis, inhibition of cell proliferation and tumour invasion. These 
findings can further contribute to the development of anticancer and antimalarial agents. 
Further studies are required in future to investigate their mode of action.  
Our data indicates distinct differences in the structure of whelk GAG and mammalian GAGs, 
which lie mainly in the abundance of different disaccharide units and the sulphation patterns 
present in these molecules. This finding might explain, at least in part, the incomplete 
digestion of whelk GAGs by heparinase enzymes. Our data has indicated that a reasonable 
amount of GAG in the retained fraction of the Nanosep centrifugal devices contain omega 
membrane (10K filter Eppendorf tube), which again could be the result of incomplete 
digestion by heparinase enzymes. Unlike the flow-through fractions, the retained fraction has 
proven but reduced, in comparison to intact GAG chains, biological activity toward cancer 
cells. This suggests that retained fractions contain the key heparinase-resistant sequences, 
which are essential for their biological activity. The structure of these fractions is still 
relatively unknown, and further research is necessary to fully explore the structure of this 
fraction.  
This study assessed the impact of crude whelk GAG extracts and its fragments on triple 
negative breast cancer (TNBC) cell proliferation and investigated their mode of action on 
TNBC using label-free proteomic approaches. In addition, it examined the activity of whelk 
GAGs toward cancer stem cells by using mammosphere assays on different breast cancer 
subtypes. 
Significant inhibition activity toward the TNBC cell lines MDA-MB-231 and MDA-MB-468 
and the mammosphere formation of several subtypes of breast cancer has been indicated in 
whelk GAGs relative to inactive GAG fragments from mammalian sources.  
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The label-free proteomic data has enabled significant new insights to be gained into the 
mechanism of action of whelk GAG activities toward TNBC. It's role has suggested many 
pathways that might be involved in whelk GAG inhibition mechanisms on MDA-MB-468 
and MDA-MB-231 cell lines. An important finding demonstrated that whelk GAG selectively 
impedes the FGF and FGFRs pathways, leading to inhibited cell growth and decreased cell 
survival. In addition to their selective activity on Notch signalling pathway that has been 
reported from MDA-MB-231 cell line. Notch signalling is known to regulate many cellular 
processes of breast cancer including proliferation, metastasis, cancer stem cell regulation and 
angiogenesis, it is very clear that activation of Notch plays a key role in breast cancer. 
Therefore, it represents a very attractive therapeutic target for many breast cancer subtypes.  
Furthermore, whelk GAG affected extracellular organisation and many pathways that are 
important in cell proliferation and survival. The study also demonstrated the influence of 
whelk GAG on glycolysis metabolism in MDA-MB-468, also shown potential attributes of 
whelk GAG in down-regulating the DNA replication process, which further induces cell 
arrest and anti-proliferation among cells.  
These findings contribute considerably to the evaluation and plans for further structure 
analysis of whelk GAG in the development of potential therapeutic approaches, which may 
have an important role as future anticancer and antimalarial agents. 
Finally, further studies are required to further analyse the structure of whelk GAGs in 
particular the bioactive compounds detected in the retained fractions. More research in this 
area is necessary to answer several questions that remained unresolved in terms of structure-
function relationship. In addition, more research require on screening the bioactivity of whelk 
GAGs toward TNBC cells that have resistance toward chemotherapy, this resistance toward 
chemotherapeutic agent could be developed in vitro by treating cells with low doses of 
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Appendix I:    Recipes for solutions and buffers 
 
Enzymatic digestion: 
 Heparin Lyase Buffer:  100 mM Sodium Acetate/0.1 mM Calcium Acetate pH 7.0  
 3.4 g NaOAc·3H2O  
 4.4 mg Ca(OAc)2·H2O. 
 Dissolve in 200 mL of Milli-Q water, adjust pH to 7.0 and bring volume to 250 mL.  
 GE-H0001-Heparinase I (EC 4.2.2.7), 2 IU, GE-H 0002- Heparinase II, 0.25 IU, GE-
H 0003-Heparinase III (EC 4.2.2.8), 0.5 IU from Grampian Enzymes.  
  
Chondroitin ABC Lyase Buffer : 50 mM Tris-Cl/50 mM Sodium Acetate pH 8.0  
 1.5 g Tris Base  
 3.4 g NaOAc·3H2O. 
 Dissolve in 200 mL of Milli-Q water, adjust pH to 8.0 and bring volume to 250 mL 
 Chondroitinase AC-50 µL- / 0.5 IU- 50-013, Chondroitinase B-50 µL- / 5 µg- 50-018 
from IBEX Technologies Inc-Canada.   
Analysis of Monosaccharides by HPAEC-PAD 
1-Preparation of 1L of 100 mM NaOH with 5 mM NaOAc:  
 0.7 g of Sodium Acetate Trihydrate  
  5.2 mL of 50% NaOH  
 Dissolve the Sodium Acetate Trihydrate in Milli-Q water that has been filtered 
through a 0.2 µm filter. Then add the 50% NaOH and bring the volume to 1 L.  
 
2-Preparation of 1L of 100 mM NaOH with 250 mM NaOAc:  
 34 g of Sodium Acetate Trihydrate  
  5.2 mL of 50% NaOH  
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 Dissolve the Sodium Acetate Trihydrate in Milli-Q water that has been filtered 
through a 0.2 µm filter. Then add the 50% NaOH and bring the volume to 1 L.  
DEAE Pre-Wash Buffer: 
50 mM NaOAc/150 mM NaCl with 0.1% Triton X-100 pH 6.0 
 6.8 g NaOAc·3H2O 
 4.4 g NaCl 
 0.5 g Triton X-100 
 Dissolve in 400 mL Milli-Q water, adjust pH to 6.0 and bring volume to 500 mL   
 
 
DEAE Wash Buffer: 
50 mM NaOAc/150 mM NaCl with pH 6.0 
 6.8 g NaOAc·3H2O 
 4.4 g NaCl 
 Dissolve in 400 mL Milli-Q water, adjust pH to 6.0 and bring volume to 500 mL 
 
DEAE Elution Buffer: 
1- 50 mM NaOAc/1M NaCl pH 6.0 
 6.8 g NaOAc·3H2O 
 29.22 g NaCl 
 Dissolve in 400 mL Milli-Q water, adjust pH to 6.0 and bring volume to 500 mL 
2- 50 mM NaOAc/2M NaCl pH 6.0 
 6.8 g NaOAc·3H2O 
 58.44g NaCl 




3- 50 mM NaOAc/3M NaCl pH 6.0 
 6.8 g NaOAc·3H2O 
 87.660g NaCl 
 Dissolve in 400 mL Milli-Q water, adjust pH to 6.0 and bring volume to 500 mL 
 
Reagents of TMS Derivatization and Analysis by GC-MS 
 3 M Methanolic-HCl (Supelco, 33355). 
  Methanol (Sigma, 322415). 
 Acetic Anhydride (Sigma, 539996). 
 Pyridine (Sigma, 270970). 
 Tri-Sil HTP Reagent (Pierce, TS-48999).  
 
Cell lines purchase  
 The human lung adenocarcinoma epithelial A549 cell line (passage 9) (86012804, 
Sigma Aldrich(UK).  
 92020424/ MDA-MB-231 Human Caucasian breast Adenocarcinoma-Frozen 
In Stock, Public health England-cell collections. 
  86012803/ MCF7- Human Caucasian breast adenocarcinoma- Frozen 
In Stock, Public health England-cell collections. 
 ATCC- HTB-132/ MDA-MB-468 Mammary gland/breast; derived from metastatic 
site: pleural effusion black female, Frozen in Stock, ATCC/LGC Promochem, 
Middlesex,UK.     
 ATCC- HTB-30/ Caucasian female, mammary gland/breast; derived from metastatic 
site: pleural effusion,  Frozen in Stock, ATCC/LGC Promochem, Middlesex,UK.   
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 ATCC- CCL-243/ Homo sapiens, human bone marrow, lymphoblast, Frozen in Stock, 
ATCC/LGC Promochem, Middlesex,UK.  
 
Mammosphere assay buffers  
 
  
 DMEM/F12 (Thermofisher, product code 11320-033).  
  Basic Fibroblast Growth Factor (bFGF), Human Recombinant (Corning, Product 
code 354060).  
 Epidermal Growth Factor (EGF), Mouse Natural (Culture Grade), (Corning, Product 
code 354001).  
 ITS Liquid Media Supplement (100x), liquid, sterile-filtered, BioReagent, suitable for 
cell culture (Sigma, Product code I3146-5ML). 
 B-27 Supplement (50X), serum free (Thermofisher, Product code 17504-044).  
 Poly (2-hydroxyethyl methacrylate) (Sigma, Product code P3932).  
   
Reagents Supplier and Instruments Details  
 PBS tablets (Phosphate Buffered Saline), 1 x tablet dissolved in 200mL water yields 
0.01M phosphate buffer, 0.0027M KCl, and 0.137M NaCl, pH 7.4 at 25°C for HPLC 
from Fisher Scientific.  
 Acetone 
 Sodium Carbonate Sigma Aldrich-1.06392.0500 
 Alcalase Enzyme 
 trichloroacetic acid Sigma Aldrich -T6399 
 potassium acetate Fisher Scientific- 11376798 
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 cetylpyridinium chloride Sigma Aldrich -C0732 
 Sodium chloride Sigma Aldrich-S7653 
 Dialysis tube Spectrum Labs.com  
 Bovine Serum Albumin BSA Sigma Aldrich A2153. 
 Sodium acetate NaOAc3H2O Sigma Aldrich- S2889. 
 Ca(OAc)2·H2O. 
 Tris Base Sigma Aldrich -697737. 
 Sodium Acetate Trihydrate Fisher Scintific-12350000. 
 Sodium hydroxide NaOH Sigma Aldrich -71687. 
 Triton X-100 Sigma Aldrich. 
The Giemsa staining solution       
 Gurr’s Giemsa stain solution (BDH/VWR international limited, UK) prepared at 1:10 
as below: 
 one tablet pH 6.4 (BDH laboratory supplies, England). 




Sample preparation for LC-MS analysis using filter-aided sample preparation (FASP)  
1- Materials and Reagents:  
 Microcon-30kDa Centrifugal Filter Unit with Ultracel-30 membrane (MRCF0R030) 
and Direct Detect® spectrometer (DDHW00010-WW) from Millipore,  
 ammonium bicarbonate (ambic, 09830) from Sigma Aldrich,   
 Trypsin (Promega, cat. no. V528A),  
 LysC MS grade (Wako Chemicals, cat. no. 129-02541),  
 Dithiothreitol (DTT, MB105) and Tris Base (B2005) from Melford laboratories,  
 Iodoacetamide (IAM; Sigma-Aldrich, cat. no. I6125) 
 Urea (Fisher, cat. no. U/0500/53),  
 POROS R3 beads (1-339-03),  
 96-well with 0.2 µM PVDF membrane (3504) from Corning.  
 Microtube -15 from Covaris (520145),  
 Formic acid (FA; Fluka, cat. no. 94318),  
 Acetonitrile (MeCN; Fisher, cat. no. A955-1),  
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 Acetonitrile with 0.1% formic acid (Sigma Aldrich, 34688),  
 Water with 0.1% formic acid, (Sigma-Aldrich, 34673),  
 
2- Buffers:  
 SDS buffer stock = 2% SDS in 50 mM Tris-HCl pH 7.4. 
 UA1 = 8M urea, 0.1M Tris-HCl (pH 8.5). 
 UA2 = 8M urea, 0.1 Tris-HCl (pH 8.5) with 15 mM DTT. 
 UA3 = 75% UA1 buffer + 25% deionised water (=6M Urea). 
 Wet solution = 50% acetonitrile. 
 Wash solution = 0.1% formic acid. 
 Elute solution = 50% acetonitrile, 0.1% formic acid 
 
 

















MDA-MB-468/ C1 – 1,2,3 0.432 16% 0.38 67 
MDA-MB-468/C1 – 4,5,6 0.313 4%   
MDA-MB-231/ C1 – 7,8,9 0.393 5% 0.37 68 
MDA-MB-231/ C1 – 10,11,12 0.344 27%   
MDA-MB-468/ T1 – 1314,15 0.590 6% 0.62 40 
MDA-MB-468/ T1 – 16,17,18 0.657 8%   
MDA-MB-231/T1 – 18,19,20 0.214 18% 0.29 87 










Appendix II:  A:    LC-MS spectra of aniline-tagged standards and whelk-GAG flow 
throw (FT) sample fractions. B: MS spectra of the unknown peak in CK1 fraction (CK-
1 sample in negative mode direct injection MS), Standard CS in negative mode direct 
injection MS, Standard GlcA in negative mode direct injection MS, and Reagent blank 
run on MS 
 
The retention times and mass spectra of aniline-tagged standards and whelk-GAG flow throw 
(FT) sample fractions from GRIL-LC-MS. A: Represent HS-Std and sample fractions 
digested with HS lyase, A1-Standard disaccharide mixture tagged with 12C-Aniline, A2-
Standard Heparin digested with Hep-lyase , 12C-aniline tagged and mixed with known 
amount of 13C-aniline tagged internal standard, A3-CK-1 GAG sample isolated in 1M NaCl 
fraction, digested with Hep-lyase and GRIL tagged with 12C-aniline and spiked with 13C-
aniline tagged disaccharide mixture as int std, A4-CK-2 GAG sample isolated in 2M NaCl 
fraction, digested with Hep-lyase and GRIL tagged with 12C-aniline and spiked with 13C-
aniline tagged disaccharide mixture as int std, A5-CK-3 GAG sample isolated in 3M NaCl 
fraction, digested with Hep-lyase and GRIL tagged with 12C-aniline and spiked with 13C-
aniline tagged disaccharide mixture as int std. 
B: Represent CS-Std and sample fractions digested with ABC lyase, B1- Standard 
disaccharide mixture tagged with 12C-Aniline, B2- Standard chondroitin digested with CS-
ABC, 12C-aniline tagged and mixed with known amount of 13C-aniline tagged internal 
standard, B3- CK-1 GAG sample isolated in 1M NaCl fraction, digested with CS-ABC and 
GRIL tagged with 12C-aniline and spiked with 13C-aniline tagged disaccharide mixture as 
int std, B4- CK-2 GAG sample isolated in 2M NaCl fraction, digested with CS-ABC and 
GRIL tagged with 12C-aniline and spiked with 13C-aniline tagged disaccharide mixture as 
int std, B5- CK-3 GAG sample isolated in 3M NaCl fraction, digested with CS-ABC and 






















































Appendix III:        Monosaccharide quantification      
 
 2N-TFA hydrolysis 5h on 10% material and 7% injected                
     











Appendix IV:    Monosaccharide analysis of the flow through fraction of the DEAE ion 



















Appendix V:    NMR spectra of whelk GAG.  
 
 
1- 1H NMR spectra of the retrained fraction of 10K filter from fractions CK1, CK2 and CK3 after digesting with Hep lyase, spectra 
recorded at frequency of 800MHz at 70 °C. 
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